Publications: Prof Thomas Powles

Barata PC, Zarrabi KK, Bex A, Grivas P, Hermann K, Hofman MS, Li R, Lopez-Beltran A et al. ( 2024 ) . Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers . European Urology

Alkaissi H, Pacak K, Rosenblum J ( 2024 ) . Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma . New England Journal of Medicine vol. 391 , ( 21 ) 2061 - 2063 .

Barragan-Carrillo R, Saad E, Saliby R-M, Sun M, Albiges L, Bex A, Heng D, Mejean A et al. ( 2024 ) . First and Second-line Treatments in Metastatic Renal Cell Carcinoma . European Urology

Semaan K, Nawfal R, Nally E, Janjigian YY, Robert C, Peters S, Powles T, Choueiri TK ( 2024 ) . Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types . The Lancet Oncology ( JAMA Netw Open 7 2024 )

Powles T, Csőszi T, Loriot Y, Matsubara N, Geczi L, Cheng SY-S, Fradet Y, Alva A et al. ( 2024 ) . Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study . Clinical Genitourinary Cancer

Powles T, Gupta S, Sridhar S, Bellmunt J, Tyroller K, Hoffman J, Grivas P ( 2024 ) . P251 Avelumab first-Line Maintenance (1LM) in advanced Urothelial Carcinoma (aUC): Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in older patients (pts) from the JAVELIN Bladder 100 trial . European Urology Open Science vol. 69 , 317 - 318 .

Necchi A, Guerrero-Ramos F, Crispen PL, Herrera B, Garje R, Powles T, Peyton CC, Pradere B et al. ( 2024 ) . P262 TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy: interim analysis of SunRISe-4 . European Urology Open Science vol. 69 , 332 - 333 .

Fléchon A, Morales-Barrera R, Powles T, Alva A, Özgüroğlu M, Csöszi T, Loriot Y, Rodriguez-Vida A et al. ( 2024 ) . Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma . Clinical Cancer Research vol. 30 , ( 23 ) 5353 - 5364 .

O’Donnell PH, Loriot Y, Csoszi T, Matsubara N, Shin SJ, Park H, Atduev V, Gumus M et al. ( 2024 ) . Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011 . Cancer

Mamtani R, Matsubara N, Pino AM, Herranz UA, Şendur MAN, Gravis G, Huillard O, Lee HJ et al. ( 2024 ) . Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial . Clinical Genitourinary Cancer vol. 23 , ( 1 )

Meade A, Frangou E, Choodari-Oskooei B, Larkin J, Powles T, Stewart GD, Albiges L, Bex A et al. ( 2024 ) . Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report . Contemporary Clinical Trials Communications vol. 42 ,

Baldini C, Patnaik A, Lakhani N, Call J, Galsky M, Garmezy B, Wei A, Carter L et al. ( 2024 ) . 165 (PB153): NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (Trial in Progress) . European Journal of Cancer vol. 211 ,

Marandino L, Campi R, Amparore D, Tippu Z, Albiges L, Capitanio U, Giles RH, Gillessen S et al. ( 2024 ) . Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions . European Urology Oncology

Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L et al. ( 2024 ) . Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer . New England Journal of Medicine vol. 391 , ( 19 ) 1773 - 1786 .

Apolo AB, Bellmunt J, Cordes L, Gupta S, Powles T, Rosenberg JE, Van Der Heijden MS ( 2024 ) . The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria . ESMO Open vol. 9 , ( 9 )

Albiges L, Powles TB, Sharma A, Venugopal B, Bedke J, Borkowetz A, Gravis G, Özdemir BC et al. ( 2024 ) . 1693P CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC) . Annals of Oncology vol. 35 ,

Saliby RM, Xie W, Wells JC, Saad E, Eid M, Semaan K, Labaki C, Ferrier E et al. ( 2024 ) . 1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study . Annals of Oncology vol. 35 , s1021 - s1022 .

Albiges L, Rodriguez CS, Procopio G, Bex A, Gruenwald V, Schmidinger M, Melichar B, De Velasco Oria GA et al. ( 2024 ) . 1717TiP CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma . Annals of Oncology vol. 35 ,

Bedke J, Liao W, Shi L, Blum SI, Patel M, Powles TB ( 2024 ) . 1962O Health-related quality of life from the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma . Annals of Oncology vol. 35 ,

Powles TB, van der Heijden MS, Gupta S, Valderrama BP, Galsky MD, Bedke J, Kikuchi E, Hoffman-Censits J et al. ( 2024 ) . 1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC) . Annals of Oncology vol. 35 , s1137 - s1138 .

Galsky MD, Koshkin VS, Campbell MT, Drakaki A, Bowman I, Rose AAN, Brown JR, Aragon-Ching JB et al. ( 2024 ) . 1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C . Annals of Oncology vol. 35 , s1138 - s1139 .

Drakaki A, Powles TB, Wang Y, Bupathi M, Joshi M, Fleming MT, de Liano Lista AG, Barrera RM et al. ( 2024 ) . 1970MO Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trial . Annals of Oncology vol. 35 ,

Grivas P, Park SH, Voog E, Su W-P, Demey W, Fong PC, Garcia JA, Jacob N et al. ( 2024 ) . 1975P Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100 . Annals of Oncology vol. 35 ,

Powles TB, van der Heijden MS, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L et al. ( 2024 ) . LBA5 A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA) . Annals of Oncology vol. 35 ,

Rini BI, Rodriguez CS, Albiges L, Jalkanen K, De Velasco Oria GA, Burotto M, Ghatalia P, Iacovelli R et al. ( 2024 ) . LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC) . Annals of Oncology vol. 35 , s1262 - s1263 .

Necchi A, Guerrero-Ramos F, Crispen PL, Imbroda BH, Garje R, Powles TB, Peyton CC, Pradere B et al. ( 2024 ) . LBA84 TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4) . Annals of Oncology vol. 35 , s1271 - s1272 .

Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R et al. ( 2024 ) . Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma . New England Journal of Medicine vol. 391 , ( 8 ) 710 - 721 .

Wong B, Peng J, Jiang DM, Fizazi K, Powles T, James N, Sridhar SS ( 2024 ) . Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom and France . Clinical Genitourinary Cancer vol. 22 , ( 6 )

Kikuchi E, Gupta S, Loriot Y, Van Der Heijden MS, Bedke J, Valderrama BP, Flechon A, Petrylak DP et al. ( 2024 ) . Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC) . Journal of Clinical Oncology vol. 42 , ( 23_suppl ) 108 - 108 .

Saliby RM, Xie W, Wells CJ, Saad E, Eid M, Semaan K, Labaki C, Ferrier E et al. ( 2024 ) . 20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study . The Oncologist vol. 29 , ( Supplement_1 ) s8 - s9 .

Albiges L, Choueiri TK, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R et al. ( 2024 ) . 42 Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma: Subgroup analysis of the phase 3 LITESPARK-005 study . The Oncologist vol. 29 , ( Supplement_1 ) s3 - s4 .

Atkins MB, Escudier B, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Plimack ER, Porta C et al. ( 2024 ) . 8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial . The Oncologist vol. 29 , ( Supplement_1 ) s17 - s18 .

Cicin I, Plimack ER, Gurney H, Leibowitz R, Alekseev BY, Parnis FX, Peer A, Necchi A et al. ( 2024 ) . Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study . BMC Cancer vol. 23 , ( Suppl 1 )

Mantia CM, Jegede OA, Plimack ER, Powles T, Motzer RJ, Tannir NM, Lee C-H, Tomita Y et al. ( 2024 ) . Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214 . Journal for ImmunoTherapy of Cancer vol. 12 , ( 7 )

Bickley LJ, Yang Y-H, Jackson-Spence F, Toms C, Sng C, Flanders L, Bex A, Powles T et al. ( 2024 ) . Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimens . World Journal of Urology vol. 42 , ( 1 )

Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, Powles T, Szabados B ( 2024 ) . Renal cell carcinoma . The Lancet vol. 404 , ( Diagn Pathol 10 2015 ) 476 - 491 .

Jackson-Spence F, Ackerman C, Jones R, Toms C, Jovaisaite A, Young M, Hussain S, Protheroe A et al. ( 2024 ) . Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel . Urologic Oncology Seminars and Original Investigations vol. 42 , ( 11 ) 372.e1 - 372.e10 .

Chakiryan NH, Strother MC ( 2024 ) . Adjuvant Pembrolizumab in Renal-Cell Carcinoma . New England Journal of Medicine vol. 391 , ( 2 ) 185 - 186 .

Sweeney CJ, Petry R, Xu C, Childress M, He J, Fabrizio D, Gjoerup O, Morley S et al. ( 2024 ) . Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer . Clinical Cancer Research vol. 30 , ( 18 ) of1 - of8 .

Muneer A, Bandini M, Compérat E, De Meerleer G, Fizazi K, Gietema J, Gillessen S, Kirkham A et al. ( 2024 ) . Penile cancer: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up ☆ . ESMO Open vol. 9 , ( 7 )

Takemura K, Yuasa T, Lemelin A, Ferrier E, Wells JC, Saad E, Saliby RM, Basappa NS et al. ( 2024 ) . Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium ☆ . ESMO Open vol. 9 , ( 7 )

Wells JC, Albiges L, Powles T ( 2024 ) . Anti-VEGF and -PD-1 Combinations in Renal Cell Carcinoma: When Are Treatment Breaks Safe? . European Urology vol. 86 , ( 5 ) 420 - 421 .

Szabados B, Powles T ( 2024 ) . On the Road Towards Curing Advanced Bladder Cancer . European Urology Focus vol. 10 , ( 2 ) 213 - 214 .

Sternberg CN, Loriot Y, Choy E, Castellano D, Lopez-Rios F, Banna GL, Zengerling F, De Giorgi U et al. ( 2024 ) . Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma . European Urology Focus .

Nally E, Young M, Wells C, Fairhead R, Baines K, Cheney-Lowe H, Jackson-Spence F, Powles T ( 2024 ) . Is HER2 the New NECTIN4 in Advanced Urothelial Cancer? . European Urology Focus vol. 10 , ( 2 ) 219 - 221 .

Powles T, Chang Y-H, Yamamoto Y, Munoz J, Reyes-Cosmelli F, Peer A, Cohen G, Yu EY et al. ( 2024 ) . Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial . Nature Medicine vol. 30 , ( 9 ) 2508 - 2516 .

Luke JJ, Long GV, Robert C, Carlino MS, Choueiri TK, Haas NB, O’Brien M, Paz-Ares L et al. ( 2024 ) . Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma . European Journal of Cancer vol. 207 ,

Gupta S, Powles T, Kearney M, Panattoni L, Land N, Flottemesch T, Sullivan P, Kirker M et al. ( 2024 ) . Age and other criteria influencing nontreatment of patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a physician survey in five European countries (Eu5) . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4570 - 4570 .

Beig N, Nofallah S, McDermott DF, Motzer RJ, Powles T, Rini BI, Koeppen H, Banchereau R et al. ( 2024 ) . Association of machine learning (ML)–derived histological features with transcriptomic molecular subtypes in advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4519 - 4519 .

Loriot Y, Gupta S, Powles T, Grivas P, Petrylak DP, Tyroller K, Jacob N, Hoffman J et al. ( 2024 ) . Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4567 - 4567 .

Bellmunt J, Powles T, Park SH, Voog E, Valderrama BP, Gurney H, Ullén A, Loriot Y et al. ( 2024 ) . Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4566 - 4566 .

Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F, Alekseev B et al. ( 2024 ) . Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4505 - 4505 .

Galsky MD, Sonpavde GP, Powles T, Claps M, Burotto M, Schenker M, Sade JP, Bamias A et al. ( 2024 ) . Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4509 - 4509 .

Sternschuss M, Toumbacaris N, Das JP, Powles T, Bajorin DF, Kotecha RR, Laccetti AL, Xiao H et al. ( 2024 ) . Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC) . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4581 - 4581 .

Bedke J, Van Der Heijden MS, Powles T, Valderrama BP, Kikuchi E, Iyer G, Vulsteke C, Swami U et al. ( 2024 ) . Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39 . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4562 - 4562 .

Van Der Heijden MS, Gupta S, Bedke J, Valderrama BP, Kikuchi E, Iyer G, Loriot Y, Dawson NA et al. ( 2024 ) . Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39 . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4563 - 4563 .

Bhatia AK, Hayashi H, Kogawa T, Nishina T, Fountzilas C, Castillo DR, McKean M, Colombo N et al. ( 2024 ) . HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) tps3164 - tps3164 .

Petrylak DP, Chia YL, Yu EY, Powles T, Flaig TW, Loriot Y, O'Donnell PH, Heath EI et al. ( 2024 ) . Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4503 - 4503 .

Gupta S, Loriot Y, Van Der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Flechon A, Petrylak DP et al. ( 2024 ) . Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC) . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4502 - 4502 .

Galsky MD, Grande E, Necchi A, Drakaki A, Loriot Y, Franco S, Ichimaru M, Zhang W et al. ( 2024 ) . Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001) . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) tps4616 - tps4616 .

Powles T, Chang WY-H, Yamamoto Y, Muñoz-Langa J, Reyes F, Peer A, Yu EY, Cohen G et al. ( 2024 ) . Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4518 - 4518 .

Zarba M, Ferrier E, Wells C, El Zarif T, Basappa NS, Ebrahimi H, McKay RR, Wood L et al. ( 2024 ) . Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC) . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4514 - 4514 .

Hasakioğulları İ, Kockx M, Szabados B, Young M, Powles T ( 2024 ) . Tumor-specific MHC class II upregulation associated with response to anti-PD-L1 therapy in patients with urothelial cancer . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4584 - 4584 .

Pal SK, Powles T, Kanesvaran R, Liu M, Wang Z, Bhatt A, Patel P, Suárez C ( 2024 ) . Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) tps4611 - tps4611 .

Powles T, Albiges L, Bex A, Comperat E, Grünwald V, Kanesvaran R, Kitamura H, McKay R et al. ( 2024 ) . Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆ . Annals of Oncology vol. 35 , ( 8 ) 692 - 706 .

Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE et al. ( 2024 ) . Исследование III фазы CLEAR у пациентов с распространенным почечно-клеточным раком: анализ в подгруппах больных, получавших ленватиниб с пембролизумабом и сунитиниб . Cancer Urology vol. 20 , ( 1 ) 24 - 35 .

Chauhan V, Diaz SS, Jara P, Efovi D, Gurung A, Young M, Wells C, Nally E et al. ( 2024 ) . Abstract B013: Novel prognostic score for patients with metastatic bladder cancer on immunotherapy . Clinical Cancer Research vol. 30 , ( 10_Supplement ) b013 - b013 .

Zollinger DR, Rivers E, Fine A, Huang Y, Son J, Kalyan A, Gray W, Baharian G et al. ( 2024 ) . Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors . PLOS ONE vol. 19 , ( 5 )

Sonpavde G, van der Heijden MS, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A et al. ( 2024 ) . PD34-11 NIVOLUMAB PLUS GEMCITABINE-CISPLATIN VERSUS GEMCITABINE-CISPLATIN ALONE IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA: RESULTS OF ANALYSES TO CHARACTERIZE BENEFIT IN RESPONDERS FROM THE PHASE 3 CHECKMATE 901 TRIAL . Journal of Urology vol. 211 , ( 5S )

Sridhar SS, Powles T, Gupta S, Duran MAC, Aragon-Ching JB, Sternberg CN, Cislo P, Costa N et al. ( 2024 ) . PD38-02 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY FIRST-LINE CHEMOTHERAPY REGIMEN AND ANALYSIS OF OVERALL SURVIVAL FROM START OF FIRST-LINE CHEMOTHERAPY . Journal of Urology vol. 211 , ( 5S )

Nally E, Young M, Chauhan V, Wells C, Szabados B, Powles T, Jackson-Spence F ( 2024 ) . Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge . Cancer Management and Research vol. 16 , 467 - 475 .

Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, Suárez C, Porta C et al. ( 2024 ) . Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial ☆ . ESMO Open vol. 9 , ( 5 )

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang Y-H et al. ( 2024 ) . Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma . New England Journal of Medicine vol. 390 , ( 15 ) 1359 - 1371 .

Saad E, Gebrael G, Semaan K, Eid M, Saliby RM, Labaki C, Sayegh N, Wells JC et al. ( 2024 ) . Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens . The Oncologist vol. 29 , ( 8 ) 699 - 706 .

Necchi A, Ramlau R, González AF, Chaudhry A, Todenhöfer T, Tahbaz R, Fontana E, Giannatempo P et al. ( 2024 ) . Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations . JNCI Cancer Spectrum vol. 8 , ( 3 )

Motzer RJ, Choueiri TK, Hutson T, Young Rha S, Puente J, Lalani A-KA, Winquist E, Eto M et al. ( 2024 ) . Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study . European Urology vol. 86 , ( 1 ) 4 - 9 .

Saliby RM, Labaki C, Jammihal TR, Xie W, Sun M, Shah V, Saad E, Kane MH et al. ( 2024 ) . Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes . Cancer Cell vol. 42 , ( 5 ) 732 - 735 .

Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP et al. ( 2024 ) . ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma . Annals of Oncology vol. 35 , ( 6 ) 485 - 490 .

Young M, Tapia JC, Szabados B, Jovaisaite A, Jackson-Spence F, Nally E, Powles T ( 2024 ) . NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors . Clinical Genitourinary Cancer vol. 22 , ( 3 )

Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C et al. ( 2024 ) . Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer . New England Journal of Medicine vol. 390 , ( 10 ) 875 - 888 .

Catto JWF, Necchi A, Powles T, Guerrero-Ramos F, Simone G, Shore N, Salinas JS, Merseburger AS et al. ( 2024 ) . A0595 SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non–muscle-invasive bladder cancer . European Urology vol. 85 ,

Diaz SS, Chauhan V, Gurung A, Nally E, Young M, Wells C, Jackson-Spence F, Szabados B et al. ( 2024 ) . A0745 Analysing resistance and progression patterns to immune checkpoint inhibitors in urothelial carcinoma . European Urology vol. 85 ,

Powles T, Grande E, Van Der Heijden M, Necchi A, Iyer G, Drakaki A, Loriot Y, Sokolowski K et al. ( 2024 ) . A0746 Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress) . European Urology vol. 85 ,

Zhang T, Choueiri TK, Tomczak P, Park H, Venugopal B, Ferguson T, Symeonides SN, Hajek J et al. ( 2024 ) . ADJUVANT PEMBROLIZUMAB FOR RENAL CELL CARCINOMA (KEYNOTE-564): EXPLORATORY ANALYSIS ACROSS UCLA INTEGRATED STAGING SYSTEM RISK GROUPS AND DISEASE STAGE . Urologic Oncology Seminars and Original Investigations vol. 42 , s7 - s8 .

Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE et al. ( 2024 ) . Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms . Frontiers in Oncology vol. 13 ,

Morgans AK, Sonpavde P, Shih V, Wright P, Hepp Z, Willmon CL, Chang N, Sesterhenn S et al. ( 2024 ) . REAL-WORLD ELIGIBILITY AND UTILIZATION OF AVELUMAB MAINTENANCE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA . Urologic Oncology Seminars and Original Investigations vol. 42 , s26 - s27 .

Rosenberg JE, Mamtani R, Sonpavde GP, Loriot Y, Duran I, Lee J-L, Matsubara N, Vulsteke C et al. ( 2024 ) . Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy . European Urology vol. 85 , ( 6 ) 574 - 585 .

Grünwald V, Powles T, Kopyltsov E, Kozlov V, Alonso-Gordoa T, Eto M, Hutson T, Motzer R et al. ( 2024 ) . Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study . Cancer Urology vol. 19 , ( 4 ) 32 - 43 .

Birtle AJ, Jones R, Chester J, Lewis R, Biscombe K, Johnson M, Blacker A, Bryan RT et al. ( 2024 ) . Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial . Journal of Clinical Oncology vol. 42 , ( 13 ) 1466 - 1471 .

Aragon-Ching JB, Petrylak DP, Sridhar SS, Gupta S, Grivas P, Powles T, Gurney H, Jacob N et al. ( 2024 ) . Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI) . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 600 - 600 .

Grivas P, Aragon-Ching JB, Bellmunt J, Loriot Y, Sridhar SS, SU P-J, Park SH, Yamamoto Y et al. ( 2024 ) . Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term patient-reported outcomes (PROs) in the phase 3 JAVELIN Bladder 100 trial . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 581 - 581 .

Powles T, Albiges L, Jalkanen KJ, De Velasco G, Burotto M, Ghatalia P, Suárez C, Lam ET et al. ( 2024 ) . Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 361 - 361 .

Bergerot CD, Castro DV, Bergerot PG, Mercier BD, Nally E, Ali AA, Philip EJ, Buso M et al. ( 2024 ) . Development of a patient-centered health-related quality of life (HRQOL) measure for metastatic renal cell carcinoma (mRCC): A three-phase study . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 365 - 365 .

Van Der Heijden MS, Powles T, Gupta S, Bedke J, Kikuchi E, De Wit R, Galsky MD, Duran I et al. ( 2024 ) . Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) lba530 - lba530 .

Sweeney C, Petry R, Xu C, Graf R, Fabrizio D, He J, Gjoerup O, Pasquina L et al. ( 2024 ) . Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC) . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 196 - 196 .

Saliby RM, Xie W, Wells JC, Saad E, Eid M, Labaki C, Semaan K, Ferrier E et al. ( 2024 ) . Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 400 - 400 .

Bedke J, Giles RH, Powles T, Derosa M, Floden L, Purnajo I, Lothgren M, Ogareva A et al. ( 2024 ) . Health-related quality of life (HRQoL) profile and clinical outcomes in first-line (1L) advanced renal cell carcinoma (aRCC): A modelling analysis based on CheckMate 9ER (CM9ER) trial . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 384 - 384 .

Jackson-Spence F, Chauhan V, Silva Diaz S, Gurung A, Young MN, Nally E, Wells C, Szabados B et al. ( 2024 ) . Identification of patients with metastatic urothelial cancer not able to receive maintenance avelumab . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 702 - 702 .

Bourlon MT, Escudier B, Burotto M, Powles T, Apolo AB, Shah AY, Porta C, Suárez C et al. ( 2024 ) . Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 362 - 362 .

Tannir NM, Escudier B, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Plimack ER, Porta C et al. ( 2024 ) . Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 363 - 363 .

Takemura K, Lemelin A, Ernst MS, Wells JC, Saliby RM, El Zarif T, Labaki C, Basappa NS et al. ( 2024 ) . Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium . European Urology

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang Y-H et al. ( 2024 ) . Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC) . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) lba359 - lba359 .

Galsky MD, Grande E, Necchi A, Koontz MZ, Iyer G, Campbell MT, Drakaki A, Loriot Y et al. ( 2024 ) . Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001) . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) tps717 - tps717 .

Gupta S, Powles T, Kearney M, Panattoni L, Land N, Flottemesch T, Sullivan P, Kirker M et al. ( 2024 ) . Platinum eligibility (PE) criteria for patients with metastatic urothelial carcinoma (mUC): Results of a physician survey in 5 European countries . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 696 - 696 .

Young MN, Szabados B, Assaf Z, Jackson-Spence F, Nally E, Wells C, Suárez C, Castellano D et al. ( 2024 ) . Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 534 - 534 .

Wells C, Ferrier E, Lemelin A, Powles T, Pal SK, Ebrahimi H, Agarwal N, Beuselinck B et al. ( 2024 ) . Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC) . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 395 - 395 .

Gupta M, Wells C, Regan MM, Xie W, Navani V, Saliby RM, Basappa NS, Donskov F et al. ( 2024 ) . Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 390 - 390 .

Jackson-Spence F, Young M, Jovaisaite A, Szabados B, Powles T ( 2024 ) . Adjuvant Therapy in Renal Cell Cancer . Kidney Cancer vol. 8 , ( 1 ) 17 - 22 .

Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY et al. ( 2024 ) . Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study . Journal of Clinical Oncology vol. 42 , ( 11 ) 1222 - 1228 .

Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, Kretkowski M, Hu H et al. ( 2024 ) . CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer . Future Oncology vol. 20 , ( 14 ) 891 - 901 .

Soares A, Bourlon MT, Wong A, Joshi A, Jardim D, Korbenfeld E, Karak FE, Orlandi F et al. ( 2024 ) . Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion . Clinical Genitourinary Cancer vol. 22 , ( 2 ) 467 - 475 .

Powles T ( 2024 ) . Annals of Oncology – passing the baton, raising the bar . Annals of Oncology vol. 35 , ( 1 )

Choueiri TK, Donahue AC, Braun DA, Rini BI, Powles T, Haanen JBAG, Larkin J, Mu XJ et al. ( 2023 ) . Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma . Cancer Discovery vol. 14 , ( 3 ) of1 - of18 .

Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F et al. ( 2023 ) . Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur Urol 84(5) (2023) 449–454] . European Urology vol. 85 , ( 2 ) e58 - e59 .

Vasudev NS, Ainsworth G, Brown S, Pickering L, Waddell T, Fife K, Griffiths R, Sharma A et al. ( 2023 ) . Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM) . Journal of Clinical Oncology vol. 42 , ( 3 ) 312 - 323 .

Albiges L, McGregor BA, Heng DYC, Procopio G, de Velasco G, Taguieva-Pioger N, Martín-Couce L, Tannir NM et al. ( 2023 ) . Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review . Cancer Treatment Reviews vol. 122 ,

Powles TB, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C et al. ( 2023 ) . 211MO EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) . Annals of Oncology vol. 34 , s1557 - s1558 .

Takemura K, Yuasa T, Lemelin A, Ferrier E, Wells JC, Saad E, Saliby RM, Basappa NS et al. ( 2023 ) . 213P Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC) . Annals of Oncology vol. 34 , s1558 - s1559 .

Grünwald V, McKay RR, Buchler T, Masatoshi E, Park SH, Takagi T, Zanetta S, Keizman D et al. ( 2023 ) . O12 Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial . European Urology Open Science vol. 57 , s15 - s16 .

Takemura K, Ernst MS, Navani V, Wells JC, Bakouny Z, Donskov F, Basappa NS, Wood LA et al. ( 2023 ) . Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium . European Urology Oncology vol. 7 , ( 3 ) 501 - 508 .

Choueiri TK, Powles T, Voss MH, Plimack ER, Gurney H, Song Y, Perini RF, Rodriguez-Lopez K et al. ( 2023 ) . LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma . Future Oncology vol. 19 , ( 40 ) 2631 - 2640 .

van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A et al. ( 2023 ) . Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma . New England Journal of Medicine vol. 389 , ( 19 ) 1778 - 1789 .

Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, Campbell MT, Compérat E et al. ( 2023 ) . Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group . Journal of Clinical Oncology vol. 41 , ( 35 ) 5437 - 5447 .

Jackson-Spence F, Rodriguez CS, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Vidal MJM, Markovets A et al. ( 2023 ) . 1888P 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer . Annals of Oncology vol. 34 ,

Navani V, Lemelin A, Powles TB, Liow ECH, Wong SSL, Meza LA, Ebrahimi H, Saliby RM et al. ( 2023 ) . 1893P Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC . Annals of Oncology vol. 34 , s1018 - s1019 .

Lemelin A, Takemura K, Boyne DJ, Warkentin MT, Brenner DR, Cheun WY, Wells JC, Labaki C et al. ( 2023 ) . 1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC) . Annals of Oncology vol. 34 , s1023 - s1024 .

Gruenwald V, McKay RR, Buchler T, Eto M, Park SH, Takagi T, Zanetta S, Keizman D et al. ( 2023 ) . 1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial . Annals of Oncology vol. 34 , s1024 - s1025 .

Szabados BE, Martinez EN, Marquez FJA, Gauna DEC, Rodriguez-Vida A, de Espana MCG, Hussain SA, Fernandez CA et al. ( 2023 ) . 2363MO A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2) . Annals of Oncology vol. 34 , s1201 - s1202 .

Gupta S, Duran MAC, Sridhar S, Powles TB, Bellmunt J, Tyroller K, Guenther S, di Pietro A et al. ( 2023 ) . 2371P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts) . Annals of Oncology vol. 34 ,

Mamtani R, Matsubara N, Pino AM, Herranz UA, Sendur MAN, Gravis G, Huillard O, Lee HJ et al. ( 2023 ) . 2373P Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361 . Annals of Oncology vol. 34 , s1208 - s1209 .

Grivas P, Sridhar S, Valderrama BP, Gauna DEC, Loriot Y, de Spéville BD, Pouessel D, van der Heijden MS et al. ( 2023 ) . 2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC) . Annals of Oncology vol. 34 , s1209 - s1210 .

Yang Y-H, Cubuk C, Gauna DEC, Banchereau R, Kockx M, Rodriguez-Vida A, Martinez ID, Crabb S et al. ( 2023 ) . 2393P Ephrin signalling mediates resistance to programmed death ligand 1 (PD-L1) inhibition in urothelial carcinoma (UC) . Annals of Oncology vol. 34 ,

Necchi A, Catto JWF, Powles TB, Guerrero-Ramos F, Simone G, Shore ND, Salinas J, Merseburger AS et al. ( 2023 ) . 2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guérin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC) . Annals of Oncology vol. 34 ,

Gupta S, Alhalabi O, Bamias A, Bellmunt J, Gauna DEC, Bedke J, Friedlander T, Garmezy B et al. ( 2023 ) . 2409TiP A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo) . Annals of Oncology vol. 34 ,

Powles TB, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C et al. ( 2023 ) . LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) . Annals of Oncology vol. 34 ,

van der Heijden MS, Sonpavde GP, Powles TB, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A et al. ( 2023 ) . LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial . Annals of Oncology vol. 34 ,

Albiges L, Rini BI, Peltola K, De Velasco Oria GA, Burotto M, Rodriguez CS, Ghatalia P, Iacovelli R et al. ( 2023 ) . LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study . Annals of Oncology vol. 34 , s1329 - s1330 .

Mellman I, Chen DS, Powles T, Turley SJ ( 2023 ) . The cancer-immunity cycle: Indication, genotype, and immunotype . Immunity vol. 56 , ( 10 ) 2188 - 2205 .

Sridhar SS, Powles T, Climent Durán MÁ, Park SH, Massari F, Thiery-Vuillemin A, Valderrama BP, Ullén A et al. ( 2023 ) . Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance . European Urology vol. 85 , ( 2 ) 154 - 163 .

Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee J-L, Matsubara N, Vulsteke C et al. ( 2023 ) . EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆ . Annals of Oncology . vol. 34 , 1047 - 1054 .

Hoffman-Censits J, Grivas P, Powles T, Hawley J, Tyroller K, Seeberger S, Guenther S, Jacob N et al. ( 2023 ) . The JAVELIN Bladder Medley Trial: Avelumab-Based Combinations as First-Line Maintenance in Advanced Urothelial Carcinoma . Future Oncology vol. 20 , ( 4 ) 179 - 190 .

Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F et al. ( 2023 ) . Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] . European Urology vol. 84 , ( 5 ) e123 - e124 .

Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C et al. ( 2023 ) . Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma) . Clinical Cancer Research vol. 29 , ( 21 ) 4373 - 4384 .

Choueiri TK, Tomczak P, Park H, Venugopal B, Symeonides S, Hajek J, Ferguson T, Chang Y-H et al. ( 2023 ) . Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma . The Oncologist vol. 29 , ( 2 ) 142 - 150 .

Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE et al. ( 2023 ) . Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms . Frontiers in Oncology vol. 13 ,

van de Putte EEF, van den Brink L, Mansour MA, van der Mijn JC, Wilgenhof S, van Thienen JV, Haanen JBAG, Boleti E et al. ( 2023 ) . Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease? . European Urology Open Science vol. 55 , 15 - 22 .

Powles T, Young A, Nimeiri H, Madison RW, Fine A, Zollinger DR, Huang Y, Xu C et al. ( 2023 ) . Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assay . Frontiers in Oncology vol. 13 ,

Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P et al. ( 2023 ) . Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma . European Urology vol. 85 , ( 2 ) 114 - 122 .

Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F et al. ( 2023 ) . Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study . European Urology vol. 84 , ( 5 ) 449 - 454 .

Jackson‐Spence F, Young M, Sweeney C, Powles T ( 2023 ) . Top advances of the year: Genitourinary cancer . Cancer vol. 129 , ( 17 ) 2603 - 2609 .

Choueiri TK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Procopio G et al. ( 2023 ) . Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study . Journal of Clinical Oncology vol. 41 , ( 17_suppl ) lba4500 - lba4500 .

Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F, Alekseev B et al. ( 2023 ) . Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426 . Journal of Clinical Oncology vol. 41 , ( 17_suppl ) lba4501 - lba4501 .

Filicevas A, Powles T ( 2023 ) . Patient and Healthcare Professional Perspectives from ESMO 2022 on Bladder and Kidney Cancer: A Podcast . Oncology and Therapy vol. 11 , ( 3 ) 277 - 289 .

Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A et al. ( 2023 ) . Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial . The Lancet vol. 402 , ( 10397 ) 185 - 195 .

Galsky MD, Wirtz HS, Bloudek B, Hepp Z, Farrar M, Timmons J, Lenero E, Powles T ( 2023 ) . Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy–Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling . Clinical Epidemiology vol. 15 , 765 - 773 .

Kamat AM, Lotan Y, Roupret M, Steinberg GD, Inman BA, Powles T, Redorta JP, Porten SP et al. ( 2023 ) . A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104) . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) 4596 - 4596 .

Albiges L, Beckermann K, Miller WH, Goh JC, Gajate P, Harris CA, Suárez C, Peer A et al. ( 2023 ) . Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) 4553 - 4553 .

Lemelin A, Takemura K, Ernst MS, Wells JC, Donskov F, Porta C, de Velasco G, Davis ID et al. ( 2023 ) . Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC) . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) 4538 - 4538 .

Siefker-Radtke AO, Powles T, Moreno V, Kang TW, Cicin I, Girvin A, Akapame S, Triantos S et al. ( 2023 ) . Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) 4504 - 4504 .

Powles T, Cislo P, Kirker M, Chang J, Gharibian N, Thompson A, Costa N, Grivas P ( 2023 ) . Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) 4515 - 4515 .

Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY et al. ( 2023 ) . Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) 4502 - 4502 .

Sternberg CN, Loriot Y, Choy E, Castellano D, Lopez-Rios Moreno F, Banna GL, De Giorgi U, Masini C et al. ( 2023 ) . Final results from SAUL, a single-arm international real-world study of atezolizumab (atezo) in 1004 patients (pts) with pretreated locally advanced/metastatic urinary tract carcinoma (UTC) . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) 4569 - 4569 .

Bergerot CD, Mercier BD, Castro DV, Bergerot PG, Toms C, Ali AA, Philip EJ, Lages DPS et al. ( 2023 ) . Health-related quality of life (HR-QOL) measures in renal cell carcinoma (RCC): Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30, and EQ-5D . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) 4540 - 4540 .

Jovaisaite A, Serrano M, Jackson-Spence F, Young M, Toms C, Wang Y, Nally E, Szabados B et al. ( 2023 ) . Immune-related adverse events after ≥12 months of starting immune checkpoint inhibitors . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) e24086 - e24086 .

Gebrael G, Saad E, Labaki C, Saliby RM, Sayegh N, Wells JC, Semaan K, Eid M et al. ( 2023 ) . Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) 4555 - 4555 .

Bellmunt J, Aragon-Ching JB, Climent MÁ, Sridhar SS, Powles T, Cislo P, Michelon E, Di Pietro A et al. ( 2023 ) . Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) 4516 - 4516 .

Tapia JC, Toms C, Wang Y, Jovaisaite A, Young MN, Jackson-Spence F, Powles T, Szabados B ( 2023 ) . Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) e16533 - e16533 .

Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M et al. ( 2023 ) . Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma . New England Journal of Medicine vol. 388 , ( 19 ) 1767 - 1778 .

Shastry M, Gupta A, Chandarlapaty S, Young M, Powles T, Hamilton E ( 2023 ) . Rise of Antibody-Drug Conjugates: The Present and Future . American Society of Clinical Oncology Educational Book vol. 43 , ( 43 )

Grivas P, Park SH, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A et al. ( 2023 ) . Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial . European Urology vol. 84 , ( 1 ) 95 - 108 .

Robertson AG, Meghani K, Cooley LF, McLaughlin KA, Fall LA, Yu Y, Castro MAA, Groeneveld CS et al. ( 2023 ) . Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer . Nature Communications vol. 14 , ( 1 )

Jackson-Spence F, Toms C, O'Mahony LF, Choy J, Flanders L, Szabados B, Powles T ( 2023 ) . IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery . Future Oncology vol. 19 , ( 7 ) 509 - 515 .

Powles T, Park H, Caserta C, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS et al. ( 2023 ) . Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up . Journal of Clinical Oncology vol. 41 , ( 19 ) 3486 - 3492 .

Sweeney C, Xu C, He J, Young A, Robertson A, Petry R, Zollinger D, Fine A et al. ( 2023 ) . Abstract 3362: Evaluation of circulating tumor DNA kinetics as a prognostic biomarker for overall survival in metastatic castrate resistant prostate cancer using a novel methylation sequencing research assay . Cancer Research vol. 83 , ( 7_Supplement ) 3362 - 3362 .

Valderrama B, Powles T, Sridhar S, Caserta C, Loriot Y, Gupta S, Bellmunt J, Sternberg C et al. ( 2023 ) . PD09-10 AVELUMAB FIRST-LINE (1L) MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA (UC): LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY RESPONSE TO 1L CHEMOTHERAPY . Journal of Urology vol. 209 , ( Supplement 4 )

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al. ( 2023 ) . Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial . Nature Medicine vol. 29 , ( 12 ) 3271 - 3271 .

Sherman E, Lee JL, Debruyne PR, Keam B, Shin SJ, Gramza A, Caro I, Amin R et al. ( 2023 ) . Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study . ESMO Open vol. 8 , ( 2 )

Bergerot CD, Malhotra J, Bergerot P, Philip EJ, Castro DV, Hsu J, de Andrade Mota AC, de Azeredo AC et al. ( 2023 ) . Patients’ Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 . The Oncologist vol. 28 , ( 6 ) 494 - 500 .

Vulsteke C, De Cocker L, de Liaño AG, Montesdeoca C, De Meulenaere A, Croes L, Delombaerde D, Szabados B et al. ( 2023 ) . First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients . Pharmaceuticals vol. 16 , ( 3 )

Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Méndez-Vidal MJ, Tjulandin S et al. ( 2023 ) . Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study . The Lancet Oncology vol. 24 , ( 3 ) 228 - 238 .

Choueiri TK, Tomczak P, Park H, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang Y-H et al. ( 2023 ) . Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) 679 - 679 .

Sridhar SS, Powles T, Gupta S, Climent MÁ, Aragon-Ching JB, Sternberg CN, Cislo P, Costa N et al. ( 2023 ) . Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) 508 - 508 .

Choueiri TK, Motzer RJ, Powles T, Burotto M, Apolo AB, Escudier B, Tomita Y, McDermott DF et al. ( 2023 ) . Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC) . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) 608 - 608 .

Albiges L, Powles T, Sharma A, Venugopal B, Bedke J, Dutailly P, Qvick B, Martin-Couce L et al. ( 2023 ) . CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) 606 - 606 .

Sweeney C, Graf R, Fabrizio D, Yuen K, Wongchenko MJ, Gupta P, Hegde P, Oxnard GR et al. ( 2023 ) . Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) lba249 - lba249 .

Jackson-Spence F, Ackerman C, Szabados B, Toms C, Jovaisaite A, Gunnell R, Suárez C, Larkin J et al. ( 2023 ) . DNA alterations in papillary renal cancer . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) 725 - 725 .

Burotto M, Powles T, Escudier B, Apolo AB, Bourlon MT, Shah AY, Suárez C, Porta C et al. ( 2023 ) . Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) 603 - 603 .

Powles T, Motzer RJ, Albiges L, Suárez C, Schutz FAB, Heng DYC, Chevreau C, Kanesvaran R et al. ( 2023 ) . Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) 605 - 605 .

Takemura K, Lemelin A, Ernst MS, Wells C, Basappa NS, Szabados B, Powles T, Davis ID et al. ( 2023 ) . Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) 600 - 600 .

Powles T, Yu EY, Iyer G, Campbell MT, Loriot Y, De Santis M, O'Donnell PH, Burgess EF et al. ( 2023 ) . Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001) . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) tps594 - tps594 .

Choueiri TK, Bedke J, Karam JA, McKay RR, Motzer RJ, Pal SM, Suárez C, Uzzo R et al. ( 2023 ) . Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC) . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) tps748 - tps748 .

Suárez C, Larkin JMG, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2023 ) . Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO) . Journal of Clinical Oncology vol. 41 , ( 14 ) 2493 - 2502 .

Kamat AM, Steinberg GD, Inman BA, Kates MR, Uchio EM, Porten SP, Roupret M, Redorta J et al. ( 2023 ) . Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) tps582 - tps582 .

Psutka SP, Cutie C, Bhanvadia SK, Keegan KA, Crist W, Tian SK, Maffeo J, Raybold B et al. ( 2023 ) . SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) tps584 - tps584 .

Powles T, Necchi A, Duran I, Loriot Y, Ramamurthy C, Recio-Boiles A, Sweis RF, Bedke J et al. ( 2023 ) . TROPHU-U-01 cohort 5: Evaluation of maintenance sacituzumab govitecan (SG) plus zimberelimab (ZIM), ZIM, or avelumab in cisplatin-eligible patients (pts) with unresectable or metastatic urothelial cancer (mUC) . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) tps598 - tps598 .

Duran I, Necchi A, Powles T, Loriot Y, Ramamurthy C, Recio-Boiles A, Sweis RF, Bedke J et al. ( 2023 ) . TROPHY-U-01 cohort 6: Sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO) + gemcitabine (GEM) in cisplatin-ineligible patients (pts) with treatment-naive metastatic urothelial cancer (mUC) . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) tps592 - tps592 .

Brown JE, Royle K-L, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P et al. ( 2023 ) . Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial . The Lancet Oncology vol. 24 , ( 3 ) 213 - 227 .

Yang Y-H, Ansel S, Meerveld-Eggink A, Jackson-Spence F, Rallis K, Brian P, Choy J, Sng C et al. ( 2023 ) . Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study . Clinical Genitourinary Cancer vol. 21 , ( 4 ) e242 - e251 .

Vogl UM, McDermott D, Powles T ( 2023 ) . Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers . The Lancet vol. 401 , ( 10379 ) 796 - 798 .

Takemura K, Ernst M, Navani V, Wells JC, Bakouny Z, Donskov F, Basappa NS, Wood LA et al. ( 2023 ) . A0326 Characterization of patients with metastatic renal cell carcinoma treated with or without cytoreductive nephrectomy in the era of combination immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) . European Urology vol. 83 , s473 - s474 .

van de Putte EEF, Van Den Brink L, Mansour M, Van Der Mijn JC, Wilgenhof S, Van Thienen JV, Haanen JBA, Boleti E et al. ( 2023 ) . A0327 Deferred cytoreductive nephrectomy following response to ipilimumab/nivolumab, is there potential for a treatment-free interval? . European Urology vol. 83 , s475 - s476 .

Grünwald V, Powles T, Kopyltsov E, Kozlov V, Alonso-Gordoa T, Eto M, Hutson T, Motzer R et al. ( 2023 ) . Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study . European Urology Oncology vol. 6 , ( 4 ) 437 - 446 .

Davies CR, Guo T, Burke E, Stankiewicz E, Xu L, Mao X, Scandura G, Rajan P et al. ( 2023 ) . The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer . Frontiers in Oncology vol. 12 ,

Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, Liu L-F, Li Y et al. ( 2023 ) . CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy . Cell Reports Medicine vol. 4 , ( 1 )

Chhaya S, Watts I, Ng K, Mustapha R, Powles T, Sharma A, Vasdev N ( 2023 ) . Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer . Oncology and Therapy vol. 11 , ( 1 ) 49 - 64 .

Powles T, Burgents JE, Xu L, Choueiri TK, Investigators K ( 2023 ) . Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma – Authors' reply . The Lancet Oncology vol. 24 , ( 1 ) e1 - e2 .

Larkin J, Oya M, Martignoni M, Thistlethwaite F, Nathan P, Ornstein MC, Powles T, Beckermann KE et al. ( 2022 ) . Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial . The Oncologist vol. 28 , ( 4 ) 333 - 340 .

Takemura K, Navani V, Ernst MS, Wells JC, Meza L, Pal SK, Lee J-L, Li H et al. ( 2022 ) . Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium . Journal of Urology vol. 209 , ( 4 ) 701 - 709 .

Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F et al. ( 2022 ) . Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma . Journal for ImmunoTherapy of Cancer vol. 10 , ( 12 )

Capitanio U, Bedke J, Albiges L, Volpe A, Giles RH, Hora M, Marconi L, Klatte T et al. ( 2022 ) . Reply to Yaxiong Tang, Xu Hu, Kan Wu, Yanxiang Shao, and Xiang Li’s Letter to the Editor re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2022;83:3–5 . European Urology vol. 83 , ( 3 ) e74 - e75 .

Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee J-L et al. ( 2022 ) . Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up ☆ . Annals of Oncology vol. 34 , ( 3 ) 289 - 299 .

Brownsword J, Scott A, Noble A, Powles TB, Harrington KJ ( 2022 ) . 242P Educational needs of healthcare professionals using immune checkpoint inhibitors across multiple tumour types: A cross-speciality survey . Immuno-Oncology Technology vol. 16 ,

Luke JJ, Long GV, Robert C, Carlino MS, Choueiri TK, Haas NB, O'Brien MER, Paz-Ares L et al. ( 2022 ) . 76P Safety profile of adjuvant pembrolizumab (pembro) in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC): Pooled analysis of phase III clinical trials . Immuno-Oncology Technology vol. 16 ,

Hora M, Albiges L, Bedke J, Campi R, Capitanio U, Giles RH, Ljungberg B, Marconi L et al. ( 2022 ) . European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist’s Point of View . European Urology vol. 83 , ( 2 ) 97 - 100 .

Galsky M, O’Donnell P, Burgess E, Heijden MVD, Krieger L, Necchi A, Yu E, Matsubara N et al. ( 2022 ) . 663 Phase 2 multi-cohort clinical study evaluating disitamab vedotin alone and in combination with pembrolizumab in patients with HER2-expressing unresectable or metastatic urothelial carcinoma (RC48G001, trial in progress) . Conference: Regular and Young Investigator Award Abstractsa693 - a693 .

Hoffman-Censits J, Grivas P, Powles T, Martincic D, Hawley J, Tyroller K, Seeberger S, Guenther S et al. ( 2022 ) . 665 JAVELIN Bladder Medley: a phase 2 trial of avelumab in combination with other antitumor drugs as first-line maintenance therapy for advanced urothelial carcinoma . Conference: Regular and Young Investigator Award Abstractsa695 - a695 .

Powles T, Bupathi M, Joshi M, Fleming M, De Liano AG, Morales-Barrera R, Vuky J, Pili R et al. ( 2022 ) . LP166 VOLGA: Results from the phase 3 safety run-in with durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) . European Urology Open Science vol. 45 , s268 - s269 .

Voss MH, Powles T, Mcgregor B, Porta C, Grünwald V, Merchan JR, Rolland F, Maroto-Rey P et al. ( 2022 ) . P113 Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN+PEMBRO) or sunitinib (SUN) in the CLEAR study . European Urology Open Science vol. 45 , s197 - s198 .

Powles T, Assaf ZJ, Mariathasan S, Hussain M, Oudard S, Albers P, Castellano D, Nishiyama H et al. ( 2022 ) . P124 IMvigor010: Updated analysis of Overall Survival (OS) by circulating tumour DNA (ctDNA) status in patients with post-operative Muscle-Invasive Urothelial Carcinoma (MIUC) treated with atezolizumab . European Urology Open Science vol. 45 , s216 - s217 .

Jackson-Spence FE, Powles T, Loriot Y, Toms C, Jovaisaite A, Choy J, Szabados BE, Nudds H et al. ( 2022 ) . P126 Trial In Progress: DISCUS: A randomized phase II study comparing 3 vs. 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer . European Urology Open Science vol. 45 ,

Jackson-Spence FE, O’Mahony LF, Toms C, Flanders L, Hockings H, Choy J, Szabados BE, Powles T ( 2022 ) . P159 Outcomes of patients with metastatic urothelial cancer who have received previous first line therapy . European Urology Open Science vol. 45 ,

Loo Gan C, Huang J, Pan E, Xie W, Schmidt AL, Labaki C, Meza L, Bouchard G et al. ( 2022 ) . Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium . European Urology Oncology vol. 6 , ( 2 ) 204 - 211 .

Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Ljungberg B, Marconi L, Klatte T et al. ( 2022 ) . The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma . European Urology vol. 83 , ( 1 ) 10 - 14 .

Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK et al. ( 2022 ) . Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma . JAMA Oncology vol. 8 , ( 10 ) 1411 - 1418 .

Capitanio U, Bedke J, Albiges L, Volpe A, Giles RH, Hora M, Marconi L, Klatte T et al. ( 2022 ) . A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel . European Urology vol. 83 , ( 1 ) 3 - 5 .

Apolo AB, Powles T, Escudier B, Burotto M, Zhang J, Simsek B, Scheffold C, Motzer RJ et al. ( 2022 ) . Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial . European Journal of Cancer vol. 177 , 63 - 71 .

Choueiri TK, Porta C, Suárez C, Hainsworth J, Voog E, Duran I, Reeves J, Czaykowski P et al. ( 2022 ) . Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy . The Oncologist vol. 27 , ( 12 ) 1048 - 1057 .

Matsubara N, Yonese J, Kojima T, Azuma H, Matsumoto H, Powles T, Rosenberg JE, Petrylak DP et al. ( 2022 ) . Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma . Cancer Medicine vol. 12 , ( 3 ) 2761 - 2771 .

Takemura K, Navani V, Ernst MS, Wells JC, Choueiri TK, Meza L, Pal SK, Lee J-L et al. ( 2022 ) . 1455P Characterization of patients with metastatic renal cell carcinoma achieving complete response to first-line therapies: Results from the international metastatic renal cell carcinoma database consortium (IMDC) . Annals of Oncology vol. 33 , s1209 - s1210 .

Navani V, Ernst MS, Takemura K, Pal SK, Powles TB, Donskov F, Wells JC, Kollmannsberger CK et al. ( 2022 ) . 1464P The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC) . Annals of Oncology vol. 33 , s1215 - s1216 .

Jurascheck L, Yang Y-H, Jackson-Spence F, Toms C, Sng CC, Flanders L, Powles TB, Szabados BE ( 2022 ) . 1467P Optimal neoadjuvant treatment choice for localised renal cell carcinoma . Annals of Oncology vol. 33 ,

Loriot Y, Csoszi T, Matsubara N, Shin SJ, Park SH, Atduev V, Gumus M, Karaca BB et al. ( 2022 ) . 1752P Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011 . Annals of Oncology vol. 33 ,

Aragon-Ching JB, Grivas P, Loriot Y, Bellmunt J, Wang J, Michelon E, di Pietro A, Powles TB et al. ( 2022 ) . 1760P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100 . Annals of Oncology vol. 33 ,

O'Mahony LFF, Jackson-Spence F, Toms C, Flanders L, Hockings HA, Choy J, Powles TB, Szabados BE ( 2022 ) . 1767P Outcomes after first line therapy in metastatic bladder and upper tract cancer . Annals of Oncology vol. 33 ,

Szabados BE, Stockem CF, Gauna DEC, de Liano Lista AG, Cardenas MR, Valderrama BP, Powles TB, van der Heijden MS ( 2022 ) . 1768P Clinical outcomes with platinum-based chemotherapy after progression on frontline immunotherapy in metastatic urothelial cancer (mUC) . Annals of Oncology vol. 33 ,

Crabb SJ, Dempsey L, Soulis E, Hinsley S, Song YP, Barber J, Frew J, Gale J et al. ( 2022 ) . 1772P Characterisation of a DNA repair deficiency (DRD) biomarker phenotype in metastatic urothelial carcinoma (mUC) within the ATLANTIS clinical trial platform . Annals of Oncology . vol. 33 ,

Koshkin VS, Powles TB, Iyer G, Loriot Y, Drakaki A, Martinez ID, De Santis M, Retz M et al. ( 2022 ) . 1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001) . Annals of Oncology . vol. 33 ,

Powles TB, Sridhar S, Bellmunt J, Sternberg C, Grivas P, Hunter E, Dezfouli M, Salter M et al. ( 2022 ) . LBA74 Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC) . Annals of Oncology vol. 33 ,

Choueiri TK, Powles TB, Albiges L, Burotto M, Szczylik C, Zurawski B, Riuz EY, Maruzzo M et al. ( 2022 ) . LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313) . Annals of Oncology vol. 33 , s1430 - s1431 .

Powles T, Tomczak P, Park H, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H et al. ( 2022 ) . Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial . The Lancet Oncology vol. 23 , ( 9 ) 1133 - 1144 .

Crabb SJ, Hussain S, Soulis E, Hinsley S, Dempsey L, Trevethan A, Song Y, Barber J et al. ( 2022 ) . A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma . Journal of Clinical Oncology vol. 41 , ( 1 ) 54 - 64 .

Bex A, Graafland N, Meerveld-Eggink A, Wilgenhof S, Van Thienen J, Lalezari F, Grant M, Szabados B et al. ( 2022 ) . 10 Real-World data of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place . European Urology Open Science vol. 42 ,

Szabados B, Ponz-Sarvisé M, Machado R, Saldana D, Kadel EE, Banchereau R, Bouquet F, Garmhausen M et al. ( 2022 ) . Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI) . Clinical Cancer Research vol. 28 , ( 18 ) 4083 - 4091 .

Navani V, Wells JC, Boyne DJ, Cheung WY, Brenner DM, McGregor BA, Labaki C, Schmidt AL et al. ( 2022 ) . CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) . Clinical Genitourinary Cancer vol. 21 , ( 1 ) 106.e1 - 106.e8 .

Bedke J, Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F et al. ( 2022 ) . Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma . European Urology vol. 82 , ( 4 ) 427 - 439 .

Stewart GD, Welsh SJ, Ursprung S, Gallagher FA, Jones JO, Shields J, Smith CG, Mitchell TJ et al. ( 2022 ) . A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA) . British Journal of Cancer vol. 127 , ( 6 ) 1051 - 1060 .

Dinneen E, Shaw GL, Kealy R, Alexandris P, Finnegan K, Chu K, Haidar N, Santos‐Vidal S et al. ( 2022 ) . Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing . BJUI Compass vol. 3 , ( 6 ) 458 - 465 .

Jones RJ, Hussain SA, Birtle AJ, Song YP, Enting D, Faust G, Hilman S, Jagdev S et al. ( 2022 ) . A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison . Journal of Clinical Oncology vol. 40 , ( 17_suppl ) lba4505 - lba4505 .

Powles T, Mendez-Vidal MJ, Rodriguez-Vida A, Pérez-Valderrama B, Esteban E, Thistlethwaite F, Patel PM, Anido Herranz U et al. ( 2022 ) . CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer . Journal of Clinical Oncology vol. 40 , ( 17_suppl ) lba4503 - lba4503 .

Navani V, Ernst M, Wells JC, Yuasa T, Takemura K, Donskov F, Basappa NS, Schmidt A et al. ( 2022 ) . Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma . JAMA Network Open vol. 5 , ( 6 )

Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A et al. ( 2022 ) . Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial . The Lancet Oncology vol. 23 , ( 7 ) 888 - 898 .

Shore ND, Powles T, Bedke J, Galsky MD, Kopyltsov E, Necchi A, Palou J, Vermette JJ et al. ( 2022 ) . A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin, unresponsiv,e high-risk, non-muscle invasive bladder cancer: CREST Study Cohort B . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) tps4614 - tps4614 .

Jackson-Spence FE, Toms C, Yang Y-H, Walshaw L, Caldwell L, Riddell A, Cutino-Moguel M-T, Szabados B et al. ( 2022 ) . A0389 The effect of anti-cancer therapy on immunological response to COVID-19 vaccination . European Urology vol. 81 ,

Choueiri TK, Tomczak P, Park H, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang Y-H et al. ( 2022 ) . Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564 . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 4512 - 4512 .

Suárez C, Choueiri TK, Burotto M, Powles T, Bourlon MT, Shah AY, Tomita Y, Bedke J et al. ( 2022 ) . Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 4501 - 4501 .

Pérez-Valderrama B, Powles T, Sridhar SS, Caserta C, Loriot Y, Gupta S, Bellmunt J, Sternberg CN et al. ( 2022 ) . Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 4559 - 4559 .

Galsky MD, Wirtz H, Bloudek B, Hepp Z, Timmons J, Lenero E, Powles T ( 2022 ) . Benchmarking maintenance therapy survival in first-line advanced urothelial carcinoma using disease modeling . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 4575 - 4575 .

Pal SK, Agarwal N, Singh P, Necchi A, McGregor BA, Hauke RJ, Powles T, Suárez C et al. ( 2022 ) . Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 4504 - 4504 .

Saliby RM, Jammihal T, Labaki C, Xie W, Motzer RJ, Powles T, Rini BI, Albiges L et al. ( 2022 ) . Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 4531 - 4531 .

Morales-Barrera R, Castellano DE, O'Donnell PH, Grivas P, Vuky J, Powles T, Potvin KR, Cheng SY et al. ( 2022 ) . Health-related quality of life (HRQoL) for patients with advanced/metastatic urothelial carcinoma (UC) enrolled in KEYNOTE-052 who are potentially platinum ineligible . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 4561 - 4561 .

Hodi FS, Spigel DR, De Andrea CE, Sanmamed MF, Garralda E, Tabernero J, Gomez-Roca CA, Szabados B et al. ( 2022 ) . Identifying mechanisms of acquired immune escape from sequential, paired biopsies . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 2519 - 2519 .

Voss MH, Powles T, McGregor BA, Porta C, Grünwald V, Merchan JR, Rolland F, Maroto-Rey P et al. ( 2022 ) . Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 4514 - 4514 .

Choueiri TK, Bedke J, Karam JA, McKay RR, Motzer RJ, Pal SK, Suárez C, Uzzo R et al. ( 2022 ) . LITESPARK-022: A phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC) . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) tps4602 - tps4602 .

Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee J-L, Matsubara N, Vulsteke C et al. ( 2022 ) . Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 4516 - 4516 .

Bellmunt J, Powles T, Duran MAC, Sridhar SS, Gurney H, Costa N, Di Pietro A, Huang B et al. ( 2022 ) . Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN Bladder 100 . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 4560 - 4560 .

Powles T, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, Nosov D, Melichar B et al. ( 2022 ) . Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426 . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) 4513 - 4513 .

Choueiri TK, Xu W, Poole L, Telaranta-Keerie A, Hartmaier R, Powles T ( 2022 ) . SAMETA: An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC) . Journal of Clinical Oncology vol. 40 , ( 16_suppl ) tps4601 - tps4601 .

Grivas P, Kopyltsov E, Su P-J, Parnis FX, Park SH, Yamamoto Y, Fong PC, Tournigand C et al. ( 2022 ) . Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma . European Urology vol. 83 , ( 4 ) 320 - 328 .

Szabados B, Kockx M, Assaf ZJ, van Dam P-J, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS et al. ( 2022 ) . Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder . European Urology vol. 82 , ( 2 ) 212 - 222 .

Szabados B, Duncan S, Choy J, Jackson-Spence F, Toms C, Trevisan G, Berney DM, Powles T et al. ( 2022 ) . Androgen Receptor Expression Is a Predictor of Poor Outcome in Urothelial Carcinoma . Frontiers in Urology vol. 2 ,

Grivas P, Bellmunt J, Park H, Voog E, Caserta C, Valderrama BP, Gurney H, Loriot Y et al. ( 2022 ) . PD10-02 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM FOLLOW-UP RESULTS FROM THE JAVELIN BLADDER 100 TRIAL . Journal of Urology vol. 207 , ( Supplement 5 )

Taneja SS ( 2022 ) . Urological Oncology: Prostate Cancer . Journal of Urology vol. 208 , ( 1 ) 214 - 216 .

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S et al. ( 2022 ) . Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer . Future Oncology vol. 18 , ( 19 ) 2361 - 2371 .

Hussain SA, Lester JF, Jackson R, Gornall M, Qureshi M, Elliott A, Crabb SJ, Huddart RA et al. ( 2022 ) . Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial . The Lancet Oncology vol. 23 , ( 5 ) 650 - 658 .

van der Heijden MS, Powles T, Petrylak D, de Wit R, Necchi A, Sternberg CN, Matsubara N, Nishiyama H et al. ( 2022 ) . Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial . Nature Communications vol. 13 , ( 1 )

Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER et al. ( 2022 ) . Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma . Cancer vol. 128 , ( 11 ) 2085 - 2097 .

Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, Fernández-Pello S, Giles RH et al. ( 2022 ) . European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update . European Urology vol. 82 , ( 4 ) 399 - 410 .

Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano Y-A, Gupta S, Yao J, Han C et al. ( 2022 ) . Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma . Journal for ImmunoTherapy of Cancer vol. 10 , ( 3 )

Kasi PM, Fehringer G, Taniguchi H, Starling N, Nakamura Y, Kotani D, Powles T, Li BT et al. ( 2022 ) . Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors . JCO Precision Oncology vol. 6 , ( 6 )

Choueiri TK, Albiges L, Atkins MB, Bakouny Z, Bratslavsky G, Braun DA, Haas NB, Haanen JBAG et al. ( 2022 ) . From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit . Clinical Cancer Research vol. 28 , ( 5 ) 831 - 839 .

Filicevas A, Powles TB ( 2022 ) . Patient and Healthcare Professional Perspectives from ESMO 2021 on Bladder and Kidney Cancer: A Podcast . Oncology and Therapy vol. 10 , ( 1 ) 1 - 11 .

Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee J-L, Fong L, Necchi A et al. ( 2022 ) . Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials . Clinical Cancer Research vol. 28 , ( 10 ) 2050 - 2060 .

Yang Y-H, Meerveld-Eggink A, Bex A, Jackson-Spence F, Rallis KS, Brian PR, Choy J, Sng CC et al. ( 2022 ) . 18P Baseline and dynamic changes in haemoglobin levels predict treatment response and disease progression in metastatic renal cell carcinoma . Annals of Oncology vol. 33 ,

Powles T, Drakaki A, Teoh JY-C, Grande E, Fontes-Sousa M, Porta C, Wu E, Goluboff ET et al. ( 2022 ) . A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA) . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) tps579 - tps579 .

Crabb SJ, Hussain SA, Soulis E, Hinsley S, Dempsey L, Trevethan A, Song YP, Barber J et al. ( 2022 ) . A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm . Journal of Clinical Oncology . vol. 40 , 436 - 436 .

Morales-Barrera R, Powles T, Ozguroglu M, Csoszi T, Loriot Y, Flechon A, Matsubara N, Rodriguez-Vida A et al. ( 2022 ) . Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro + chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361 . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 540 - 540 .

Powles T, Park H, Voog E, Caserta C, Pérez-Valderrama B, Gurney H, Loriot Y, Sridhar SS et al. ( 2022 ) . Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 487 - 487 .

Navani V, Wells C, Boyne DJ, Cheung WY, Brenner D, McGregor BA, Labaki C, Schmidt AL et al. ( 2022 ) . CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 318 - 318 .

Szabados B, Ponz-Sarvise M, Machado R, Saldana D, Kadel EE, Banchereau R, Bouquet F, Powles T et al. ( 2022 ) . Clinico-genomic characterization of patients with metastatic urothelial carcinoma in real-world practice and development of a novel bladder immune prognostic index (BIPI) . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 548 - 548 .

Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F et al. ( 2022 ) . Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 352 - 352 .

Bex A, Abu-Ghanem Y, Van Thienen JV, Graafland N, Lagerveld B, Zondervan P, Beerlage H, van Moorselaar J et al. ( 2022 ) . Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx) . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 289 - 289 .

Powles T, Choueiri TK, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A et al. ( 2022 ) . Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 350 - 350 .

Csoszi T, Powles T, Alva AS, Castellano DE, Ozguroglu M, O'Donnell PH, Loriot Y, Hahn NM et al. ( 2022 ) . First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 521 - 521 .

O'Donnell PH, Balar AV, Castellano DE, De Wit R, Vaughn DJ, Powles T, Vuky J, Lee J-L et al. ( 2022 ) . Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 516 - 516 .

Young A, Nimeiri H, Madison R, Fine AD, Zollinger D, Gjoerup O, Aushev VN, Wu H-T et al. ( 2022 ) . Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring assay: An exploratory analysis of the IMvigor-010 observation arm . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 448 - 448 .

Choueiri TK, Tomczak P, Park H, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang Y-H et al. ( 2022 ) . Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564 . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 290 - 290 .

Choueiri TK, Plimack ER, Powles T, Voss MH, Gurney H, Silverman RK, Perini RF, Rodriguez-Lopez K et al. ( 2022 ) . Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) tps399 - tps399 .

Castellano DE, Balar AV, O'Donnell PH, Grivas P, Vaughn DJ, Powles T, Vuky J, Lee J-L et al. ( 2022 ) . Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052 . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 512 - 512 .

Powles T, Alva AS, Ozguroglu M, O'Donnell PH, Loriot Y, Csoszi T, Vuky J, Morales-Barrera R et al. ( 2022 ) . Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361 . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 519 - 519 .

Van Der Heijden MS, Gupta S, Galsky MD, Derleth CL, Lee S, Kataria RS, Powles T ( 2022 ) . Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress) . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) tps589 - tps589 .

Jackson-Spence F, Toms C, Yang Y-H, Walshaw L, Riddell A, Cutino-Moguel M-T, Szabados B, Propper D et al. ( 2022 ) . The effect of anti-cancer therapy on immunological response to COVID-19 vaccination . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 319 - 319 .

Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Alekseev BY, Lee J-L, Suarez C et al. ( 2022 ) . Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma . JAMA Oncology vol. 8 , ( 2 ) 275 - 280 .

Martini A, Raggi D, Fallara G, Nocera L, Schultz JG, Belladelli F, Marandino L, Salonia A et al. ( 2022 ) . Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis . Cancer Treatment Reviews vol. 104 ,

de Wit R, Powles T, Castellano D, Necchi A, Lee J, van der Heijden MS, Matsubara N, Bamias A et al. ( 2022 ) . Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy . British Journal of Clinical Pharmacology vol. 88 , ( 7 ) 3182 - 3192 .

Kamat AM, Steinberg G, Inman B, Kates M, Uchio E, Porten S, Rouperet M, Palou J et al. ( 2022 ) . A0328 Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) (Trial in Progress) . European Urology vol. 81 ,

Martini A, Raggi D, Fallara G, Nocera L, Belladelli F, Marandino L, Salonia A, Briganti A et al. ( 2022 ) . A0907 Immuno- versus chemo-therapy as first line treatment for advanced urothelial cancer: A systematic review and meta-analysis . European Urology vol. 81 , s1337 - s1338 .

Jackson-Spence F, Szabados B, Toms C, Yang Y-H, Sng C, Powles T ( 2022 ) . Avelumab in locally advanced or metastatic urothelial carcinoma . Expert Review of Anticancer Therapy vol. 22 , ( 2 ) 135 - 140 .

Oldenburg J, Berney DM, Bokemeyer C, Climent MA, Daugaard G, Gietema JA, De Giorgi U, Haugnes HS et al. ( 2022 ) . Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up ☆ . Annals of Oncology vol. 33 , ( 4 ) 362 - 375 .

Sonpavde GP, Sternberg CN, Loriot Y, Marabelle A, Lee JL, Fléchon A, Roubaud G, Pouessel D et al. ( 2022 ) . Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma . European Journal of Cancer vol. 163 , 55 - 65 .

Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkopf D, Matsubara N, Drake CG, Fizazi K et al. ( 2022 ) . Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial . Nature Medicine vol. 28 , ( 1 ) 144 - 153 .

Meerveld-Eggink A, Graafland N, Wilgenhof S, Van Thienen JV, Lalezari F, Grant M, Szabados B, Abu-Ghanem Y et al. ( 2022 ) . Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment . European Urology Open Science vol. 35 , 54 - 58 .

Tomita Y, Yamamoto Y, Tsuchiya N, Kanayama H, Eto M, Miyake H, Powles T, Yoshida M et al. ( 2022 ) . Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis . International Journal of Clinical Oncology vol. 27 , ( 2 ) 383 - 395 .

Jackson-Spence F, Toms C, Yang Y-H, Jurascheck L, Choy J, Flanders L, Szabados B, Powles T ( 2022 ) . The role of modern immunotherapy in metastatic urothelial cancer: mini review . Journal of Cancer Metastasis and Treatment vol. 8 , ( 0 ) null - null .

Graafland NM, Szabados B, Tanabalan C, Kuusk T, Mumtaz F, Barod R, Nicol D, Boleti E et al. ( 2021 ) . Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor–based Dual Combination Therapy . European Urology Oncology vol. 5 , ( 3 ) 373 - 374 .

Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB, Ljungberg B, Marconi L et al. ( 2021 ) . 2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma . European Urology vol. 81 , ( 2 ) 134 - 137 .

Powles T, Sridhar SS, Loriot Y, Bellmunt J, Mu XJ, Ching KA, Pu J, Sternberg CN et al. ( 2021 ) . Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial . Nature Medicine vol. 27 , ( 12 ) 2200 - 2211 .

Kanesvaran R, Porta C, Wong A, Powles T, Ng QS, Schmidinger M, Ye D, Malhotra H et al. ( 2021 ) . Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma . ESMO Open vol. 6 , ( 6 )

Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP et al. ( 2021 ) . Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆ . Annals of Oncology vol. 33 , ( 3 ) 244 - 258 .

Abu‐Ghanem Y, van Thienen JV, Blank C, Aarts MJB, Jewett M, de Jong IJ, Lattouf J, van Melick HHE et al. ( 2021 ) . Cytoreductive nephrectomy and exposure to sunitinib – a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial . BJU International vol. 130 , ( 1 ) 68 - 75 .

Sharma A, Sahoo RK, Batra A ( 2021 ) . Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma . New England Journal of Medicine vol. 385 , ( 20 ) 1919 - 1920 .

Choueiri T, Plimack E, Powles T, Voss M, Gurney H, Silverman R, Perini R, Rodriguez-Lopez K et al. ( 2021 ) . 417 Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma . Conference: Regular and Young Investigator Award Abstractsa447 - a447 .

Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee C-H et al. ( 2021 ) . Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial . Clinical Cancer Research vol. 27 , ( 24 ) 6687 - 6695 .

Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T et al. ( 2021 ) . First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial . European Urology vol. 81 , ( 3 ) 266 - 271 .

Escudier B, Porta C, Burotto M, Suarez C, Bourlon M, Hsieh J, Shah A, Hamzaj A et al. ( 2021 ) . Nivolumab + Cabozantinib (N+C) vs Sunitinib (S) en première ligne (1L) de traitement chez des patients atteints d’un carcinome rénal avancé (ACCR) dans l’essai de phase III checkmate 9ER : analyse en sous-groupes basée sur l’absence ou présence de néphrectomie antérieure . The French Journal of Urology vol. 31 , ( 13 )

Loriot Y, Vuillet M, Mamtani R, Rosenberg J, Powles T, Sonpavde G, Duran I, Lee J et al. ( 2021 ) . Qualité de vie et symptômes chez les patients atteints d’un carcinome urothélial localement avancé ou métastatique précédemment traité de l’étude Ev-301 : une étude randomisée de phase 3 comparant enfortumab vedotin à la chimiothérapie . The French Journal of Urology vol. 31 , ( 13 ) 813 - 814 .

Escudier B, Tannir N, Mcdermott D, Burotto M, Choueiri T, Hammers H, Plimack E, Porta C et al. ( 2021 ) . Survie conditionnelle et suivi à 5 ans dans l’étude checkmate 214 : Nivolumab+Ipilimumab (N+I) versus Sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (ACCR) . The French Journal of Urology vol. 31 , ( 13 )

Szabados B, Powles T ( 2021 ) . Urological Anti-cancer Agents . Basic Urological Sciences , Taylor & Francis

Venugopal B, Pillai M, Powles T, Savage P, Michael A, Fife K, Klair B, Perrot V et al. ( 2021 ) . Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes . Clinical Genitourinary Cancer vol. 20 , ( 1 ) 94 - 94.e10 .

Powles T, Albiges L, Bex A, Grünwald V, Porta C, Procopio G, Schmidinger M, Suárez C et al. ( 2021 ) . ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma . Annals of Oncology vol. 32 , ( 12 ) 1511 - 1519 .

Meade A, Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T et al. ( 2021 ) . RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting . Contemporary Clinical Trials vol. 108 ,

Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T, Stewart GD et al. ( 2021 ) . RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse . Contemporary Clinical Trials vol. 108 ,

Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R et al. ( 2021 ) . Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma . BMC Cancer vol. 21 , ( 1 )

Powles T, Petrylak DP, Rosenberg JE ( 2021 ) . Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma . Journal of Clinical Oncology vol. 39 , ( 30 ) 3411 - 3412 .

Choueiri TK, Tomczak P, Park SH, Venugopal B, Symeonides S, Hajek J, Ferguson T, Chang Y-H et al. ( 2021 ) . 653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564 . Annals of Oncology vol. 32 , s679 - s680 .

Choueiri TK, Eto M, Kopyltsov E, Rha SY, Porta CG, Motzer R, Grünwald V, Hutson TE et al. ( 2021 ) . 660P Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update . Annals of Oncology vol. 32 , s683 - s685 .

Motzer RJ, Tannir NM, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Plimack ER, Porta CG et al. ( 2021 ) . 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) . Annals of Oncology vol. 32 , s685 - s687 .

Porta CG, Burotto M, Rodriguez CS, Bourlon MT, Hsieh J, Shah AY, Hamzaj A, Bedke J et al. ( 2021 ) . 663P First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial . Annals of Oncology vol. 32 , s688 - s689 .

Gafanov R, Powles TB, Bedke J, Stus V, Waddell TS, Nosov D, Pouliot F, Soulieres D et al. ( 2021 ) . 669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study . Annals of Oncology vol. 32 ,

Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C et al. ( 2021 ) . 698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma . Annals of Oncology vol. 32 , s710 - s711 .

Bellmunt J, Powles TB, van der Heijden MS, Galsky MD, He P, Wang Z, Xiao F, Jones F et al. ( 2021 ) . 708P PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D+T) versus standard of care chemotherapy (SoC) . Annals of Oncology vol. 32 , s716 - s717 .

Powles TB, Gschwend JE, Bracarda S, Castellano D, Gross-Goupil M, Jensen JB, Kann A, Nishiyama H et al. ( 2021 ) . 716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy . Annals of Oncology vol. 32 ,

Rini BI, Plimack ER, Powles TB, Voss MH, Gurney HP, Silverman R, Perini R, Rodriguez-Lopez K et al. ( 2021 ) . 717TiP Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC) . Annals of Oncology vol. 32 , s722 - s723 .

Powles TB, Chistyakov V, Beliakouski V, Semenov A, Everaert E, Baranau Y, Moreno V, Valderrama BP et al. ( 2021 ) . LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study . Annals of Oncology vol. 32 ,

Brown JE, Royle K-L, Ralph C, Meads D, Martin A, Howard H, Linsley C, Swain J et al. ( 2021 ) . LBA28 STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC) . Annals of Oncology . vol. 32 , s1303 - s1304 .

Vasudev NS, Ainsworth G, Brown S, Pickering L, Waddell TS, Fife K, Griffiths R, Sharma A et al. ( 2021 ) . LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM) . Annals of Oncology . vol. 32 , s1304 - s1305 .

Grivas P, Park H, Voog E, Kopyltsov E, Gurney H, Muniz DQB, Rolland F, Als AB et al. ( 2021 ) . MP41-12 AVELUMAB FIRST-LINE MAINTENANCE PLUS BEST SUPPORTIVE CARE VS BEST SUPPORTIVE CARE ALONE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF TIME TO END OF NEXT-LINE THERAPY IN JAVELIN BLADDER 100 . Journal of Urology vol. 206 , ( Supplement 3 ) e765 - e765 .

Powles T, Petrylak DP, Park H, Sridhar SS, Caserta C, Thiery-Vuillemin A, Lee HJ, Bellmunt J et al. ( 2021 ) . MP41-13 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF CLINICAL AND GENOMIC SUBGROUPS FROM THE JAVELIN BLADDER 100 TRIAL . Journal of Urology vol. 206 , ( Supplement 3 ) e765 - e766 .

Sridhar SS, Powles T, Loriot Y, Durán MAC, Gupta S, Tsuchiya N, Bamias A, Ardizzoni A et al. ( 2021 ) . PD55-01 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA IN THE JAVELIN BLADDER 100 TRIAL: SUBGROUP ANALYSIS BY DURATION OF TREATMENT-FREE INTERVAL FROM END OF CHEMOTHERAPY TO START OF MAINTENANCE . Journal of Urology vol. 206 , ( Supplement 3 ) e997 - e997 .

Choueiri T, Tomczak P, Park H, Venugopal B, Ferguson T, Chang Y-H, Hajek J, Symeonides SN et al. ( 2021 ) . PLLBA-01 PEMBROLIZUMAB (PEMBRO) VS PLACEBO AS POST NEPHRECTOMY ADJUVANT THERAPY FOR PATIENTS (pts) WITH RENAL CELL CARCINOMA (RCC): RANDOMIZED, DOUBLE-BLIND, PHASE 3 KEYNOTE-564 STUDY . Journal of Urology vol. 206 , ( Supplement 3 ) e1181 - e1181 .

Crusz SM, Hall PE, Earwicker K, Dexter S, Patel-Walker G, Powles T, Diamantis N ( 2021 ) . Providing an acute oncology service during the COVID-19 pandemic . Clinical Medicine vol. 21 , ( 5 ) e548 - e551 .

Butters T, Liu WK, Grant M, Jackson-Spence F, Zaynub G, So A, Lam J, Ashfar M et al. ( 2021 ) . What do Emergency Physicians Know About Immune Checkpoint Inhibitor-Related Toxicities: A Brief Report . International Journal of Cancer Management vol. 14 , ( 8 )

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y-H, Hajek J, Symeonides SN et al. ( 2021 ) . Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma . New England Journal of Medicine vol. 385 , ( 8 ) 683 - 694 .

Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R et al. ( 2021 ) . Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma . BMC Cancer . vol. 21 ,

Rini BI, Atkins MB, Plimack ER, Soulières D, McDermott RS, Bedke J, Tartas S, Alekseev B et al. ( 2021 ) . Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial . European Urology Oncology vol. 5 , ( 2 ) 225 - 234 .

Grant M, Hockings H, Lapuente M, Adeniran P, Saud RA, Sivajothi A, Amin J, Crusz SM et al. ( 2021 ) . Learning from Crisis: a Multicentre Study of Oncology Telemedicine Clinics Introduced During COVID-19 . Journal of Cancer Education vol. 37 , ( 6 ) 1861 - 1869 .

Rini BI, Atkins MB, Escudier B, Powles T, McDermott DF, Alekseev BY, Lee J-L, Stroyakovskiy D et al. ( 2021 ) . Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) . Cancer Research vol. 81 , ( 13_Supplement ) ct188 - ct188 .

Yeon SH, Lee HJ ( 2021 ) . Enfortumab Vedotin in Advanced Urothelial Carcinoma . New England Journal of Medicine vol. 385 , ( 1 ) 93 - 94 .

Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, Maund S, Liu L-F et al. ( 2021 ) . Molecular determinants of response to PD-L1 blockade across tumor types . Nature Communications vol. 12 , ( 1 )

Choueiri TK, Tomczak P, Park H, Venugopal B, Ferguson T, Chang Y-H, Hajek J, Symeonides SN et al. ( 2021 ) . Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study . Journal of Clinical Oncology vol. 39 , ( 18_suppl ) lba5 - lba5 .

Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M et al. ( 2021 ) . ctDNA guiding adjuvant immunotherapy in urothelial carcinoma . Nature vol. 595 , ( 7867 ) 432 - 437 .

Mori K, Pradere B, Quhal F, Katayama S, Mostafaei H, Laukhtina E, Schuettfort VM, D'Andrea D et al. ( 2021 ) . Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis . Cancer Treatment Reviews vol. 99 ,

Parikh M, Powles T ( 2021 ) . Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management . American Society of Clinical Oncology Educational Book vol. 41 , ( 41 ) e182 - e189 .

Jackson-Spence FE, Ackerman C, Khan M, Grant M, Soosaipillai G, Nally E, Choy J, Powles TB et al. ( 2021 ) . P0461 The role of angiogenic signatures in advanced urothelial carcinoma (aUC) treated with VEGF-targeted therapy . European Urology vol. 79 ,

Choy J, Szabados B, Abu-Ghanem Y, Powles T, Wimalasingham A, Bex A ( 2021 ) . P0644 Optimizing patient selection for deferred cytoreductive nephrectomy in the contemporary era of targeted therapy . European Urology vol. 79 ,

Graafland NM, Szabados B, Mumtaz F, Barod R, Nicol D, Tanabalan C, Boleti E, Powles T et al. ( 2021 ) . P0649 Surgical safety of Cytoreductive Nephrectomy (CN) following pretreatment with Immune Checkpoint Inhibition (ICI) combination therapy in primary metastatic clear-cell Renal Carcinoma (mccRCC) . European Urology vol. 79 ,

Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Motlagh RS, Soria F et al. ( 2021 ) . P0833 First-line treatments for cisplatin-eligible patients with metastatic urothelial carcinoma: A meta-analysis . European Urology vol. 79 , s1161 - s1163 .

Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB, Ljungberg B, Marconi L et al. ( 2021 ) . The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor–based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care . European Urology vol. 80 , ( 4 ) 393 - 397 .

Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY-S, Fradet Y, Oudard S et al. ( 2021 ) . Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial . The Lancet Oncology vol. 22 , ( 7 ) 931 - 945 .

Kuusk T, Cullen D, Neves JB, Campain N, Barod R, Boleti E, El‐Sheihk S, Grant L et al. ( 2021 ) . Impact of the first surge of the COVID‐19 pandemic on a tertiary referral centre for kidney cancer . BJU International vol. 128 , ( 6 ) 752 - 758 .

Grünwald V, Powles T, Kopyltsov E, Kozlov V, Gordoa TA, Eto M, Hutson TE, Motzer RJ et al. ( 2021 ) . Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4560 - 4560 .

Sridhar SS, Powles T, Loriot Y, Durán MAC, Gupta S, Tsuchiya N, Bamias A, Ardizzoni A et al. ( 2021 ) . Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4527 - 4527 .

Powles T, Petrylak DP, Park H, Sridhar SS, Caserta C, Vuillemin AT, Lee HJ, Bellmunt J et al. ( 2021 ) . Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4520 - 4520 .

Grivas P, Park H, Voog E, Kopyltsov E, Gurney H, Muniz DQB, Rolland F, Als AB et al. ( 2021 ) . Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100 . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4525 - 4525 .

Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer RJ, Lee RJ, Jain RK, Davis NB et al. ( 2021 ) . CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies . Journal of Clinical Oncology . vol. 39 , 4501 - 4501 .

Shah AY, Motzer RJ, Apolo AB, Powles T, Escudier B, Zhang J, Scheffold C, Karumanchi S et al. ( 2021 ) . Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4561 - 4561 .

de Vries-Brilland M, McDermott DF, Suárez C, Powles T, Gross-Goupil M, Ravaud A, Flippot R, Escudier B et al. ( 2021 ) . Checkpoint inhibitors in metastatic papillary renal cell carcinoma . Cancer Treatment Reviews vol. 99 ,

Rodriguez CS, Larkin J, Patel PM, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2021 ) . Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4511 - 4511 .

Bex A, Abu-Ghanem Y, Van Thienen JV, Graafland N, Lagerveld B, Zondervan P, Beerlage H, van Moorselaar J et al. ( 2021 ) . Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4573 - 4573 .

O'Donnell PH, Balar AV, Vuky J, Castellano D, Bellmunt J, Powles T, Bajorin DF, Grivas P et al. ( 2021 ) . First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4508 - 4508 .

Choueiri TK, Donahue AC, Rini BI, Powles T, Haanen JBAG, Larkin J, Mu XJ, Pu J et al. ( 2021 ) . Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4547 - 4547 .

Apolo AB, Powles T, Burotto M, Bourlon MT, Hsieh JJ, Basso U, Shah AY, Suarez C et al. ( 2021 ) . Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4553 - 4553 .

Gan CL, Wells JC, Schmidt AL, Powles T, Tran B, Meza LA, Labaki C, Lee J-L et al. ( 2021 ) . Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4554 - 4554 .

Khan MA, Szabados B, Choy J, Jackson-Spence F, Powles T, Castellano D, Valderrama BP ( 2021 ) . Patient outcomes following disease progression with enfortumab-vedotin (EV) in metastatic urothelial carcinoma (mUC) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) e16516 - e16516 .

Rini BI, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, Nosov D, Melichar B et al. ( 2021 ) . Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426 . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4500 - 4500 .

Hutson TE, Choueiri TK, Motzer RJ, Rha SY, Alyasova A, Merchan JR, Gurney H, Peer A et al. ( 2021 ) . Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4562 - 4562 .

Mamtani R, Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee J-L, Matsubara N et al. ( 2021 ) . Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4539 - 4539 .

Perez-Gracia JL, Hansen AR, Eefsen RHL, Gomez-Roca CA, Negrier S, Pedrazzoli P, Lee J-L, Gordoa TA et al. ( 2021 ) . Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4556 - 4556 .

Rallis KS, Kleeman SO, Grant M, Ordidge KL, Sahdev A, Powles T ( 2021 ) . Radiomics for Renal Cell Carcinoma: Predicting Outcomes from Immunotherapy and Targeted Therapies—A Narrative Review . European Urology Focus vol. 7 , ( 4 ) 717 - 721 .

Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Motlagh RS, Soria F et al. ( 2021 ) . First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis . European Journal of Cancer vol. 151 , 35 - 48 .

Powles T, Carroll D, Chowdhury S, Gravis G, Joly F, Carles J, Fléchon A, Maroto P et al. ( 2021 ) . An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer . Nature Medicine vol. 27 , ( 5 ) 793 - 801 .

Abu‐Ghanem Y, Powles T, Capitanio U, Beisland C, Järvinen P, Stewart GD, Gudmundsson E, Lam TBL et al. ( 2021 ) . Should patients with low‐risk renal cell carcinoma be followed differently after nephron‐sparing surgery vs radical nephrectomy? . BJU International vol. 128 , ( 3 ) 386 - 394 .

van der Heijden MS, Loriot Y, Durán I, Ravaud A, Retz M, Vogelzang NJ, Nelson B, Wang J et al. ( 2021 ) . Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial . European Urology . vol. 80 , 7 - 11 .

Merseburger AS, Castellano D, Powles T, Loriot Y, Retz M, Voortman J, Huddart RA, Gedye C et al. ( 2021 ) . Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice . Journal of Urology vol. 206 , ( 2 ) 240 - 251 .

Banchereau R, Chitre AS, Scherl A, Wu TD, Patil NS, de Almeida P, Kadel IEE, Madireddi S et al. ( 2021 ) . Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade . Journal for ImmunoTherapy of Cancer vol. 9 , ( 4 )

Szabados B, Prendergast A, Jackson-Spence F, Choy J, Powles T ( 2021 ) . Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer . European Urology Oncology vol. 4 , ( 6 ) 943 - 947 .

Wells JC, Dudani S, Gan CL, Stukalin I, Azad AA, Liow E, Donskov F, Yuasa T et al. ( 2021 ) . Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study . Clinical Genitourinary Cancer vol. 19 , ( 4 ) 354 - 361 .

Kuusk T, Abu-Ghanem Y, Mumtaz F, Powles T, Bex A ( 2021 ) . Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy . Current Opinion in Urology vol. 31 , ( 3 ) 262 - 269 .

Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H et al. ( 2021 ) . Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial . The Lancet Oncology vol. 22 , ( 4 ) 525 - 537 .

Powles T, Atkins MB, Escudier B, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK et al. ( 2021 ) . Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial . European Urology vol. 79 , ( 5 ) 665 - 673 .

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ et al. ( 2021 ) . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma . New England Journal of Medicine vol. 384 , ( 9 ) 829 - 841 .

Araujo DV, Wells JC, Hansen AR, Dizman N, Pal SK, Beuselinck B, Donskov F, Gan CL et al. ( 2021 ) . Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis . Journal of Geriatric Oncology . vol. 12 , 820 - 826 .

Powles T, Csőszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY, Fradet Y, Oudard S et al. ( 2021 ) . 1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361 . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 450 - 450 .

Powles T, Meeks JJ, Galsky MD, Van Der Heijden MS, Nishiyama H, Al-Ahmadie HA, Goluboff ET, Hois S et al. ( 2021 ) . A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA) . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) tps505 - tps505 .

Sonpavde G, Marabelle A, Loriot Y, Sternberg CN, Lee J-L, Flechon A, Roubaud G, Pouessel D et al. ( 2021 ) . An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A) . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 429 - 429 .

Ozguroglu M, Alva AS, Csőszi T, Matsubara N, Geczi L, Cheng SY, Fradet Y, Oudard S et al. ( 2021 ) . Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC) . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 448 - 448 .

Tsuchiya N, Yamamoto Y, Uemura H, Kanayama H-O, Eto M, Miyake H, Powles T, Yoshida M et al. ( 2021 ) . Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 425 - 425 .

Loriot Y, Powles T, Climent Durán MÁ, Sridhar SS, Bellmunt J, Petrylak DP, Wang J, Costa NM et al. ( 2021 ) . Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 438 - 438 .

Alva AS, Csőszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY, Fradet Y, Oudard S et al. ( 2021 ) . Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC) . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 439 - 439 .

Choueiri TK, Albiges L, Fan L, Perini RF, Vickery D, Powles T, Rini BI ( 2021 ) . MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) tps368 - tps368 .

Motzer RJ, Choueiri TK, Powles T, Burotto M, Bourlon MT, Hsieh JJ, Maruzzo M, Shah AY et al. ( 2021 ) . Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 308 - 308 .

Plimack ER, Powles T, Bedke J, Pouliot F, Stus V, Waddell T, Gafanov R, Nosov D et al. ( 2021 ) . Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 327 - 327 .

Tannir NM, Motzer RJ, Albiges L, Plimack ER, George S, Powles T, Donskov F, Rini BI et al. ( 2021 ) . Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214 . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 313 - 313 .

Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY et al. ( 2021 ) . Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study) . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 269 - 269 .

Loriot Y, Alva AS, Csőszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY, Fradet Y et al. ( 2021 ) . Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361 . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 435 - 435 .

Powles T, Rosenberg JE, Sonpavde G, Loriot Y, Duran I, Lee J-L, Matsubara N, Vulsteke C et al. ( 2021 ) . Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 393 - 393 .

Birtle AJ, Chester JD, Jones RJ, Jenkins B, Johnson M, Catto JW, Powles T, Bryan RT et al. ( 2021 ) . Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC) . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 455 - 455 .

Szabados B, Rodriguez-Vida A, Durán I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA et al. ( 2021 ) . Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial . European Urology Oncology vol. 4 , ( 3 ) 456 - 463 .

Regan JT, Mirczuk SM, Scudder CJ, Stacey E, Khan S, Worwood M, Powles T, Dennis-Beron JS et al. ( 2021 ) . Sensitivity of the Natriuretic Peptide/cGMP System to Hyperammonaemia in Rat C6 Glioma Cells and GPNT Brain Endothelial Cells . Cells vol. 10 , ( 2 )

Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T, Grünwald V, Hutson TE et al. ( 2021 ) . Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma . New England Journal of Medicine vol. 384 , ( 14 ) 1289 - 1300 .

Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee J-L, Matsubara N, Vulsteke C et al. ( 2021 ) . Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma . New England Journal of Medicine vol. 384 , ( 12 ) 1125 - 1135 .

Petrylak DP, Loriot Y, Shaffer DR, Braiteh F, Powderly J, Harshman LC, Conkling P, Delord J-P et al. ( 2021 ) . Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyAtezolizumab in Castration-Resistant Prostate Cancer . Clinical Cancer Research vol. 27 , ( 12 ) 3360 - 3369 .

Yuen KC, Liu L-F, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P et al. ( 2021 ) . Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade . Nature Medicine vol. 27 , ( 3 ) 560 - 560 .

Huang J, Leung DK-W, Chan EO-T, Lok V, Leung S, Wong I, Lao X-Q, Zheng Z-J et al. ( 2021 ) . A Global Trend Analysis of Kidney Cancer Incidence and Mortality and Their Associations with Smoking, Alcohol Consumption, and Metabolic Syndrome . European Urology Focus vol. 8 , ( 1 ) 200 - 209 .

Guo T, Wang Y, Jia J, Mao X, Stankiewicz E, Scandura G, Burke E, Xu L et al. ( 2021 ) . The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing . Frontiers in Cell and Developmental Biology vol. 8 ,

Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon J-C, Ficial M et al. ( 2021 ) . Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma . Clinical Cancer Research vol. 27 , ( 1 ) 78 - 86 .

Pook D, Sridhar S, Powles T, Loriot Y, Duran CM, Gupta S, Tsuchiya N, Bamias A et al. ( 2021 ) . Avelumab first-line maintenance for advanced urothelial carcinoma in the phase 3 JAVELIN Bladder 100 trial: subgroup analysis by duration of treatment-free interval from end of chemotherapy to start of maintenance . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 17 , 43 - 44 .

Lumba S, Powles T, Petrylak DP, Park SH, Sridhar SS, Caserta C, Thiery-Vuillemin A, Lee HJ et al. ( 2021 ) . Avelumab first-line maintenance for advanced urothelial carcinoma: analysis of clinical and genomic subgroups from the phase 3 JAVELIN Bladder 100 trial . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 17 , 44 - 45 .

Lumba S, Grivas P, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H et al. ( 2021 ) . Avelumab first-line maintenance plus best supportive care vs best supportive care alone for advanced urothelial carcinoma not progressed with first-line chemotherapy: Prespecified subgroup analyses from JAVELIN Bladder 100 . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 17 , 126 - 126 .

Powles T, Loriot Y, Duran MAC, Sridhar S, Bellmunt J, Petrylak DP, Wang J, Costa N et al. ( 2021 ) . Avelumab first-line maintenance plus best supportive care vs best supportive care alone for advanced urothelial carcinoma: JAVELIN Bladder 100 subgroup analysis based on duration and cycles of first-line chemotherapy . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 17 , 132 - 133 .

Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Sari MR, Soria F et al. ( 2021 ) . First-line treatments for cisplatin-eligible patients with metastatic urothelial carcinoma: A meta-analysis . EUROPEAN UROLOGY . vol. 79 , S1161 - S1163 .

Pook D, Powles T, Burotto M, Bourlon MT, Hsieh JJ, Basso U, Shah AY, Suarez C et al. ( 2021 ) . Nivolumab plus cabozantinib (N plus C) vs sunitinib for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 17 , 131 - 131 .

Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB, Ljungberg B, Marconi L et al. ( 2020 ) . Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma . European Urology vol. 79 , ( 3 ) 339 - 342 .

Mollica V, Rizzo A, Massari F ( 2020 ) . Avelumab Maintenance for Urothelial Carcinoma . New England Journal of Medicine vol. 383 , ( 25 )

Wildsmith S, Walker J, L’Hernault A, Li W, Bye H, He P, Xiao F, Zhang Q et al. ( 2020 ) . 266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC) . Journal for ImmunoTherapy of Cancer vol. 8 , ( Suppl 3 ) a163 - a164 .

Powles TB, van der Heijden MS, Balar AV, O'Donnell P, Massard C, Walker J, Gupta A, Angra N et al. ( 2020 ) . 13P PD-L1 prevalence in advanced urothelial carcinoma by demographic and clinical characteristics . Annals of Oncology vol. 31 , s1421 - s1422 .

Powles TB, Assaf ZJ, Davarpanah N, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D et al. ( 2020 ) . 1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy . Annals of Oncology vol. 31 ,

Choy J, Rodriguez CS, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F et al. ( 2020 ) . 69P Outcomes with durvalumab and savolitinib in metastatic papillary renal cancer (mPRC) according to international metastatic renal cell carcinoma database consortium (IMDC) risk groups . Annals of Oncology vol. 31 ,

Powles T, Szabados B, Castellano D, Rodriguez-Vida A, Valderrama B, Crabb S, Van Der Heijden M, Pous A et al. ( 2020 ) . CtDNA as a predictor of outcome in patients treated with neoadjuvant atezolizumab in muscle invasive urothelial cancer . Urologic Oncology Seminars and Original Investigations vol. 38 , ( 12 )

Grünwald V, Voss MH, Rini BI, Powles T, Albiges L, Giles RH, Jonasch E ( 2020 ) . Axitinib plus Immuncheckpoint-Inhibitor: evidenz- und expertenbasierte Konsensusempfehlungen für die Behandlungsoptimierung und das Management von therapieassoziierten Nebenwirkungen . Kompass Onkologie vol. 7 , ( 4 ) 180 - 189 .

Powles T, Committee EG ( 2020 ) . Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 1 . Annals of Oncology vol. 32 , ( 3 ) 422 - 423 .

Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T et al. ( 2020 ) . Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial . ESMO Open vol. 5 , ( 6 )

Wood CG, Ferguson JE, Parker JS, Moore DT, Whisenant JG, Maygarden SJ, Wallen EM, Kim WY et al. ( 2020 ) . Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma . JCI Insight vol. 5 , ( 22 )

Rini B, Abel EJ, Albiges L, Bex A, Brugarolas J, Bukowski RM, Coleman JA, Drake CG et al. ( 2020 ) . Summary from the Kidney Cancer Association’s Inaugural Think Thank: Coalition for a Cure . Clinical Genitourinary Cancer vol. 19 , ( 2 ) 167 - 175 .

Choueiri T, Albiges L, Powles T, Mohamed N, Wang F, Motzer R ( 2020 ) . 342 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk . Conference: Regular and young investigator award abstractsa209.1 - a2a209 .

Rouanne M, Bajorin DF, Hannan R, Galsky MD, Williams SB, Necchi A, Sharma P, Powles T ( 2020 ) . Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder . European Urology Oncology vol. 3 , ( 6 ) 728 - 738 .

Necchi A, Nishiyama H, Matsubara N, Lee J-L, Petrylak DP, de Wit R, Drakaki A, Liepa AM et al. ( 2020 ) . Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE) . BMC Urology vol. 20 , ( 1 )

Bedke J, Merseburger AS, Loriot Y, Castellano D, Choy E, Duran I, Rosenberg JE, Petrylak DP et al. ( 2020 ) . Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma . European Urology Focus vol. 7 , ( 5 ) 1084 - 1091 .

Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu L-F et al. ( 2020 ) . Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade . Cancer Cell vol. 38 , ( 6 ) 803 - 817.e4 .

van Dijk N, Gómez de Liaño Lista A, Szabados B, Powles T, van der Heijden MS ( 2020 ) . Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al’s Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation . European Urology vol. 79 , ( 1 ) e20 - e21 .

Szabados BE, Rodriguez-Vida A, Duran I, Crabb SJ, van der Heijden MS, Pous AF, Gravis G, Herranz UA et al. ( 2020 ) . 199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis . Annals of Oncology vol. 31 ,

Kondoh CN, Bae WK, Tamada S, Matsubara N, Lee HJ, Mizuno R, Ani S, Kimura G et al. ( 2020 ) . 200O Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia . Annals of Oncology vol. 31 ,

Albiges L, Tannir N, Burotto M, Mcdermott D, Plimack E, Barthélémy P, Porta C, Powles T et al. ( 2020 ) . Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés . The French Journal of Urology vol. 30 , ( 13 ) 785 - 786 .

Szabados B, Michael A, Powles T, Fife K, Klair B, Perrot V, Venugopal B ( 2020 ) . P070 CERES, a retrospective study of patients with advanced renal cell carcinoma who received cabozantinib as part of the UK Managed Access Program: Baseline characteristics and clinical outcomes . European Urology Open Science vol. 21 , s190 - s191 .

Abu-Ghanem Y, Powles T, Capitanio U, Beisland C, Järvinen P, Stewart GD, Gudmundsson EO, Lam TB et al. ( 2020 ) . The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery—Results from RECUR Consortium . European Urology Oncology vol. 4 , ( 3 ) 473 - 482 .

Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F et al. ( 2020 ) . Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial . The Lancet Oncology vol. 21 , ( 12 ) 1563 - 1573 .

Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J ( 2020 ) . Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol 2021;79:655–6 . European Urology vol. 79 , ( 5 ) 657 - 658 .

Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park H et al. ( 2020 ) . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial . The Lancet Oncology vol. 21 , ( 12 ) 1574 - 1588 .

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S et al. ( 2020 ) . Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma . New England Journal of Medicine vol. 383 , ( 13 ) 1218 - 1230 .

Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF et al. ( 2020 ) . PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer . Future Oncology vol. 17 , ( 2 ) 137 - 149 .

Wei XX, Werner L, Teo MY, Rosenberg JE, Koshkin VS, Grivas P, Szabados B, Morrison L et al. ( 2020 ) . Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma . Journal of Urology vol. 205 , ( 2 ) 414 - 419 .

Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, Mu XJ, Ching KA et al. ( 2020 ) . Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial . Nature Medicine vol. 26 , ( 11 ) 1733 - 1741 .

Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK et al. ( 2020 ) . The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future . European Urology vol. 78 , ( 5 ) 731 - 742 .

Powles TB, Oudard S, Grünwald V, Calvo E, Michaelson MD, Burotto M, Melichar B, Tyagi R et al. ( 2020 ) . A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment . Annals of Oncology vol. 31 ,

Powles TB, van der Heijden MS, Gauna DC, Loriot Y, Galsky MD, Petrylak DP, Ogawa O, Park SH et al. ( 2020 ) . A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) . Annals of Oncology vol. 31 , s550 - s551 .

Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee J-L, Fong L, Necchi A et al. ( 2020 ) . Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052 . Annals of Oncology vol. 31 , s580 - s581 .

Powles TB, Loriot Y, Bellmunt J, Sternberg CN, Sridhar S, Petrylak DP, Tambaro R, Dourthe LM et al. ( 2020 ) . Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers . Annals of Oncology vol. 31 , s552 - s553 .

Grivas P, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S et al. ( 2020 ) . Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100 . Annals of Oncology vol. 31 , s555 - s556 .

Mckean M, Bendell JC, Petrylak DP, Powles TB, Sonpavde GP, Dickson A, Dosunmu L, Hennessy MG et al. ( 2020 ) . BT8009-100 phase I/II study of the safety, pharmacokinetics, & preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced malignancies . Annals of Oncology vol. 31 , s500 - s501 .

Choueiri TK, Powles T, Burotto M, Bourlon MT, Zurawski B, Juárez VMO, Hsieh JJ, Basso U et al. ( 2020 ) . Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial . Annals of Oncology vol. 31 ,

Albiges L, Tannir N, Burotto M, McDermott DF, Plimack ER, Barthélémy P, Porta CG, Powles TB et al. ( 2020 ) . Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy . Annals of Oncology vol. 31 , s559 - s560 .

Powles TB, Kopyltsov E, Su P-J, Parnis FX, Park SH, Yamamoto Y, Fong PC, Tournigand C et al. ( 2020 ) . Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC) . Annals of Oncology vol. 31 , s578 - s579 .

Alva A, Csőszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY-S, Fradet Y, Oudard S et al. ( 2020 ) . Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 . Annals of Oncology vol. 31 ,

Steinberg GD, Saltstein D, Shore N, Cesari R, Vermette J, Pierce K, Blake-Haskins JA, Hariharan S et al. ( 2020 ) . Phase III study of the programmed cell death protein 1 inhibitor PF-06801591 plus bacillus Calmette-Guérin for non-muscle invasive bladder cancer . Annals of Oncology . vol. 31 ,

van der Heijden MS, Gupta S, Galsky MD, Derleth C, Steinberg J, Kataria R, Powles TB ( 2020 ) . Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer . Annals of Oncology vol. 31 , s605 - s606 .

Meerveld-Eggink A, Graafland N, Wilgenhof S, van Thienen JV, Grant M, Szabados BE, Abu-Ghanem Y, Boleti E et al. ( 2020 ) . Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place . Annals of Oncology vol. 31 ,

Regan M, Jegede OA, Mantia C, Powles T, Werner L, Huo S, Del Tejo V, Stwalley B et al. ( 2020 ) . Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214 . Annals of Oncology vol. 31 ,

Lee LYW, Cazier J-B, Starkey T, Briggs SEW, Arnold R, Bisht V, Booth S, Campton NA et al. ( 2020 ) . COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study . The Lancet Oncology vol. 21 , ( 10 ) 1309 - 1316 .

Sweeney CJ, Gillessen S, Rathkopf D, Matsubara N, Drake C, Fizazi K, Piulats JM, Wysocki PJ et al. ( 2020 ) . Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) . Cancer Research . vol. 80 , ct014 - ct014 .

Lopez JS, Camidge R, Iafolla M, Rottey S, Schuler M, Hellmann M, Balmanoukian A, Dirix L et al. ( 2020 ) . Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors . Cancer Research . vol. 80 , ct301 - ct301 .

Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J ( 2020 ) . Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy . European Urology vol. 79 , ( 5 ) 635 - 654 .

Petrylak D, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Bertrandt AM et al. ( 2020 ) . Abstract B26: EV-301: A phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy . Clinical Cancer Research vol. 26 , ( 15_Supplement ) b26 - b26 .

Motzer RJ, Escudier B, McDermott DF, Frontera OA, Melichar B, Powles T, Donskov F, Plimack ER et al. ( 2020 ) . Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial . Journal for ImmunoTherapy of Cancer vol. 8 , ( 2 )

Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK et al. ( 2020 ) . Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival . Urologic Oncology Seminars and Original Investigations vol. 38 , ( 12 ) 934.e1 - 934.e9 .

Rini BI, Motzer RJ, Powles T, McDermott DF, Escudier B, Donskov F, Hawkins R, Bracarda S et al. ( 2020 ) . Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial . European Urology vol. 79 , ( 5 ) 659 - 662 .

Wells JC, Dudani S, Gan CL, Stukalin I, Azad A, Liow E, Donskov F, Yuasa T et al. ( 2020 ) . 721 Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma . European Urology Open Science vol. 19 , e1105 - e1106 .

Abu-Ghanem Y, Van Thienen H, Blank C, Powles T, Collette L, Tombal B, Haanen J, Bex A ( 2020 ) . 835 Variations in the exposure to sunitinib with immediate and deferred cytoreductive nephrectomy (CN). A post-hoc analysis of the randomized controlled EORTC SURTIME trial . European Urology Open Science vol. 19 ,

Abu-Ghanem Y, Fernández-Pello S, Bex A, Ljungberg B, Albiges L, Dabestani S, Giles R, Hofmann F et al. ( 2020 ) . PT065 Bias of available data makes it unreliable to compare outcomes of thermo-ablation versus surgery for the treatment of T1 renal tumours: A systematic review from the European Association of Urology Renal Cell Cancer Guideline Panel . European Urology Open Science vol. 19 ,

Montes SF-P, Kuusk T, Hora M, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles R et al. ( 2020 ) . PT074 Management of sporadic renal angiomyolipomas. A systematic review of available evidence to guide recommendations from the EAU RCC Guidelines panel . European Urology Open Science vol. 19 , e1809 - e1810 .

Grünwald V, Voss MH, Rini BI, Powles T, Albiges L, Giles RH, Jonasch E ( 2020 ) . Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events . British Journal of Cancer vol. 123 , ( 6 ) 898 - 904 .

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S et al. ( 2020 ) . Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis . Journal of Clinical Oncology vol. 38 , ( 18_suppl ) lba1 - lba1 .

Sonpavde G, Manitz J, Gao C, Tayama D, Kaiser C, Hennessy D, Makari D, Gupta A et al. ( 2020 ) . Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors . Journal of Urology vol. 204 , ( 6 ) 1173 - 1179 .

Vuky J, Balar AV, Castellano D, O'Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin D et al. ( 2020 ) . Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer . Journal of Clinical Oncology vol. 38 , ( 23 ) 2658 - 2666 .

Atkins MB, Rini BI, Motzer RJ, Powles T, McDermott DF, Suarez C, Bracarda S, Stadler WM et al. ( 2020 ) . Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma . Clinical Cancer Research vol. 26 , ( 11 ) 2506 - 2514 .

Lee LY, Cazier J-B, Angelis V, Arnold R, Bisht V, Campton NA, Chackathayil J, Cheng VW et al. ( 2020 ) . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study . The Lancet vol. 395 , ( 10241 ) 1919 - 1926 .

Szabados B, Abu-Ghanem Y, Grant M, Choy J, Bex A, Powles T ( 2020 ) . Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors . European Urology vol. 78 , ( 2 ) 276 - 280 .

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N et al. ( 2020 ) . Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250] . European Urology vol. 78 , ( 1 ) e48 - e50 .

Pillai M, Powles T, Szabados B, Savage P, Fife K, Klair B, Perrot V, Michael A et al. ( 2020 ) . A non-interventional retrospective study to describe early clinical experience with cabozantinib in patients with advanced renal cell carcinoma (aRCC) in the United Kingdom . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) e17089 - e17089 .

Choueiri TK, Albiges L, Powles T, Scheffold C, Wang F, Motzer RJ ( 2020 ) . A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) tps5102 - tps5102 .

Dudani S, Gan CL, Wells C, Bakouny Z, Dizman N, Pal SK, Wood L, Kollmannsberger CK et al. ( 2020 ) . Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5063 - 5063 .

Motzer RJ, Choueiri TK, McDermott DF, Powles T, Yao J, Ammar R, Papillon-Cavanagh S, Saggi SS et al. ( 2020 ) . Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC) . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5009 - 5009 .

Kleeman SO, Grant M, Rallis KS, Wozniak A, So A, Tejpaul R, Heller N, Weight CJ et al. ( 2020 ) . CT-based radiomic classifier of primary renal tumors to distinguish between metastatic and non-metastatic disease . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5074 - 5074 .

Bellmunt J, Powles T, Henriksson R, Steinberg GD, Batyrbekova N, Schain F, Fleming S, Shalaby W et al. ( 2020 ) . Clinical outcomes and economic burden for bladder cancer patients: An analysis from a Swedish cancer registry . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5026 - 5026 .

Abu Ghanem Y, Choy J, Jackson-Spence F, Jovaisaite A, Grant M, Bex A, Powles T, Szabados B ( 2020 ) . Dynamic changes in full blood count (FBC) occurring in patients treated with immune checkpoint inhibitors (ICIs) to predict responses in patients with metastatic renal cell carcinoma (mRCC) . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) e17110 - e17110 .

Araujo DV, Wells C, Hansen AR, Dizman N, Pal SK, Beuselinck B, Donskov F, Gan CL et al. ( 2020 ) . Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5068 - 5068 .

Hussain MHA, Powles T, Albers P, Castellano D, Daneshmand S, Gschwend J, Nishiyama H, Oudard S et al. ( 2020 ) . IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC) . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5000 - 5000 .

Retz M, Seseke F, Banna GL, De Giorgi U, Powles T, Basso U, McDermott RS, Llado A et al. ( 2020 ) . Impact of renal impairment on clinical outcomes in patients (pts) with locally advanced or metastatic (LA/M) urinary tract carcinoma (UTC) treated with atezolizumab (atezo): Analysis of the international SAUL study . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5036 - 5036 .

Plimack ER, Rini BI, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F, Soulieres D et al. ( 2020 ) . Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426 . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5001 - 5001 .

Choueiri TK, Albiges L, Fan L, Perini RF, Zojwalla NJ, Powles T, Rini BI ( 2020 ) . Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC) . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) tps5094 - tps5094 .

Meerveld-Eggink A, Graafland N, Wilgenhof S, Van Thienen JV, Grant M, Szabados B, Abu-Ghanem Y, Boleti E et al. ( 2020 ) . Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) e17083 - e17083 .

Khan Z, Di Nucci F, Kwan A, Hammer C, Mariathasan S, Rouilly V, Carroll J, Fontes M et al. ( 2020 ) . Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer . Proceedings of the National Academy of Sciences of the United States of America vol. 117 , ( 22 ) 12288 - 12294 .

Grivas P, Plimack ER, Balar AV, Castellano D, O’Donnell PH, Bellmunt J, Powles T, Hahn NM et al. ( 2020 ) . Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status . European Urology Oncology vol. 3 , ( 3 ) 351 - 359 .

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al. ( 2020 ) . Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial . Nature Medicine vol. 26 , ( 6 ) 983 - 983 .

Yuen KC, Liu L-F, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P et al. ( 2020 ) . High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade . Nature Medicine vol. 26 , ( 5 ) 693 - 698 .

Loveday C, Litchfield K, Proszek PZ, Cornish AJ, Santo F, Levy M, Macintyre G, Holryod A et al. ( 2020 ) . Genomic landscape of platinum resistant and sensitive testicular cancers . Nature Communications vol. 11 , ( 1 )

Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N et al. ( 2020 ) . Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic . European Urology vol. 78 , ( 1 ) 29 - 42 .

Szabados B, Powles T ( 2020 ) . Immune checkpoint inhibition in urothelial carcinoma . The Lancet vol. 395 , ( 10236 ) 1522 - 1523 .

Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW et al. ( 2020 ) . Patient‐reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma . BJU International vol. 126 , ( 1 ) 73 - 82 .

Fulton B, Jones R, Powles T, Crabb S, Paul J, Birtle A, Chowdhury S, Hussain S et al. ( 2020 ) . ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer . Trials vol. 21 , ( 1 )

Gillessen S, Powles T ( 2020 ) . Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic . European Urology vol. 77 , ( 6 ) 667 - 668 .

Al-Lamki RS, Hudson NJ, Bradley JR, Warren AY, Eisen T, Welsh SJ, Riddick ACP, O’Mahony FC et al. ( 2020 ) . The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro . Biology vol. 9 , ( 4 )

Abu-Ghanem Y, Fernández-Pello S, Bex A, Ljungberg B, Albiges L, Dabestani S, Giles RH, Hofmann F et al. ( 2020 ) . Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel . European Urology Oncology vol. 3 , ( 4 ) 433 - 452 .

Tannir NM, Powles T, Escudier B, Donskov F, Grünwald V, Sternberg CN, Schmidinger M, Schöffski P et al. ( 2020 ) . Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma . Kidney Cancer vol. 4 , ( 1 ) 29 - 39 .

Drakaki A, Kirby CJ, van der Heijden MS, Petrylak DP, Powles T, N. K, Fléchon A, Necchi A et al. ( 2020 ) . Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial . Bladder Cancer vol. 6 , ( 1 ) 43 - 52 .

Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A et al. ( 2020 ) . Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial . The Lancet vol. 395 , ( 10232 ) 1268 - 1277 .

Liu WK, Lam JM, Butters T, Grant M, Jackson-Spence F, Bex A, Powles T, Szabados B ( 2020 ) . Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach . World Journal of Urology vol. 38 , ( 12 ) 3199 - 3205 .

Choueiri TK, Albiges L, Powles T, Scheffold C, Wang F, Motzer RJ ( 2020 ) . A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) tps767 - tps767 .

Bedke J, Merseburger AS, Loriot Y, Castellano D, Choy E, Duran I, Rosenberg JE, Petrylak DP et al. ( 2020 ) . Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 492 - 492 .

Abu-Ghanem Y, Van Thienen JV, Blank CU, Powles T, TOMBAL BF, Collette L, Haanen JBAG, Bex A ( 2020 ) . Differences in the exposure to sunitinib in the immediate and deferred cytoreductive nephrectomy (CN) arms of the randomized controlled trial SURTIME . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 703 - 703 .

Chaudhry A, Sternberg CN, De Santis M, Bellmunt J, Necchi A, Powles T, Cantero F, Marszewska M et al. ( 2020 ) . FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) tps590 - tps590 .

Galsky MD, Powles T, Dreicer R, Kitamura H, Asatiani E, Howe J, Zhen H, Oliveira N et al. ( 2020 ) . FIGHT-205: Phase II study of first-line pemigatinib (PEMI) plus pembrolizumab (PEMBRO) versus PEMI alone versus standard of care (SOC) for cisplatin (CIS)—Ineligible urothelial carcinoma (UC) with FGFR3 mutation or rearrangement . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) tps592 - tps592 .

Jiang DM, Wong B, Morgans AK, Sweeney C, Fizazi K, Chi KN, Powles T, Perlis N et al. ( 2020 ) . Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 58 - 58 .

Jiang DM, Wong B, Bellmunt J, Powles T, Morgans AK, Vaughn DJ, Sridhar SS ( 2020 ) . Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic urothelial carcinoma (mUC) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 467 - 467 .

Szabados B, Kockx M, Van Dam P-J, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Font A et al. ( 2020 ) . MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 541 - 541 .

Jackson-Spence F, Jovaisaite A, Grant M, Liu W-K, Butters T, Powles T, Szabados B ( 2020 ) . Outcomes after first-line therapy for immune/immune or immune/VEGF combinations . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 706 - 706 .

Tannir NM, McDermott DF, Escudier B, Hammers HJ, Aren OR, Plimack ER, Barthelemy P, Neiman V et al. ( 2020 ) . Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 609 - 609 .

Suarez Rodriguez C, Larkin JMG, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2020 ) . Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 619 - 619 .

Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF et al. ( 2020 ) . PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) tps589 - tps589 .

Hussain SA, Lester JF, Jackson R, Gornall M, Elliott A, Crabb SJ, Huddart RA, Vasudev N et al. ( 2020 ) . Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 438 - 438 .

Drakaki A, Rezazadeh Kalebasty A, Lee J-L, Martin-Liberal J, Kim M, Shin SJ, Shi J, Mariathasan S et al. ( 2020 ) . Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) tps591 - tps591 .

Stukalin I, Dudani S, Wells C, Gan CL, Pal SK, Dizman N, Powles T, Donskov F et al. ( 2020 ) . Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 684 - 684 .

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS et al. ( 2020 ) . Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5 . European Urology vol. 77 , ( 4 ) 436 - 438 .

Powles T ( 2020 ) . Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer . European Urology vol. 77 , ( 4 ) 454 - 456 .

de Bruijn R, Wimalasingham A, Szabados B, Stewart GD, Welsh SJ, Kuusk T, Blank C, Haanen J et al. ( 2020 ) . Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor–targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data . European Urology Oncology vol. 3 , ( 2 ) 168 - 173 .

Chalabi M, Cardona A, Nagarkar DR, Scala AD, Gandara DR, Rittmeyer A, Albert ML, Powles T et al. ( 2020 ) . Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials . Annals of Oncology vol. 31 , ( 4 ) 525 - 531 .

Kuebler HR, Powles T, Meeks JJ, Galsky M, van der Heijdens MS, Nishiyama H, Al-Ahmadie H, Gupta A et al. ( 2020 ) . A Phase 3, Randomized, Open-Label, Multicenter, Global Study of Efficacy and Safety of Durvalumab in Combination with Gemcitabine plus CiSPLATiN (G plus C) for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Muscle-Invasive Bladder Cancer (MiBC) (NiAGARA) . ONCOLOGY RESEARCH AND TREATMENT . vol. 43 , 82 - 82 .

Choueiri TK, Albiges L, Powles T, Scheffold C, Wang F, Motzer RJ ( 2020 ) . A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Choueiri TK, Albiges L, Powles T, Scheffold C, Wang F, Motzer RJ ( 2020 ) . A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Bedke J, Merseburger AS, Loriot Y, Castellano D, Choy E, Duran I, Rosenberg JE, Petrylak DP et al. ( 2020 ) . Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Dudani S, Gan CL, Wells C, Bakouny Z, Dizman N, Pal SK, Wood L, Kollmannsberger CK et al. ( 2020 ) . Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Gruenwald V, Choueiri TK, Rini BI, Powles T, George S, Grimm M-O, Mchenry MB, Maurer M et al. ( 2020 ) . Association Between Depth of Response (DepOR) and Overall Survival (OS): Exploratory Analysis of Nivolumab plus Ipilimumab (N plus I) vs Sunitinib (S) in Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) in Checkmate 214 . ONCOLOGY RESEARCH AND TREATMENT . vol. 43 , 74 - 75 .

Motzer RJ, Choueiri TK, McDermott DF, Powles T, Yao J, Ammar R, Papillon-Cavanagh S, Saggi SS et al. ( 2020 ) . Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Kleeman SO, Grant M, Rallis KS, Wozniak A, So A, Tejpaul R, Heller N, Weight CJ et al. ( 2020 ) . CT-based radiomic classifier of primary renal tumors to distinguish between metastatic and non-metastatic disease . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Grimm M-O, Mcdermott DF, Choueiri TK, Motzer RJ, Frontera OA, George S, Powles T, Donskov F et al. ( 2020 ) . Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 43 , 70 - 71 .

Zengerling F, Sternberg CN, Merseburger AS, Choy E, Castellano D, Lopez-Rios F, James N, Banna GL et al. ( 2020 ) . Clinical Outcomes According to PD-L1 Status and Age in the Prospective International Saul Study of atezolizumab (ATEZO) for Locally Advanced or Metastatic Urothelial Carcinoma (UC) or Non-UC of the Urinary Tract . ONCOLOGY RESEARCH AND TREATMENT . vol. 43 , 73 - 74 .

Bellmunt J, Powles T, Henriksson R, Steinberg GD, Batyrbekova N, Schain F, Fleming S, Shalaby W et al. ( 2020 ) . Clinical outcomes and economic burden for bladder cancer patients: An analysis from a Swedish cancer registry . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Grant M, Szabados B, Kuusk T, Powles T, Bex A ( 2020 ) . Cytoreductive nephrectomy: does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything? . Curr Opin Urol vol. 30 , ( 1 ) 36 - 40 .

Abu-Ghanem Y, Van Thienen JV, Blank CU, Powles T, Tombal BF, Collette L, Haanen JBAG, Bex A ( 2020 ) . Differences in the exposure to sunitinib in the immediate and deferred cytoreductive nephrectomy (CN) arms of the randomized controlled trial SURTIME . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Abu Ghanem Y, Choy J, Jackson-Spence F, Jovaisaite A, Grant M, Bex A, Powles T, Szabados B ( 2020 ) . Dynamic changes in full blood count (FBC) occurring in patients treated with immune checkpoint inhibitors (ICIs) to predict responses in patients with metastatic renal cell carcinoma (mRCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Petrylak D, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A et al. ( 2020 ) . EV-301: A phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy . CLINICAL CANCER RESEARCH . vol. 26 , 59 - 60 .

Chaudhry A, Sternberg CN, De Santis M, Bellmunt J, Necchi A, Powles T, Cantero F, Marszewska M et al. ( 2020 ) . FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Galsky MD, Powles T, Dreicer R, Kitamura H, Asatiani E, Howe J, Zhen H, Oliveira N et al. ( 2020 ) . FIGHT-205: Phase II study of first-line pemigatinib (PEMI) plus pembrolizumab (PEMBRO) versus PEMI alone versus standard of care (SOC) for cisplatin (CIS)-Ineligible urothelial carcinoma (UC) with <i>FGFR3</i> mutation or rearrangement . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Khan Z, Di Nucci F, Kwan A, Hammer C, Mariathasan S, Rouilly V, Carroll J, Fontes M et al. ( 2020 ) . Genetic risk for skin autoimmunity impacts the safety and efficacy of immune checkpoint blockade in urothelial carcinoma . CLINICAL CANCER RESEARCH . vol. 26 , 19 - 20 .

Hussain MHA, Powles T, Albers P, Castellano D, Daneshmand S, Gschwend J, Nishiyama H, Oudard S et al. ( 2020 ) . IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Retz M, Seseke F, Banna GL, De Giorgi U, Powles T, Basso U, McDermott RS, Llado A et al. ( 2020 ) . Impact of renal impairment on clinical outcomes in patients (pts) with locally advanced or metastatic (LA/M) urinary tract carcinoma (UTC) treated with atezolizumab (atezo): Analysis of the international SAUL study . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Jiang DM, Wong B, Morgans AK, Sweeney C, Fizazi K, Chi KN, Powles T, Perlis N et al. ( 2020 ) . Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Jiang DM, Wong B, Bellmunt J, Powles T, Morgans AK, Vaughn DJ, Sridhar SS ( 2020 ) . Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic urothelial carcinoma (mUC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Grimm M-O, Tannir N, McDermott D, Escudier B, Hammers H, Aren Frontera O, Plimack E, Barthelemy P et al. ( 2020 ) . Long-term follow-up on overall survival and independent review of response in CheckMate 214: first-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 43 , 208 - 208 .

Szabados B, Kockx M, Van Dam P-J, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Font A et al. ( 2020 ) . MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S et al. ( 2020 ) . Maintenance avelumab plus best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Jackson-Spence F, Jovaisaite A, Grant M, Liu W-K, Butters T, Powles T, Szabados B ( 2020 ) . Outcomes after first-line therapy for immune/immune or immune/VEGF combinations . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Tannir NM, McDermott DF, Escudier B, Hammers HJ, Aren OR, Plimack ER, Barthelemy P, Neiman V et al. ( 2020 ) . Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Suarez Rodriguez C, Larkin JMG, Patel P, Perez Valderrama B, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2020 ) . Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF et al. ( 2020 ) . PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Plimack ER, Rini BI, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F, Soulieres D et al. ( 2020 ) . Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426 . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Hussain SA, Lester JF, Jackson R, Gornall M, Elliott A, Crabb SJ, Huddart RA, Vasudev N et al. ( 2020 ) . Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Choueiri TK, Albiges L, Fan L, Perini RF, Zojwalla NJ, Powles T, Rini BI ( 2020 ) . Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Drakaki A, Kalebasty AR, Lee J-L, Martin-Liberal J, Kim M, Shin SJ, Shi J, Mariathasan S et al. ( 2020 ) . Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Meerveld-Eggink A, Graafland N, Wilgenhof S, Van Thienen JV, Grant M, Szabados B, Abu-Ghanem Y, Boleti E et al. ( 2020 ) . Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Stukalin I, Dudani S, Wells C, Gan CL, Pal SK, Dizman N, Powles T, Donskov F et al. ( 2020 ) . Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T et al. ( 2019 ) . Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma . European Journal of Cancer vol. 126 , 1 - 10 .

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N et al. ( 2019 ) . EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort† Under the Auspices of the EAU-ESMO Guidelines Committees . European Urology vol. 77 , ( 2 ) 223 - 250 .

Petrylak DP, de Wit R, N K, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA et al. ( 2019 ) . Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial . The Lancet Oncology vol. 21 , ( 1 ) 105 - 120 .

Buckley HL, Collinson FJ, Ainsworth G, Poad H, Flanagan L, Katona E, Howard HC, Murden G et al. ( 2019 ) . PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma . BMC Cancer . vol. 19 ,

Powles T, Walker J, Williams JA, Bellmunt J ( 2019 ) . The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma . Cancer Treatment Reviews vol. 82 ,

Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordoa T, Maroto P et al. ( 2019 ) . Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer . European Urology vol. 77 , ( 2 ) 269 - 276 .

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al. ( 2019 ) . Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial . Nature Medicine vol. 25 , ( 11 ) 1706 - 1714 .

Petrylak DP, Rosenberg JE, Lee J, Yonese J, Duran I, Loriot Y, Sonpavde G, Wu C et al. ( 2019 ) . 223TiP EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma . Annals of Oncology vol. 30 , ix75 - ix76 .

Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N et al. ( 2019 ) . EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees . Ann Oncol vol. 30 , ( 11 ) 1697 - 1727 .

Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N et al. ( 2019 ) . EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees † . Annals of Oncology vol. 30 , ( 11 ) 1697 - 1727 .

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong Y-N, Pal SK, De Giorgi U, Ladoire S et al. ( 2019 ) . Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) . Annals of Oncology vol. 30 , ( 11 )

Szabados B, Ruiz MD, Grant M, Liu W-K, Butters T, Pouliot F, Nosov D, Rini B et al. ( 2019 ) . P096 Clinical outcomes of patients with metastatic renal cell carcinoma receiving subsequent therapy after progression on front-line immune-VEGF TKI combination therapy . European Urology Open Science vol. 18 , ( 11 )

Grant M, Liu W, Butters T, Powles T, Szabados B ( 2019 ) . P130 Outcome of patients with metastatic urothelial cancer treated with chemotherapy following immune checkpoint inhibition . European Urology Open Science vol. 18 , ( 11 )

Butters T, Szabados B, Grant M, Liu W-K, Lam J, Powles T ( 2019 ) . P133 Do emergency department physicians understand immunotherapy?: Survey in the largest London University Hospital Trust . European Urology Open Science vol. 18 , ( 11 )

Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B et al. ( 2019 ) . PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN . Clinical Cancer Research vol. 25 , ( 20 ) 6080 - 6088 .

Powles T, Balar A, Gravis G, Jones R, Ravaud A, Florence J, Grivas P, Petrylak DP et al. ( 2019 ) . 902O An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies . Annals of Oncology vol. 30 , v356 - v357 .

Van der Heijden MS, Loriot Y, Duran I, Ravaud A, Retz MM, Vogelzang NJ, Nelson B, Wang J et al. ( 2019 ) . 918P Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study . Annals of Oncology vol. 30 , v365 - v366 .

van der Heijden M, Powles T, Petrylak D, de Wit R, Chi K, Necchi A, Sternberg CN, Matsubara N et al. ( 2019 ) . 929P Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study . Annals of Oncology vol. 30 , v373 - v374 .

Grünwald V, Choueiri TK, Rini BI, Powles T, George S, Grimm M-O, McHenry MB, Maurer M et al. ( 2019 ) . 950P Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214 . Annals of Oncology vol. 30 , v382 - v383 .

Regan MM, Atkins MB, Powles T, Werner L, Mantia C, Yang S, Johansen JL, Rao S et al. ( 2019 ) . 971P Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma . Annals of Oncology vol. 30 , v393 - v394 .

Kuusk T, Szabados B, Liu K, Powles T, Bex A ( 2019 ) . Cytoreductive nephrectomy in the current treatment algorithm . Therapeutic Advances in Medical Oncology vol. 11 ,

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS et al. ( 2019 ) . A Consensus Molecular Classification of Muscle-invasive Bladder Cancer . European Urology vol. 77 , ( 4 ) 420 - 433 .

Motzer RJ, Rini BI, McDermott DF, Frontera OA, Hammers HJ, Carducci MA, Salman P, Escudier B et al. ( 2019 ) . Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial . The Lancet Oncology vol. 20 , ( 10 ) 1370 - 1385 .

de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, Heng DYC, Escudier B ( 2019 ) . Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma . European Urology Oncology vol. 2 , ( 5 ) 505 - 514 .

Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB et al. ( 2019 ) . Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma . European Urology vol. 76 , ( 2 ) 151 - 156 .

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T et al. ( 2019 ) . Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ [Eur J Cancer 108 (February 2019) 33–40] . European Journal of Cancer vol. 119 , 200 - 201 .

Alifrangis C, McGovern U, Freeman A, Powles T, Linch M ( 2019 ) . Molecular and histopathology directed therapy for advanced bladder cancer . Nature Reviews Urology vol. 16 , ( 8 ) 465 - 483 .

Choueiri TK, Quinn DI, Zhang T, Gurney H, Doshi GK, Cobb PW, Parnis F, Lee J-L et al. ( 2019 ) . Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study . Cancer Research . vol. 79 , ct162 - ct162 .

Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M et al. ( 2019 ) . Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer . Cancer Cell vol. 36 , ( 1 ) 35 - 50.e9 .

Klaassen Z, Satkunasivam R, Wallis CJD ( 2019 ) . Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma . New England Journal of Medicine vol. 380 , ( 26 ) 2581 - 2582 .

Song D, Powles T, Shi L, Zhang L, Ingersoll MA, Lu Y ( 2019 ) . Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches . The Journal of Pathology vol. 249 , ( 2 ) 151 - 165 .

Grimm M-O, Bex A, De Santis M, Ljungberg B, Catto JWF, Rouprêt M, Hussain SA, Bellmunt J et al. ( 2019 ) . Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019 . European Urology vol. 76 , ( 3 ) 368 - 380 .

De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L et al. ( 2019 ) . Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME) . European Urology vol. 76 , ( 4 ) 437 - 440 .

Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U et al. ( 2019 ) . A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors . The Oncologist vol. 24 , ( 9 ) 1151 - e817 .

Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles RH et al. ( 2019 ) . Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel . European Urology Oncology vol. 3 , ( 1 ) 57 - 72 .

Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY et al. ( 2019 ) . Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer . Cancer vol. 125 , ( 18 ) 3155 - 3163 .

Sonpavde G, Manitz J, Gao C, Hennessy D, Makari D, Niegisch G, Rosenberg JE, Bajorin DF et al. ( 2019 ) . 5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors . Journal of Clinical Oncology vol. 37 , ( 15_suppl ) 4552 - 4552 .

Powles T, Meeks JJ, Galsky MD, Van Der Heijden MS, Nishiyama H, Al-Ahmadie H, Gupta AK, Ye J et al. ( 2019 ) . A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA) . Journal of Clinical Oncology . vol. 37 , tps4592 - tps4592 .

Rudd P, Hines J, Watkins E, Powles T, Tipples K ( 2019 ) . Assessment of 2,000 patients presenting to a multidisciplinary prostate cancer clinic in the United Kingdom . Journal of Clinical Oncology . vol. 37 , 5077 - 5077 .

Rini BI, Motzer RJ, Powles T, McDermott DF, Escudier B, Donskov F, Hawkins RE, Bracarda S et al. ( 2019 ) . Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis . Journal of Clinical Oncology . vol. 37 , 4512 - 4512 .

McDermott DF, Choueiri TK, Motzer RJ, Aren OR, George S, Powles T, Donskov F, Harrison MR et al. ( 2019 ) . CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features . Journal of Clinical Oncology . vol. 37 , 4513 - 4513 .

Sternberg CN, Merseburger AS, Choy E, Castellano DE, Lopez-Rios F, James N, Banna GL, De Giorgi U et al. ( 2019 ) . Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract . Journal of Clinical Oncology . vol. 37 , 4519 - 4519 .

Carroll D, McEwen R, Kozarewa I, Harrington E, L'Hernault A, Ratnayake J, Mather R, Hodgson D et al. ( 2019 ) . Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY) . Journal of Clinical Oncology . vol. 37 , 4553 - 4553 .

Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK et al. ( 2019 ) . Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival . Journal of Clinical Oncology . vol. 37 , e16017 - e16017 .

O'Donnell PH, Balar AV, Vuky J, Castellano DE, Bellmunt J, Powles T, Bajorin DF, Grivas P et al. ( 2019 ) . KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— Updated response and survival results . Journal of Clinical Oncology . vol. 37 , 4546 - 4546 .

Szabados B, Rebelatto M, Barker C, Milner A, Lewis A, Stokes M, Zajac M, Powles T et al. ( 2019 ) . Molecular biomarker analysis and survival in patients (pts) with advanced urothelial cancer (UC) previously treated with chemotherapy . Journal of Clinical Oncology . vol. 37 , 4529 - 4529 .

Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW et al. ( 2019 ) . Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC) . Journal of Clinical Oncology . vol. 37 , 4515 - 4515 .

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Soulieres D et al. ( 2019 ) . Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study . Journal of Clinical Oncology . vol. 37 , 4500 - 4500 .

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM et al. ( 2019 ) . Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial . The Lancet vol. 393 , ( 10189 ) 2404 - 2415 .

Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, von Loga K et al. ( 2019 ) . CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids . Journal for ImmunoTherapy of Cancer vol. 7 , ( 1 )

Lam JM, Liu WK, Powles T, Tang YZ, Szabados B ( 2019 ) . Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition . European Urology Oncology vol. 4 , ( 4 ) 659 - 662 .

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U et al. ( 2019 ) . The Impact of Cisplatin‐ or Non‐Cisplatin‐Containing Chemotherapy on Long‐Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer . The Oncologist vol. 24 , ( 10 ) 1348 - 1355 .

Porta C, Cosmai L, Leibovich BC, Powles T, Gallieni M, Bex A ( 2019 ) . The adjuvant treatment of kidney cancer: a multidisciplinary outlook . Nature Reviews Nephrology vol. 15 , ( 7 ) 423 - 433 .

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2019 ) . Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.) . Scandinavian Journal of Urology vol. 53 , ( 1 ) 14 - 20 .

Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U et al. ( 2019 ) . Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract . European Urology vol. 76 , ( 1 ) 73 - 81 .

Szabados B, Duran I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A et al. ( 2019 ) . 1121 Surgical outcome of pre-operative atezolizumab before radical cystectomy for muscle-invasive urothelial carcinoma of the bladder . European Urology Open Science vol. 18 , ( 1 )

Dabestani S, Beisland C, Stewart GD, Capitanio U, Järvinen P, Nisen H, Bensalah K, Gudmundsson EO et al. ( 2019 ) . 868 Should stage III renal cell carcinoma with pN1 be classified as stage IV of the American Joint Committee on Cancer classification? A RECUR external validation . European Urology Open Science vol. 18 , ( 1 )

Powles T, Larkin JMG, Patel P, Pérez-Valderrama B, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2019 ) . A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO) . Journal of Clinical Oncology . vol. 37 , 545 - 545 .

Petrylak DP, Rosenberg JE, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner EM, Melhem-Bertrandt A et al. ( 2019 ) . EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC) . Journal of Clinical Oncology . vol. 37 , tps497 - tps497 .

Jiang DM, Brundage MD, Sweeney C, Fizazi K, Bellmunt J, Vaughn DJ, Powles T, Perlis N et al. ( 2019 ) . Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC) . Journal of Clinical Oncology . vol. 37 , 478 - 478 .

Tannir NM, Motzer RJ, Plimack ER, McDermott DF, Barthelemy P, Porta C, George S, Powles T et al. ( 2019 ) . Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214 . Journal of Clinical Oncology . vol. 37 , 581 - 581 .

Petrylak D, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A et al. ( 2019 ) . PT126 A phase 3 study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC): EV-301, a trial-in-progress . European Urology Open Science vol. 18 , ( 1 ) e1836 - e1837 .

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2019 ) . PT338 Intensive imaging-based follow-up of surgically treated localised renal cell carcinoma does not improve post-recurrence survival: Results from a European Multicentre Database (RECUR) . European Urology Open Science vol. 18 , ( 1 )

MacLennan S, Bruins HM, Plass KMJ, Babjuk M, Bellmunt J, Gillessen S, James ND, Ribal MJ et al. ( 2019 ) . PT339 An international collaborative study from the EAU and ESMO to develop consensus statements for muscle invasive bladder cancer . European Urology Open Science vol. 18 , ( 1 ) e2124 - e2125 .

Powles T, Plimack ER, Stus V, Gafanov RA, Hawkins RE, Nosov D, Pouliot F, Alekseev BY et al. ( 2019 ) . Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study . Journal of Clinical Oncology . vol. 37 , 543 - 543 .

Dabestani S, Beisland C, Stewart G, Capitanio U, Jarvinen P, Nisen H, Bensalah K, Guðmundsson E et al. ( 2019 ) . Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis . Journal of Clinical Oncology . vol. 37 , 636 - 636 .

De Wit R, Powles T, Castellano DE, Necchi A, Lee J-L, Van Der Heijden MS, Matsubara N, Bamias A et al. ( 2019 ) . Ramucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts) . Journal of Clinical Oncology . vol. 37 , 353 - 353 .

Tannir NM, Frontera OA, Hammers HJ, Carducci MA, McDermott DF, Salman P, Escudier B, Beuselinck B et al. ( 2019 ) . Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) . Journal of Clinical Oncology . vol. 37 , 547 - 547 .

McDermott DF, Rini BI, Motzer RJ, Tannir NM, Escudier B, Kollmannsberger CK, Hammers HJ, Porta C et al. ( 2019 ) . Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214 . Journal of Clinical Oncology . vol. 37 , 564 - 564 .

Sonpavde G, Hennessy D, Manitz J, Niegisch G, Powles T, Rosenberg JE, Bajorin DF, Apolo AB et al. ( 2019 ) . Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors . Journal of Clinical Oncology . vol. 37 , 476 - 476 .

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F et al. ( 2019 ) . European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update . European Urology vol. 75 , ( 5 ) 799 - 810 .

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B et al. ( 2019 ) . Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma . New England Journal of Medicine vol. 380 , ( 12 ) 1116 - 1127 .

Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, del Pilar Laguna M et al. ( 2019 ) . Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib . JAMA Oncology vol. 5 , ( 2 ) 164 - 170 .

Neves JB, Shepherd S, Cullen D, Powles T, Aitchison M, Tran MGB ( 2019 ) . Performance and cost of a renal cancer specialist multidisciplinary team meeting: Results from 1500 discussions . Journal of Clinical Urology vol. 12 , ( 4 ) 314 - 319 .

Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S et al. ( 2019 ) . Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy . European Urology Focus vol. 6 , ( 5 ) 999 - 1005 .

Chanza NM, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE et al. ( 2019 ) . Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers . European Urology Oncology vol. 3 , ( 5 ) 671 - 679 .

Grnwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY et al. ( 2019 ) . Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale . Future Oncology vol. 15 , ( 9 ) 929 - 941 .

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T et al. ( 2019 ) . Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma . European Journal of Cancer vol. 108 , 33 - 40 .

Plimack ER, Rini BI, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Soulieres D et al. ( 2019 ) . AUTHOR INDEX . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 15 , 33 - 34 .

Powles T, Balar A, Gravis G, Jones R, Ravaud A, Florence J, Grivas P, Petrylak DP et al. ( 2019 ) . An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies . ANNALS OF ONCOLOGY . vol. 30 ,

Gruenwald V, Choueiri TK, Rini BI, Powles T, George S, Grimm M-O, McHenry MB, Maurer M et al. ( 2019 ) . Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214 . ANNALS OF ONCOLOGY . vol. 30 , 382 - + .

Van der Heijden M, Powles T, Petrylak D, de Wit R, Chi K, Necchi A, Sternberg CN, Matsubara N et al. ( 2019 ) . Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study . ANNALS OF ONCOLOGY . vol. 30 ,

Gruenwald V, Tannir NM, Motzer RJ, Plimack ER, McDermott DF, Barthelemy P, Porta C, George S et al. ( 2019 ) . CheckMate 214 patients who discontinued first-line Nivolumab plus Ipilimumab or sunitinib due to treatment-related adverse events . ONCOLOGY RESEARCH AND TREATMENT . vol. 42 , 150 - 150 .

Petrylak DP, Rosenberg JE, Lee J, Yonese J, Duran I, Loriot Y, Sonpavde G, Wu C et al. ( 2019 ) . EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma . ANNALS OF ONCOLOGY . vol. 30 ,

Gruellich C, Rini BI, Huseni M, Atkins M, McDermott D, Powles T, Escudier B, Banchereau R et al. ( 2019 ) . Molecular correlates differentiate response to atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 42 , 148 - 148 .

Retz M, Merseburger AS, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL et al. ( 2019 ) . Primary results from SAUL, a prospective multinational single-arm study of Atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract . ONCOLOGY RESEARCH AND TREATMENT . vol. 42 , 104 - 105 .

Cathomas R, Merseburger AS, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL et al. ( 2019 ) . Primary results from the SAUL study: atezolizumab for locally advanced or metastatic urothelial carcinoma (UC) or non-UC . SWISS MEDICAL WEEKLY . vol. 149 , 12S - 13S .

Regan MM, Atkins MB, Powles T, Werner L, Mantia C, Yang S, Johansen JL, Rao S et al. ( 2019 ) . Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma . ANNALS OF ONCOLOGY . vol. 30 , 393 - + .

SMITH KJ ( 2018 ) . Identifying and targeting LIM-domain loss in clear cell renal cell carcinoma . Supervisors: SHARP, T, POWLES, T ,

Chalabi M, Cardona A, Nagarkar D, Scala AMD, Albert M, Kok M, Powles TB, Herrera F ( 2018 ) . 50O Effects of antibiotics and proton pump inhibitors in NSCLC patients treated with atezolizumab and docetaxel: Pooled analysis of the OAK and POPLAR trials . Annals of Oncology vol. 29 ,

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM et al. ( 2018 ) . Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” [Eur Urol 2018;73:462–8] . European Urology vol. 75 , ( 3 ) e82 - e83 .

Del Bene G, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK et al. ( 2018 ) . Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database . Frontiers in Oncology vol. 8 ,

Escudier B, Thezenas S, Méjean A ( 2018 ) . Sunitinib Alone or after Nephrectomy in Renal Cancer . New England Journal of Medicine vol. 379 , ( 19 ) 1877 - 1878 .

Rini BI, Tannir NM, Escudier B, McDermott DF, Grimm M-O, Porta C, Powles T, Kollmannsberger C et al. ( 2018 ) . Caractérisation de la réponse au traitement par nivolumab plus ipilimumab (N+I) ou sunitinib (S) chez des patients (pts) atteints d’un carcinome à cellules rénales avancé (CCRa) non préalablement traité : CheckMate 214 . The French Journal of Urology vol. 28 , ( 13 ) 624 - 625 .

Szabados B, Kelly JD, Lam JJM, Liu W-K, Powles T ( 2018 ) . LP212 Surgical outcome of pre-operative atezolizumab before radical cystectomy for muscle-invasive urothelial carcinoma of the bladder . European Urology Open Science vol. 17 , ( 14 )

Liu WK, Szabados B, Morrison L, Powles T ( 2018 ) . LP219 The efficacy of targeted therapy after progression on Bevacizumab and Atezolizumab combination therapy in metastatic renal cell carcinoma . European Urology Open Science vol. 17 , ( 14 )

Schmidinger M, Powles T, Motzer RJ, Rolland F, Gravis G, Staehler M, Rink M, Retz M et al. ( 2018 ) . O2 Cabozantinib versus everolimus in patients with advanced renal cell carcinoma from Europe and the rest of the world: subgroup analysis of the METEOR trial . European Urology Open Science vol. 17 , ( 14 ) e3022 - e3023 .

Beisland C, Dabestani S, Stewart G, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2018 ) . O4 Making a judgement on the potential curability of recurrent Renal Cell Carcinoma (RCC): Differences in global per protocol vs. investigator based assessment . European Urology Open Science vol. 17 , ( 14 ) e3025 - e3026 .

Vari S, Morrison L, Crolley V, Powles T ( 2018 ) . P112 VEGF tyrosine kinase inhibitors after bevacizumab and atezolizumab in metastatic clear cell renal cancer . European Urology Open Science vol. 17 , ( 14 )

Powles T, Calvo E, Grünwald V, Heng D, Michaelson D, Dezzani L, Hirschberg Y, Acharya S et al. ( 2018 ) . P121 Efficacy and safety of pazopanib in patients with advanced and/or metastatic renal cell carcinoma (mRCC) after previous checkpoint inhibitor treatment . European Urology Open Science vol. 17 , ( 14 )

Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B et al. ( 2018 ) . Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing . Clinical Chemistry vol. 64 , ( 11 ) 1626 - 1635 .

Powles T, Rini B ( 2018 ) . Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer . Journal of Clinical Oncology vol. 36 , ( 36 ) 3639 - 3644 .

Tshuma N, Glynn N, Evanson J, Powles T, Drake WM ( 2018 ) . Hypothalamitis and severe hypothalamic dysfunction associated with anti–programmed cell death ligand 1 antibody treatment . European Journal of Cancer vol. 104 , 247 - 249 .

Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ et al. ( 2018 ) . Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma . European Urology vol. 75 , ( 1 ) 111 - 128 .

Lalani A-KA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, Wood C, Bex A ( 2018 ) . Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions . European Urology vol. 75 , ( 1 ) 100 - 110 .

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2018 ) . Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR) . European Urology vol. 75 , ( 2 ) 261 - 264 .

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW et al. ( 2018 ) . Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma . Nature Medicine vol. 24 , ( 12 ) 1941 - 1941 .

Petrylak DP, Sternberg CN, Drakaki A, de Wit R, Nishiyama H, Necchi A, Castellano D, Bamias A et al. ( 2018 ) . 865PD RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results . Annals of Oncology vol. 29 , viii304 - viii305 .

Suarez C, Choueiri TK, McDermott DF, Escudier B, Atkins MB, Powles TB, Rini BI, Motzer RJ et al. ( 2018 ) . 873P Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151 . Annals of Oncology . vol. 29 ,

McDermott DF, Rini BI, Motzer RJ, Tannir NM, Escudier B, Kollmannsberger CK, Hammers HJ, Porta C et al. ( 2018 ) . 874P Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis . Annals of Oncology . vol. 29 ,

Rini BI, Tannir NM, Escudier B, McDermott DF, Grimm M-O, Porta C, Powles T, Kollmannsberger CK et al. ( 2018 ) . 875P Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214 . Annals of Oncology vol. 29 , viii309 - viii310 .

de Liano Lista AG, Venugopal B, Fife K, Symeonides S, Vasudev NS, Rudman SM, Vohra S, Khasati L et al. ( 2018 ) . 893P Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP) . Annals of Oncology . vol. 29 ,

Castellano D, Duran I, Rodríguez-Vida A, Crabb SJ, van der Heijden MS, Pous AF, Gravis G, Herranz UA et al. ( 2018 ) . 899P A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS) . Annals of Oncology vol. 29 ,

Galsky MD, Banchereau R, Kadel EE, Ramirez-Montagut T, Mariathasan S, Thåström A, Rosenberg J, Powles T et al. ( 2018 ) . 902P Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC) . Annals of Oncology vol. 29 ,

Walker J, Zajac M, Ye J, Scott M, Ratcliffe M, Scorer P, Barker C, Al-Masri H et al. ( 2018 ) . 904P Impact of different programmed cell death ligand-1 (PD-L1) expression algorithms on patient selection and durvalumab efficacy in urothelial carcinoma (UC) . Annals of Oncology . vol. 29 ,

Petrylak DP, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A et al. ( 2018 ) . 922TiP EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC) . Annals of Oncology vol. 29 ,

Collinson F, Brown S, Buckley H, Ainsworth G, Howard H, Poad H, Carr G, Banks RE et al. ( 2018 ) . 931TiP PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma . Annals of Oncology vol. 29 ,

Rini BI, Huseni M, Atkins MB, McDermott DF, Powles TB, Escudier B, Banchereau R, Liu L-F et al. ( 2018 ) . LBA31 Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC) . Annals of Oncology . vol. 29 , viii724 - viii725 .

Choueiri TK, Flaifel A, Xie W, Braun D, Ficial M, Jennings R, Nassar A, Escudier B et al. ( 2018 ) . LBA34 PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials . Annals of Oncology . vol. 29 ,

van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS ( 2018 ) . The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer . European Urology vol. 75 , ( 3 ) 435 - 444 .

Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, Georgiou A, Furness AJS et al. ( 2018 ) . Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment . Journal of Experimental Medicine vol. 215 , ( 11 ) 2748 - 2759 .

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T et al. ( 2018 ) . SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer . World Journal of Urology vol. 37 , ( 1 ) 95 - 105 .

Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY et al. ( 2018 ) . Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma . British Journal of Cancer vol. 119 , ( 6 ) 663 - 669 .

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M et al. ( 2018 ) . A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations . European Urology vol. 74 , ( 6 ) 849 - 851 .

Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J et al. ( 2018 ) . Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma . Journal of Urology vol. 200 , ( 6 ) 1207 - 1214 .

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al. ( 2018 ) . Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma . European Urology vol. 74 , ( 6 ) 805 - 809 .

Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T et al. ( 2018 ) . Rituximab in the treatment of pembrolizumab-induced myasthenia gravis . European Journal of Cancer vol. 102 , 49 - 51 .

Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M et al. ( 2018 ) . Imaging in Suspected Renal-Cell Carcinoma: Systematic Review . Clinical Genitourinary Cancer vol. 17 , ( 2 ) e345 - e355 .

Powles T ( 2018 ) . Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma . European Urology vol. 74 , ( 5 ) 679 - 680 .

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G et al. ( 2018 ) . ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up . Annals of Oncology vol. 29 , ( 8 ) 1658 - 1686 .

Powles T, Morrison L ( 2018 ) . Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma . Nature Reviews Urology vol. 15 , ( 10 ) 585 - 587 .

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H et al. ( 2018 ) . Abstract 2979: A balance of genomic instability, tumor-immune contexture and TGF-β signaling contributing to exclusion of T cells governs response to PD-L1 checkpoint blockade . Cancer Research . vol. 78 , 2979 - 2979 .

O'Donnell P, Massard C, Keam B, Kim S-W, Friedlander T, Ahn M-J, Ong M, Gordon M et al. ( 2018 ) . Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma . Cancer Research . vol. 78 , ct031 - ct031 .

Balar AV, Mahipal A, Grande E, Villalobos VM, Salas S, Kang TW, Kim SH, Powles T et al. ( 2018 ) . Abstract CT112: Durvalumab + tremelimumab in patients with metastatic urothelial cancer . Cancer Research . vol. 78 , ct112 - ct112 .

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW et al. ( 2018 ) . Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma . Nature Medicine vol. 24 , ( 6 ) 749 - 757 .

Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM ( 2018 ) . Role of Checkpoint Inhibition in Localized Bladder Cancer . European Urology Oncology vol. 1 , ( 3 ) 190 - 198 .

Barata PC, De Liano AG, Mendiratta P, Crolley V, Szabados B, Morrison L, Wood L, Allman K et al. ( 2018 ) . The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma . British Journal of Cancer vol. 119 , ( 2 ) 160 - 163 .

Powles T ( 2018 ) . Choosing Front-line Treatment for Metastatic Renal Cancer: Which Data Are Meaningful? . European Urology vol. 74 , ( 3 ) 322 - 323 .

Galsky MD, Powles T, Li S, Hennicken D, Sonpavde G ( 2018 ) . A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901) . Journal of Clinical Oncology . vol. 36 , tps4588 - tps4588 .

Choueiri TK, Apolo AB, Powles T, Escudier B, Aren OR, Shah A, Kessler ER, Hsieh JJ et al. ( 2018 ) . A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER) . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) tps4598 - tps4598 .

Powles T, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Font Pous A, Gravis G, Anido Herranz U et al. ( 2018 ) . A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS) . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) 4506 - 4506 .

Matsubara N, Petrylak DP, Nishiyama H, Su W-P, Lee J-L, Li J-R, Walgren RA, Hamid O et al. ( 2018 ) . A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC) . Journal of Clinical Oncology . vol. 36 , 4542 - 4542 .

Legrand FA, Gandara DR, Mariathasan S, Powles T, He X, Zhang W, Jhunjhunwala S, Nickles D et al. ( 2018 ) . Association of high tissue TMB and atezolizumab efficacy across multiple tumor types . Journal of Clinical Oncology . vol. 36 , 12000 - 12000 .

Gomez de Liano A, Venugopal B, Fife K, Khasti L, Symeonides SN, Pettinger C, Powles T, Rudman SM et al. ( 2018 ) . Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) e16578 - e16578 .

Wei XX, Lundgren K, Teo MY, Rosenberg JE, Koshkin VS, Grivas P, Carril L, Castellano DE et al. ( 2018 ) . First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts) . Journal of Clinical Oncology . vol. 36 , e16517 - e16517 .

Choueiri TK, Quinn DI, Zhang T, Gurney H, Doshi GK, Cobb PW, Parnis F, Lee J-L et al. ( 2018 ) . KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) tps4599 - tps4599 .

Escudier B, Motzer RJ, Rini BI, Powles T, McDermott DF, Suarez C, Bracarda S, Stadler WM et al. ( 2018 ) . Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC) . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) 4511 - 4511 .

Powles T, Bellmunt J, Petrylak DP, Fong L, Nishiyama H, Sternberg CN, Chen M, Pang L et al. ( 2018 ) . Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303 . Journal of Clinical Oncology . vol. 36 , tps4586 - tps4586 .

De Wit R, Powles T, Castellano DE, Necchi A, Lee J-L, Van Der Heijden MS, Matsubara N, Bamias A et al. ( 2018 ) . Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) 4526 - 4526 .

Vuky J, Balar AV, Castellano DE, O'Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin DF et al. ( 2018 ) . Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC) . Journal of Clinical Oncology . vol. 36 , 4524 - 4524 .

Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI et al. ( 2018 ) . Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis . European Urology vol. 74 , ( 5 ) 611 - 620 .

Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW et al. ( 2018 ) . Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study . JAMA Oncology vol. 4 , ( 4 ) 537 - 544 .

Birtle A, Catto J, Johnson M, Kockelbergh R, Keeley F, Bryan R, Chester J, Jones R et al. ( 2018 ) . MP18-03 RESULTS OF POUT - A PHASE III RANDOMISED TRIAL OF PERI-OPERATIVE CHEMOTHERAPY VERSUS SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER (UTUC) . Journal of Urology vol. 199 , ( 4 ) e213 - e214 .

Neves JB, Shepherd S, Cullen D, Powles T, Aitchison M, Tran MG ( 2018 ) . MP80-12 PERFORMANCE AND COST OF THE RENAL CANCER SPECIALIST MULTIDISCIPLINARY TEAM MEETING: RESULTS FROM 1500 DISCUSSIONS . Journal of Urology vol. 199 , ( 4 )

Motzer RJ, Escudier B, Powles T, Scheffold C, Choueiri TK ( 2018 ) . Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma . British Journal of Cancer vol. 118 , ( 9 ) 1176 - 1178 .

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P et al. ( 2018 ) . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma . New England Journal of Medicine vol. 378 , ( 14 ) 1277 - 1290 .

Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D et al. ( 2018 ) . Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial . The Lancet Oncology vol. 19 , ( 4 ) 451 - 460 .

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2018 ) . Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis . European Urology Focus vol. 5 , ( 5 ) 857 - 866 .

Jepson M, Elliott D, Conefrey C, Wade J, Rooshenas L, Wilson C, Beard D, Blazeby JM et al. ( 2018 ) . An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment . Journal of Clinical Epidemiology vol. 99 , 75 - 83 .

Bex A, Mulders P, Jewett M, Wagstaff J, Van Velthoven R, Laguna P, Wood L, Van Melick H et al. ( 2018 ) . 1 Surgical safety of immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib. Data from the EORTC randomized trial 30073 SURTIME . European Urology Open Science vol. 17 , ( 2 ) e1 - e2 .

Birtle A, Johnson M, Kockelbergh R, Keeley F, Catto J, Bryan R, Chester J, Jones R et al. ( 2018 ) . 1017 Results of POUT - a phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC) . European Urology Open Science vol. 17 , ( 2 ) e1431 - e1432 .

Raggi D, Pond G, Giannatempo P, Plimack E, Niegisch G, Yu E, Pal S, Bamias A et al. ( 2018 ) . 368 Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study . European Urology Open Science vol. 17 , ( 2 ) e519 - e520 .

Powles T, Loriot Y, Gschwend JE, Bellmunt J, Geczi L, Vulsteke C, Abdelsalam M, Gafanov R et al. ( 2018 ) . 801 KEYNOTE-361: Phase 3 trial of pembrolizumab ± chemotherapy versus chemotherapy alone in advanced urothelial cancer . European Urology Open Science vol. 17 , ( 2 ) e1147 - e1148 .

Sommer SG, Powles T, Drake C, Rathkopf D, Narayanan S, Green M, Leng N, Schiff C et al. ( 2018 ) . 808 IMbassador250: A phase III trial in patients with metastatic castration-resistant prostate cancer (mCRPC) comparing atezolizumab plus enzalutamide vs enzalutamide alone . European Urology Open Science vol. 17 , ( 2 )

Powles T, Zhang T, Gurney H, Doshi G, Cobb P, Parnis F, Lee JL, Park SH et al. ( 2018 ) . 809 Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564 . European Urology Open Science vol. 17 , ( 2 ) e1156 - e1157 .

Castellano D, Grivas P, Plimack E, Balar A, O’Donnell P, Bellmunt J, Powles T, Hahn N et al. ( 2018 ) . 86 Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): Results from Keynote-052 . European Urology Open Science vol. 17 , ( 2 ) e124 - e125 .

Necchi A, Mariani L, Vullo SL, Raggi D, Giannatempo P, Bamias A, Crabb S, Bellmunt J et al. ( 2018 ) . 89 Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma . European Urology Open Science vol. 17 , ( 2 ) e131 - e132 .

Bamias A, Van Der Heijden M, De Wit R, Fléchon A, Nishiyama H, Castellano D, Drakaki A, Matsubara N et al. ( 2018 ) . 94 Healthcare resource utilization in RANGE: Ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced or metastatic urothelial cancer . European Urology Open Science vol. 17 , ( 2 ) e140 - e141 .

Montes SF-P, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE et al. ( 2018 ) . PT011 A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma . European Urology Open Science vol. 17 , ( 2 ) e1733 - e1734 .

Shaw G, Oliver T, Kealy R, Powles T, Hillman P, Cuzick J ( 2018 ) . The PROVENT study, a multicentre double blind placebo controlled randomised trial to evaluate the effects of Vitamin D and aspirin on progression of low risk prostate cancer during active surveillance . European Journal of Surgical Oncology vol. 44 ,

Motzer RJ, Grünwald V, Hutson TE, Porta C, Powles T, Eto M, Dutcus CE, Baig MA et al. ( 2018 ) . A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma . Journal of Clinical Oncology . vol. 36 , tps706 - tps706 .

Galsky MD, Powles T, Li S, Hennicken D, Sonpavde G ( 2018 ) . A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901) . Journal of Clinical Oncology . vol. 36 , tps539 - tps539 .

Kim JW, Shaffer DR, Massard C, Powles T, Harshman LC, Braiteh FS, Conkling PR, Sarkar I et al. ( 2018 ) . A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) . Journal of Clinical Oncology . vol. 36 , 187 - 187 .

Powles T, Loriot Y, Ravaud A, Vogelzang NJ, Duran I, Retz M, De Giorgi U, Oudard S et al. ( 2018 ) . Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study . Journal of Clinical Oncology . vol. 36 , 409 - 409 .

Jonasch E, Motzer RJ, Escudier B, Powles T, Markby DW, Nielsen J, Lacy S, Choueiri TK ( 2018 ) . Cabozantinib (C) exposure-response (ER) modeling of efficacy and safety endpoints as a function of clearance in patients (pts) with renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 36 , 645 - 645 .

Barata PC, Gomez de Liano A, Mendiratta P, Crolley V, Szabados B, Wood LS, Zanick B, Allman KD et al. ( 2018 ) . Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens . Journal of Clinical Oncology . vol. 36 , 613 - 613 .

Drakaki A, Kirby CJ, Van Der Heijden MS, Petrylak DP, Powles T, Chi KN, Flechon A, Necchi A et al. ( 2018 ) . Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial . Journal of Clinical Oncology . vol. 36 , 434 - 434 .

Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM et al. ( 2018 ) . IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC) . Journal of Clinical Oncology . vol. 36 , 578 - 578 .

Beisland C, Dabestani S, Stewart G, Bensalah K, Guðmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2018 ) . Imaging modalities used for follow-up of localized renal cell carcinoma (RCC) and subsequent effect on overall survival after recurrence: RECUR-database analysis . Journal of Clinical Oncology . vol. 36 , 637 - 637 .

Necchi A, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J et al. ( 2018 ) . Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma . Journal of Clinical Oncology . vol. 36 , 426 - 426 .

Pond GR, Niegisch G, Rosenberg JE, Dreicer R, Powles T, Necchi A, Wei XX, Grivas P et al. ( 2018 ) . New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab . Journal of Clinical Oncology . vol. 36 , 413 - 413 .

Necchi A, Pond GR, Plimack ER, Niegisch G, Yu EY, Pal SK, Bamias A, Agarwal N et al. ( 2018 ) . Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study . Journal of Clinical Oncology . vol. 36 , 448 - 448 .

Agarwal N, Vaishampayan UN, McGregor BA, Green MC, Mohamed N, Chang P-Y, Powles T, Pal SK ( 2018 ) . Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 36 , tps541 - tps541 .

Quinn DI, Zhang T, Gurney H, Doshi GK, Cobb PW, Parnis F, Lee J-L, Park SH et al. ( 2018 ) . Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564 . Journal of Clinical Oncology . vol. 36 , tps712 - tps712 .

Necchi A, Nishiyama H, Matsubara N, Lee J-L, Petrylak DP, De Wit R, Drakaki A, Liepa AM et al. ( 2018 ) . Quality-of-life (QoL) in RANGE: A phase 3 study of ramucirumab (RAM) plus docetaxel (DOC) versus placebo (P) plus DOC in platinum-refractory locally advanced or metastatic urothelial carcinoma (UC) . Journal of Clinical Oncology . vol. 36 , 419 - 419 .

Birtle AJ, Chester JD, Jones RJ, Johnson M, Hill M, Bryan RT, Catto J, Donovan J et al. ( 2018 ) . Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC) . Journal of Clinical Oncology . vol. 36 , 407 - 407 .

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel III EE, Koeppen H et al. ( 2018 ) . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells . Nature vol. 554 , ( 7693 ) 544 - 548 .

Bruno R, Claret L, Wu B, Jin JY, Winter H, Cui N, Derleth CL, Shen X et al. ( 2018 ) . A tumor growth rate/overall survival model for atezolizumab as an early predictor of OS in patients with first or second line metastatic urothelial carcinoma . Journal of Clinical Oncology . vol. 36 , 62 - 62 .

Maia MC, Agarwal N, McGregor BA, Vaishampayan UN, Choueiri TK, Green MC, Hessel C, Scheffold C et al. ( 2018 ) . Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 36 , tps42 - tps42 .

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong Y-N, Pal SK, De Giorgi U, Ladoire S et al. ( 2018 ) . Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) . Annals of Oncology vol. 29 , ( 2 ) 361 - 369 .

Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC et al. ( 2018 ) . Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial . Journal of Clinical Oncology vol. 36 , ( 8 )

Hodi FS, Ballinger M, Lyons B, Soria J-C, Nishino M, Tabernero J, Powles T, Smith D et al. ( 2018 ) . Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy . Journal of Clinical Oncology vol. 36 , ( 9 )

Escudier B, Powles T, Motzer RJ, Olencki T, Arén Frontera O, Oudard S, Rolland F, Tomczak P et al. ( 2018 ) . Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial . Journal of Clinical Oncology vol. 36 , ( 8 )

Waller CF, Galsky MD, Powles T, van der Heijden MS, Li S, Hennicken D, Sonpavde G ( 2018 ) . A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients with previously untreated unresectable or metastatic urothelial carcinoma (CheckMate 901) . ONCOLOGY RESEARCH AND TREATMENT . vol. 41 , 324 - 325 .

von Amsberg G, Powles T, Loriot Y, Ravaud A, Vogelzang NJ, Duran I, Retz M, De Giorgi U et al. ( 2018 ) . Atezolizumab (atezo) vs chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): immune biomarkers, tumor mutational burden (TMB) and clinical outcomes from the Phase III IMvigor211 study . ONCOLOGY RESEARCH AND TREATMENT . vol. 41 , 325 - 326 .

de Liano AG, Venugopal B, Fife K, Khasti L, Symeonides SN, Pettinger C, Powles T, Rudman SM et al. ( 2018 ) . Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK . JOURNAL OF CLINICAL ONCOLOGY . vol. 36 ,

Schmidinger M, Tannir NM, Powles T, Escudier BJ, Donskov F, Gruenwald V, Sternberg CN, Schoffski P et al. ( 2018 ) . Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 41 , 200 - 200 .

Chalabi M, Cardona A, Nagarkar D, Scala AMD, Albert M, Kok M, Powles TB, Herrera F ( 2018 ) . Effects of antibiotics and proton pump inhibitors in NSCLC patients treated with atezolizumab and docetaxel: Pooled analysis of the OAK and POPLAR trials . ANNALS OF ONCOLOGY . vol. 29 ,

Gruellich C, Motzer RJ, Powles T, Atkins M, Escudier BJ, McDermott D, Suarez C, Bracarda S et al. ( 2018 ) . IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic Renal Cell Carcinoma (mRCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 41 , 41 - 42 .

Bergmann L, Donskov F, Motzer RJ, Voog E, Hovey EJ, Gruellich C, Nott LM, Cuff KE et al. ( 2018 ) . Outcomes based on age in the phase 3 Meteor trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 41 , 200 - 201 .

Gruellich C, Powles T, Motzer RJ, George DJ, Jonasch E, Pal SK, Tannir NM, Signoretti S et al. ( 2018 ) . Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (RCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 41 , 201 - 201 .

Agarwal N, Vaishampayan UN, McGregor BA, Green MC, Mohamed N, Chang P-Y, Powles T, Pal SK ( 2018 ) . Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 36 ,

Petrylak DP, Sternberg CN, Drakaki A, de Wit R, Nishiyama H, Necchi A, Castellano D, Bamias A et al. ( 2018 ) . RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results . ANNALS OF ONCOLOGY . vol. 29 ,

Birtle A, Johnson M, Kockelbergh R, Keeley FJ, Catto J, Bryan R, Jones R, Chester J et al. ( 2018 ) . Results of POUT - A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC) . BRITISH JOURNAL OF CANCER . vol. 119 , 44 - 45 .

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM et al. ( 2017 ) . Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens . European Urology vol. 73 , ( 3 ) 462 - 468 .

Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM et al. ( 2017 ) . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial . The Lancet vol. 391 , ( 10122 ) 748 - 757 .

Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al. ( 2017 ) . Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer . European Urology vol. 73 , ( 3 ) 311 - 315 .

Powles T, Necchi A, Rosen G, Hariharan S, Apolo AB ( 2017 ) . Anti–Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development . Clinical Genitourinary Cancer vol. 16 , ( 2 ) 117 - 129 .

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, E KE, Koeppen H et al. ( 2017 ) . 8O_PR TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma . Annals of Oncology vol. 28 ,

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S et al. ( 2017 ) . Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population . Clinical Genitourinary Cancer vol. 16 , ( 2 ) e483 - e490 .

Powles T, Choueiri TK, Agarwal N, Necchi A, Loriot Y, McKay RR, Chang P-Y, Kondo A et al. ( 2017 ) . P138 Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma and Urothelial Carcinoma . European Urology Open Science vol. 16 , ( 10 )

Necchi A, Pond G, Plimack E, Niegisch G, Yu E, Pal SK, Bamias A, Agarwal N et al. ( 2017 ) . P143 Pattern of relapse after perioperative chemotherapy and radical cystectomy versus radical cystectomy alone in patients with muscle-invasive bladder cancer (MIBC): A multicenter study . European Urology Open Science vol. 16 , ( 10 ) e2794 - e2795 .

Shaw G, Oliver T, Kealy R, Powles T, Hillman P, Cuzick J ( 2017 ) . The PROVENT study, a multicentre double blind placebo controlled randomised trial to evaluate the effects of vitamin D and aspirin on progression of low risk prostate cancer during active surveillance . European Journal of Surgical Oncology vol. 43 , ( 11 ) 2212 - 2213 .

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM et al. ( 2017 ) . First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study . The Lancet Oncology vol. 18 , ( 11 ) 1483 - 1492 .

Szabados B, van Dijk N, Tang YZ, van der Heijden MS, Wimalasingham A, de Liano AG, Chowdhury S, Hughes S et al. ( 2017 ) . Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer . European Urology vol. 73 , ( 2 ) 149 - 152 .

Petrylak DP, de Wit R, N K, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S et al. ( 2017 ) . Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial . The Lancet vol. 390 , ( 10109 ) 2266 - 2277 .

Badreldin W, Powles T, Menard L, Ho-Yen C, Kermorgant S ( 2017 ) . 60P Understanding and targeting Met signalling in bladder cancer . Annals of Oncology vol. 28 ,

Grivas P, Plimack E, Balar AV, Castellano D, O'Donnell PH, Bellmunt J, Powles T, Hahn N et al. ( 2017 ) . 857P Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status . Annals of Oncology vol. 28 ,

de Liano Lista AG, Necchi A, Lavaud P, Galceran JC, Castellano D, Ravaud A, Duran I, van Dijk N et al. ( 2017 ) . 862P Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective . Annals of Oncology vol. 28 ,

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Wong Y-N, Pal SK, De Giorgi U et al. ( 2017 ) . 866P Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC) . Annals of Oncology vol. 28 ,

Powles T, Motzer RJ, George DJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Mai TH et al. ( 2017 ) . 872P Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc) . Annals of Oncology vol. 28 , v307 - v308 .

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles D, Plimack E, Yu EY, Ladoire S et al. ( 2017 ) . 875P Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population . Annals of Oncology vol. 28 , v308 - v309 .

Wong YNS, Joshi K, Khetrapal P, Ismail M, Linares J, Akarca AU, Reading JL, Furness A et al. ( 2017 ) . 879P Urine-derived lymphocytes (UDLs) as a non-invasive surrogate marker of tumour infiltrating lymphocytes (TILs) in patients with muscle invasive bladder cancer (MIBC) . Annals of Oncology vol. 28 , v309 - v310 .

Powles T, Gschwend JE, Loriot Y, Bellmunt J, Geczi L, Vulsteke C, Abdelsalam M, Gafanov R et al. ( 2017 ) . 919TiP Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial . Annals of Oncology vol. 28 ,

Choueiri TK, Powles T, Zhang T, Quinn DI, Gschwend JE, Wan SS, Poehlein C ( 2017 ) . 922TiP KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC) . Annals of Oncology vol. 28 ,

Choueiri TK, Porta C, Rodriguez CS, Alter R, Czaykowski P, Duran I, Gross-Goupil M, Kalinka-Warzocha E et al. ( 2017 ) . 925TiP A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy . Annals of Oncology vol. 28 ,

Bex A, Mulders P, Jewett MAS, Wagstaff J, van Velthoven R, Pes PML, Wood L, van Melick HHE et al. ( 2017 ) . LBA35 Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME) . Annals of Oncology vol. 28 ,

Powles T, McDermott DF, Rini B, Motzer RJ, Atkins MB, Fong L, Joseph RW, Pal SK et al. ( 2017 ) . LBA39 IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) . Annals of Oncology vol. 28 ,

Petrylak DP, Chi KN, Drakaki A, Sternberg CN, de Wit R, Nishiyama H, Yu EY, Castellano D et al. ( 2017 ) . LBA4_PR RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma . Annals of Oncology vol. 28 ,

Escudier B, Tannir NM, McDermott DF, Frontera OA, Melichar B, Plimack ER, Barthelemy P, George S et al. ( 2017 ) . LBA5 CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups . Annals of Oncology vol. 28 , v621 - v622 .

Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, Daneshmand S, Lowrance WT et al. ( 2017 ) . Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm . Journal of Clinical Oncology vol. 35 , ( 31 )

Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC et al. ( 2017 ) . Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators . Acta Oncologica vol. 57 , ( 4 ) 491 - 497 .

Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G et al. ( 2017 ) . Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors . Clinical Genitourinary Cancer vol. 16 , ( 1 ) e161 - e167 .

Powles T, O'Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ, Lee JL, Ong M et al. ( 2017 ) . Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study . JAMA Oncol vol. 3 , ( 9 ) e172411 - e172411 .

Paul J, Kelly C, Stobo J, Powles T ( 2017 ) . Reply to M. Horiguchi et al . Journal of Clinical Oncology vol. 35 , ( 29 )

Powles T ( 2017 ) . Clinical Trials Corner . Kidney Cancer vol. 1 , ( 1 ) 89 - 91 .

Powles T ( 2017 ) . Interview with Thomas Powles: The use of durvalumab in urothelial cancer - the latest strides in immuno-oncology . Future Oncology vol. 13 , ( 18 ) 1581 - 1583 .

McDermott D, Huseni M, Rini B, Motzer R, Atkins M, Escudier B, Nickles D, Boyd Z et al. ( 2017 ) . Abstract CT081: Molecular correlates of differential response to Atezolizumab +/- Bevacizumab vs Sunitnib in a Phase II study in untreated metastatic renal cell carcinoma (RCC) patients . Cancer Research vol. 77 , ( 13_Supplement ) ct081 - ct081 .

Lubbock ALR, Stewart GD, O’Mahony FC, Laird A, Mullen P, O’Donnell M, Powles T, Harrison DJ et al. ( 2017 ) . Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer . BMC Medicine vol. 15 , ( 1 )

Choueiri TK, Plimack E, Arkenau H-T, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA et al. ( 2017 ) . Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer . Journal of Clinical Oncology vol. 35 , ( 26 )

Powles T, de Liaño AG, Ackerman C ( 2017 ) . Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed . European Urology vol. 72 , ( 5 ) e137 - e138 .

Necchi A, Mariani L, Vullo SL, Yu EY, Woods ME, Wong Y-N, Harshman LC, Alva A et al. ( 2017 ) . Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis . European Urology Focus vol. 5 , ( 2 ) 242 - 249 .

Powles T, Fizazi K, Gillessen S, Drake CG, Rathkopf DE, Narayanan S, Green MC, Mecke A et al. ( 2017 ) . A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) . Journal of Clinical Oncology . vol. 35 , tps5090 - tps5090 .

Motzer RJ, Grünwald V, Hutson TE, Porta C, Powles T, Eto M, Dutcus CE, Baig MA et al. ( 2017 ) . A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 35 , tps4595 - tps4595 .

Michaelson MD, Gupta S, Agarwal N, Szmulewitz RZ, Powles T, Pili R, Bruce JY, Vaishampayan UN et al. ( 2017 ) . Axitinib plus crizotinib in patients with advanced solid tumors and metastatic renal cell carcinoma (mRCC): Preliminary phase 1b results . Journal of Clinical Oncology . vol. 35 , 2551 - 2551 .

O'Donnell PH, Grivas P, Balar AV, Bellmunt J, Vuky J, Powles T, Plimack ER, Hahn NM et al. ( 2017 ) . Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC) . Journal of Clinical Oncology vol. 35 , ( 15_suppl ) 4502 - 4502 .

Shepherd STC, Hall P, Brown JE, Larkin JMG, Jones RJ, Ralph C, Hawkins RE, Chowdhury S et al. ( 2017 ) . Can dynamic changes in prognostic markers predict survival in patients receiving VEGF-targeted therapy in clear cell renal cell carcinoma? . Journal of Clinical Oncology . vol. 35 , e16061 - e16061 .

Tannir NM, Powles T, Escudier BJ, Donskov F, Grünwald V, Sternberg CN, Schmidinger M, Schoffski P et al. ( 2017 ) . Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 35 , 4570 - 4570 .

Choueiri TK, Larkin JMG, Oya M, Thistlethwaite FC, Martignoni M, Nathan PD, Powles T, McDermott DF et al. ( 2017 ) . First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial . Journal of Clinical Oncology vol. 35 , ( 15_suppl ) 4504 - 4504 .

Atkins MB, McDermott DF, Powles T, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK et al. ( 2017 ) . IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun) . Journal of Clinical Oncology vol. 35 , ( 15_suppl ) 4505 - 4505 .

Donskov F, Motzer RJ, Voog E, Hovey EJ, Grüllich C, Nott LM, Cuff KE, Gil T et al. ( 2017 ) . Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 35 , 4578 - 4578 .

Powles T, Gschwend JE, Loriot Y, Bellmunt J, Geczi L, Vulsteke C, Abdelsalam M, Gafanov R et al. ( 2017 ) . Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer . Journal of Clinical Oncology . vol. 35 , tps4590 - tps4590 .

Rini BI, Powles T, Chen M, Puhlmann M, Atkins MB ( 2017 ) . Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC) . Journal of Clinical Oncology . vol. 35 , tps4597 - tps4597 .

Szabados B, Van Der Heijden MS, Gomez De Liano Lista A, Tang YZ, Powles T ( 2017 ) . Responses to chemotherapy in patients with metastatic urothelial cancer (MUC) after frontline immunotherapy . Journal of Clinical Oncology . vol. 35 , e16004 - e16004 .

Powles T, Jin C, Zheng Y, Baverel P, Narwal R, Mukhopadhyay P, Jin X, Dennis PA et al. ( 2017 ) . Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab . Journal of Clinical Oncology . vol. 35 , 3035 - 3035 .

Hahn NM, Powles T, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ, Lee J-L, Ong M et al. ( 2017 ) . Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC) . Journal of Clinical Oncology . vol. 35 , 4525 - 4525 .

Stewart GD, De Santis M, Escudier B, Powles T, Sonpavde G ( 2017 ) . Immunotherapy for Renal Cancer: Sequencing and Combinations . European Urology Focus vol. 2 , ( 6 ) 582 - 588 .

Powles T, Smith K, Stenzl A, Bedke J ( 2017 ) . Immune Checkpoint Inhibition in Metastatic Urothelial Cancer . European Urology vol. 72 , ( 4 ) 477 - 481 .

Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A et al. ( 2017 ) . Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer . Journal of Clinical Oncology vol. 35 , ( 16 )

Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles T, Bex A ( 2017 ) . Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer . Angiogenesis vol. 20 , ( 2 ) 205 - 215 .

Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong Y-N, Viterbo R, Sonpavde et al. ( 2017 ) . Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study . European Urology Focus vol. 4 , ( 6 ) 937 - 945 .

Powles T, Bellmunt J, Castellano D, O’Donnell P, Grivas P, Vuky J, Plimack E, Hahn N et al. ( 2017 ) . 170 Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052 . European Urology Open Science vol. 16 , ( 3 ) e285 - e286 .

Gschwend J, Bellmunt J, Castellano D, Daneshmand S, Hussain M, Nishiyama H, Powles T, Degaonkar V et al. ( 2017 ) . 212 IMvigor010, a phase III study of adjuvant atezolizumab vs observation in patients (pts) with muscle-invasive urothelial carcinoma (UC) . European Urology Open Science vol. 16 , ( 3 ) e367 - e368 .

Dabestani S, Beisland C, Gudmundsson E, Stewart G, Lam T, Gietzmann W, Zakikhani P, Marconi L et al. ( 2017 ) . 647 Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes – a RECUR database analysis . European Urology Open Science vol. 16 , ( 3 ) e1119 - e1120 .

Szabados B, De Liano Lista AG, Wimalasingham A, De Bruijn R, Haanen J, Blank C, Hall P, Staehler M et al. ( 2017 ) . 921 Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer . European Urology Open Science vol. 16 , ( 3 )

Rudd P, Maroun P, Patrikidou A, Blanchard P, Powles T, Tipples K ( 2017 ) . Patient Satisfaction with Multidisciplinary Clinics for Early Prostate Cancer: a Comparison of the French and UK Patient Experience . Clinical Oncology . vol. 29 , e86 - e87 .

McDermott DF, Atkins MB, Motzer RJ, Rini BI, Escudier BJ, Fong L, Joseph RW, Pal SK et al. ( 2017 ) . A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts) . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 431 - 431 .

Choueiri TK, Plimack ER, Arkenau H-T, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark E et al. ( 2017 ) . A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC) . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 436 - 436 .

Pal SK, Motzer RJ, Fishman MN, McDermott RS, Passos-Coelho J, Kopyltsov E, Garcia del Muro X, Donas JG et al. ( 2017 ) . Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 522 - 522 .

Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Morales R, Burris HA, Kim JW et al. ( 2017 ) . Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 290 - 290 .

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales R, Retz M et al. ( 2017 ) . Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 323 - 323 .

Lacy S, Hutmacher MM, Yang B, Motzer RJ, Escudier BJ, Powles T, Choueiri TK, Nielsen J ( 2017 ) . Cabozantinib (C) exposure-response (ER) modeling of safety endpoints in patients (pts) with renal cell carcinoma (RCC) in the phase III METEOR study . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 447 - 447 .

Kattan MW, Van Der Graaf WTA, Powles T, Lam S, Ahmad Q, Dezzani L, Han J, Sternberg CN ( 2017 ) . Development of a prognostic nomogram for liver toxicity in patients treated with pazopanib . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 455 - 455 .

Szabados B, Wimalasingham AG, Tang YZ, Sahdev A, Gomez De Liano Lista A, Lim L, Hopkins T, Berner A et al. ( 2017 ) . High responses to chemotherapy in patients with metastatic urothelial cancer (MUC) after frontline immunotherapy . Journal of Clinical Oncology . vol. 35 , 377 - 377 .

Wimalasingham AG, Gomez De Liano Lista A, de Bruijn R, Haanen JBAG, Szabados B, Hall P, Blank CU, Chowdhury S et al. ( 2017 ) . Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer . Journal of Clinical Oncology . vol. 35 , 514 - 514 .

Ackerman C, Mariathasan S, Nickles D, Gomez De Liano Lista A, Wimalasingham AG, Szabados B, Powles T ( 2017 ) . Molecular subtyping of metastatic urothelial bladder cancer . Journal of Clinical Oncology . vol. 35 , 326 - 326 .

Donskov F, Motzer RJ, Voog E, Hovey EJ, Grüllich C, Nott LM, Cuff K, Gil T et al. ( 2017 ) . Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 517 - 517 .

Balar AV, Castellano DE, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM et al. ( 2017 ) . Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 284 - 284 .

Powles T, O'Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes C, Lee J-L, Ong M et al. ( 2017 ) . Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma . Journal of Clinical Oncology . vol. 35 , 286 - 286 .

Bellmunt J, Powles T, Vogelzang NJ ( 2017 ) . A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now . Cancer Treatment Reviews vol. 54 , 58 - 67 .

Schmidinger M, Motzer RJ, Powles T, Escudier B, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ et al. ( 2017 ) . 2117 Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR) . European Journal of Cancer . vol. 72 , s187 - s188 .

Bracarda S, Choueiri TK, Powles T, Motzer RJ, Olencki T, Frontera OA, Oudard S, Rolland F et al. ( 2017 ) . 2196 Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study . European Journal of Cancer . vol. 72 ,

Grande E, Choueiri TK, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H et al. ( 2017 ) . 2199 Effect of prior systemic therapy on clinical outcomes with cabozantinib vs everolimus in advanced renal cell carcinoma: Results from the phase 3 METEOR study . European Journal of Cancer . vol. 72 , s197 - s198 .

BALKWILL F, Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, Jangani M et al. ( 2017 ) . A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer . Journal of Clinical Investigation

Van Neste C, Laird A, O’Mahony F, Van Criekinge W, Deforce D, Van Nieuwerburgh F, Powles T, Harrison DJ et al. ( 2017 ) . Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome . Cellular Oncology vol. 40 , ( 3 ) 293 - 297 .

Motzer RJ, Grunwald V, Hutson TE, Porta C, Powles T, Eto M, Dutcus C, Baig MA et al. ( 2017 ) . A Phase III Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab vs Sunitinib Alone in First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma (RCC) . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 13 , 169 - 169 .

Choueiri TK, Porta C, Rodriguez CS, Alter R, Czaykowski P, Duran I, Gross-Goupil M, Kalinka-Warzocha E et al. ( 2017 ) . A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy . ANNALS OF ONCOLOGY . vol. 28 ,

Gruenwald V, McDermott DF, Atkins M, Motzer R, Rini B, Escudier B, Fong L, Joseph R et al. ( 2017 ) . A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts) . ONCOLOGY RESEARCH AND TREATMENT . vol. 40 , 113 - + .

Schulz C, Schmid P, Hedge P, Zou W, Kowanetz M, Mariathasan S, Gadgeel S, Powles T et al. ( 2017 ) . Association of PD-L2 expression in human tumors with atezolizumab activity . ONCOLOGY RESEARCH AND TREATMENT . vol. 40 , 134 - 134 .

von Amsberg G, Perez-Garcia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R et al. ( 2017 ) . Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): outcomes by prior therapy . ONCOLOGY RESEARCH AND TREATMENT . vol. 40 , 115 - 115 .

Escudier B, Tannir NM, McDermott DF, Frontera OA, Melichar B, Plimack ER, Barthelemy P, George S et al. ( 2017 ) . CheckMate 214: Efficacy and safety of nivolumab plus ipilimumab (N plus I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups . ANNALS OF ONCOLOGY . vol. 28 ,

Powles T, McDermott DF, Rini B, Motzer RJ, Atkins MB, Fong L, Joseph RW, Pal SK et al. ( 2017 ) . IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) . ANNALS OF ONCOLOGY . vol. 28 ,

Bex A, Mulders P, Jewett MAS, Wagstaff J, van Velthoven R, Pes PML, Wood L, van Melick HHE et al. ( 2017 ) . Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME) . ANNALS OF ONCOLOGY . vol. 28 ,

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Wong Y-N, Pal SK, De Giorgi U et al. ( 2017 ) . Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC) . ANNALS OF ONCOLOGY . vol. 28 ,

Choueiri TK, Powles T, Zhang T, Quinn DI, Gschwend JE, Wan SS, Poehlein C ( 2017 ) . KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC) . ANNALS OF ONCOLOGY . vol. 28 ,

Sonpavde G, Pond GR, Mullane S, Ramirez AA, Vogelzang NJ, Necchi A, Powles T, Bellmunt J ( 2017 ) . Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy . BJU INTERNATIONAL vol. 119 , ( 4 ) 579 - 584 .

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles D, Plimack E, Yu EY, Ladoire S et al. ( 2017 ) . Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population . ANNALS OF ONCOLOGY . vol. 28 ,

Mainwaring P, Powles T, Escudier BJ, Tannir NM, Rini BI, Hammers HJ, Donskov F, Roth BJ et al. ( 2017 ) . Overall Survival (OS) in Meteor, A Randomised Phase III Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma (RCC) . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 13 , 109 - 109 .

Grivas P, Plimack E, Balar AV, Castellano D, O'Donnell PH, Bellmunt J, Powles T, Hahn N et al. ( 2017 ) . Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status . ANNALS OF ONCOLOGY . vol. 28 ,

Powles T, Gschwend JE, Loriot Y, Bellmunt J, Geczi L, Vulsteke C, Abdelsalam M, Gafanov R et al. ( 2017 ) . Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial . ANNALS OF ONCOLOGY . vol. 28 ,

Powles T, Huddart RA, Elliott T, Sarker S-J, Ackerman C, Jones R, Hussain S, Crabb S et al. ( 2017 ) . Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer . J Clin Oncol vol. 35 , ( 1 ) 48 - 55 .

Mariathasan S, Turley SJ, Nickles D, Wang Y, Kadel EEIII, Koeppen H, Yuen K, Castiglioni A et al. ( 2017 ) . Pre-existing T cell immunity, mutational burden and stromal TGF-β signaling drives clinical responses to atezolizumab in locally advanced or metastatic urothelial carcinoma (mUC) . JOURNAL FOR IMMUNOTHERAPY OF CANCER . vol. 5 ,

Petrylak DP, Chi KN, Drakaki A, Sternberg CN, de Wit R, Nishiyama H, Yu EY, Castellano D et al. ( 2017 ) . RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma . ANNALS OF ONCOLOGY . vol. 28 ,

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Edward KEIII, Koeppen H et al. ( 2017 ) . TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma . ANNALS OF ONCOLOGY . vol. 28 , 30 - 30 .

Lista AGDL, Necchi A, Lavaud P, Carles Galceran J, Castellano D, Ravaud A, Duran I, van Dijk N et al. ( 2017 ) . Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective . ANNALS OF ONCOLOGY . vol. 28 ,

Badreldin W, Powles T, Menard L, Ho-Yen C, Kermorgant S ( 2017 ) . Understanding and targeting Met signalling in bladder cancer . ANNALS OF ONCOLOGY . vol. 28 ,

Wong YNS, Joshi K, Khetrapal P, Ismail M, Linares J, Akarca AU, Reading JL, Furness A et al. ( 2017 ) . Urine-derived lymphocytes (UDLs) as a non-invasive surrogate marker of tumour infiltrating lymphocytes (TILs) in patients with muscle invasive bladder cancer (MIBC) . ANNALS OF ONCOLOGY . vol. 28 ,

Park SH, Castellano D, Petrylak DP, Galsky MD, van der Heijden MS, Loriot Y, Ogawa O, Su W-P et al. ( 2016 ) . 285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC) . Annals of Oncology vol. 27 , ( suppl_9 )

Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong Y, Bellmunt J, De Giorgi U et al. ( 2016 ) . Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival . Cancer Medicine vol. 6 , ( 1 ) 186 - 194 .

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al. ( 2016 ) . Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma . European Urology vol. 71 , ( 5 ) 719 - 722 .

Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE et al. ( 2016 ) . A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma . European Urology vol. 71 , ( 3 ) 426 - 436 .

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A et al. ( 2016 ) . Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial . The Lancet vol. 389 , ( 10064 ) 67 - 76 .

Park SH, Castellano D, Petrylak DP, Galsky MD, van der Heijden MS, Loriot Y, Ogawa O, Su W-P et al. ( 2016 ) . 285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) 6 tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC) . Annals of Oncology vol. 27 , ix88 - ix89 .

Powles T, Motzer RJ, Escudier B, Heng DYC, Scheffold C, Clary DO, Choueiri TK ( 2016 ) . O4 Patient outcomes based on prognostic risk groups in METEOR, a randomized phase 3 study of cabozantinib (cabo) versus everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC) . European Urology Open Science vol. 15 , ( 13 ) e1546 - e1547 .

Lundqvist A, van Hoef V, Zhang X, Wennerberg E, Lorent J, Witt K, Sanz LM, Liang S et al. ( 2016 ) . 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one . Journal for ImmunoTherapy of Cancer vol. 4 , ( Suppl 1 )

Crusz SM, Tang YZ, Sarker SJ, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A et al. ( 2016 ) . Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma . BMC Medicine vol. 14 , ( 1 ) 185 - 185 .

Powles THOMAS, Huddart RA, Elliott T, SARKER S-J, Ackerman CHARLOTTE, Jones R, Hussaine S, Crabb S et al. ( 2016 ) . A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients . Journal of Clinical Oncology

Sonpavde G, Pond GR, Mullane S, Ramirez AA, Vogelzang NJ, Necchi A, Powles T, Bellmunt J ( 2017 ) . Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)‐1 or PD ligand 1 inhibitor therapy . BJU International . vol. 119 , 579 - 584 .

Necchi A, Sonpavde, Vullo SL, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J et al. ( 2016 ) . Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) . European Urology vol. 71 , ( 2 ) 281 - 289 .

Loriot Y, Rosenberg JE, Powles TB, Necchi A, Hussain S, Morales R, Retz M, Niegisch G et al. ( 2016 ) . 783P Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study . Annals of Oncology . vol. 27 ,

Bamias A, Tzannis K, Liontos M, Harshman L, Crabb SJ, Wong Y-N, Pal SK, Powles TB et al. ( 2016 ) . 798P Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database . Annals of Oncology . vol. 27 ,

Bamias A, Tzannis K, Liontos M, Crabb SJ, Harshman L, De Giorgi U, Bellmunt J, Wong Y-N et al. ( 2016 ) . 799P Adherence to cisplatin-based regimens prescription in "fit" patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis . Annals of Oncology . vol. 27 ,

Powles TB, Escudier B, de Souza P, Chowdhury S, Pook D, Harmenberg U, Basappa N, Geynisman D et al. ( 2016 ) . 814P Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial . Annals of Oncology . vol. 27 ,

Hessel C, Mangeshkar M, Motzer RJ, Escudier B, Powles TB, Schwab G, Choueiri TK ( 2016 ) . 815P Evaluation of the novel “trial within a trial” design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC) . Annals of Oncology . vol. 27 ,

Cella D, Escudier B, Tannir N, Powles T, Donskov F, Peltola K, Schmidinger M, Heng D et al. ( 2016 ) . 816P Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC) . Annals of Oncology . vol. 27 ,

Tannir N, Powles T, Motzer RJ, Rolland F, Gravis G, Staehler M, Rink M, Retz M et al. ( 2016 ) . 818P Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC) . Annals of Oncology . vol. 27 ,

Heng D, Park J, Signorovitch JE, Yang H, Song J, Weiss J, Dezzani L, Powles TB ( 2016 ) . 827P Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: a retrospective chart review in the EU . Annals of Oncology vol. 27 ,

Powles T, Grivas P, Aragon-Ching JB, Faroun Y, Kessler ER, Tomita Y, Chakrabarti D, Laliberte RJ et al. ( 2016 ) . 842TiP A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100) . Annals of Oncology vol. 27 ,

Balar A, Bellmunt J, O'Donnell PH, Castellano D, Grivas P, Vuky J, Powles T, Plimack ER et al. ( 2016 ) . LBA32_PR Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study . Annals of Oncology . vol. 27 ,

Powles T ( 2016 ) . Where next in kidney cancer? . Annals of Oncology vol. 27 , ( 8 ) 1376 - 1377 .

González-Billalabeitia E, Sepúlveda JM, Maroto P, Aparicio J, Arranz JA, Esteban E, Gironés R, López-Brea M et al. ( 2016 ) . Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer . European Urology Focus vol. 3 , ( 2-3 ) 280 - 286 .

Bex A, Ljungberg B, van Poppel H, Powles T, Association of Urology OBOTE ( 2016 ) . The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016 . European Urology vol. 70 , ( 6 ) 901 - 905 .

Smith K, Sheaff M, Elia G, Clear A, Trevisan G, Foxler D, Bridge K, Shepherd S et al. ( 2016 ) . 888 Loss of LIM-domain proteins LIMD1, Ajuba and WTIP as a novel molecular mechanism for disease aetiology in clear cell renal cell carcinoma (ccRCC) . European Journal of Cancer vol. 61 ,

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hofmann F et al. ( 2016 ) . European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy . European Urology vol. 70 , ( 5 ) 705 - 706 .

Balar AV, Galsky MD, Loriot Y, Dawson NA, Necchi A, Srinivas S, Joseph RW, Vaishampayan UN et al. ( 2016 ) . Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1 . Journal of Clinical Oncology . vol. 34 , lba4500 - lba4500 .

Feber A, Worth DC, Chakravarthy A, de Winter P, Shah K, Arya M, Saqib M, Nigam R et al. ( 2016 ) . CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma . Cancer Research vol. 76 , ( 16 ) 4720 - 4727 .

Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F et al. ( 2016 ) . Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial . The Lancet Oncology vol. 17 , ( 7 ) 917 - 927 .

Powles T, Sarwar N, Stockdale A, Sarker S-J, Boleti E, Protheroe A, Jones R, Chowdhury S et al. ( 2016 ) . Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer . JAMA Oncology vol. 2 , ( 10 ) 1303 - 1309 .

Powles T, Galsky MD, Castellano D, Van Der Heijden MS, Petrylak DP, Armstrong J, Belli R, Ferro S et al. ( 2016 ) . A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE . Journal of Clinical Oncology . vol. 34 , tps4574 - tps4574 .

Schmid P, Hegde PS, Zou W, Kowanetz M, Mariathasan S, Molinero L, Gadgeel SM, Powles T et al. ( 2016 ) . Association of PD-L2 expression in human tumors with atezolizumab activity . Journal of Clinical Oncology . vol. 34 , 11506 - 11506 .

Balar AV, Galsky MD, Loriot Y, Dawson NA, Necchi A, Srinivas S, Joseph RW, Vaishampayan UN et al. ( 2016 ) . Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1 . Journal of Clinical Oncology vol. 34 , ( 15_suppl ) lba4500 - lba4500 .

Powles T, Kilgour E, Mather R, Galer A, Arkenau H-T, Farnsworth A, Wilde J, Ratnayake J et al. ( 2016 ) . BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer . Journal of Clinical Oncology . vol. 34 , tps4577 - tps4577 .

Escudier BJ, Powles T, Motzer RJ, Olencki T, Aren OR, Oudard S, Bracarda S, Tomczak P et al. ( 2016 ) . Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study . Journal of Clinical Oncology . vol. 34 , 4558 - 4558 .

Powles T, Motzer RJ, Escudier BJ, Pal SK, Kollmannsberger CK, Pikiel J, Gurney H, Rha SY et al. ( 2016 ) . Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 34 , 4557 - 4557 .

Choueiri TK, Powles T, Escudier BJ, Tannir NM, Mainwaring P, Rini BI, Hammers HJ, Donskov F et al. ( 2016 ) . Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 34 , 4506 - 4506 .

Rosenberg JE, Petrylak DP, Van Der Heijden MS, Necchi A, O'Donnell PH, Loriot Y, Retz M, Perez-Gracia JL et al. ( 2016 ) . PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210) . Journal of Clinical Oncology . vol. 34 , 104 - 104 .

Rose TL, Ladoire S, Crehange G, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Wong Y-N et al. ( 2016 ) . Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC) . Journal of Clinical Oncology . vol. 34 , 4536 - 4536 .

Lacy S, Hutmacher MM, Yang B, Motzer RJ, Escudier BJ, Powles T, Choueiri TK, Miles D et al. ( 2016 ) . Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study . Journal of Clinical Oncology . vol. 34 , 2565 - 2565 .

Rudd P, Hines J, Cathcart P, Wilkinson K, Shaw G, Wilson P, Shamash J, Richards TM et al. ( 2016 ) . Results of the first thousand patients from a multidisciplinary prostate cancer clinic . Journal of Clinical Oncology . vol. 34 , e16602 - e16602 .

Gulley JL, Mulders P, Albers P, Banchereau J, Bolla M, Pantel K, Powles T ( 2016 ) . Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm . OncoImmunology vol. 5 , ( 4 )

Stewart GD, Powles T, Van Neste C, Meynert A, O'Mahony F, Laird A, Deforce D, Van Nieuwerburgh F et al. ( 2016 ) . Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer . Oncotarget vol. 7 , ( 18 ) 25241 - 25250 .

Xu C-F, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS et al. ( 2016 ) . HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer . Clinical Cancer Research vol. 22 , ( 6 ) 1371 - 1377 .

Powles T, Lackner MR, Oudard S, Escudier B, Ralph C, Brown JE, Hawkins RE, Castellano D et al. ( 2016 ) . Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma . Journal of Clinical Oncology vol. 34 , ( 14 ) 1660 - 1668 .

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH et al. ( 2016 ) . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial . The Lancet vol. 387 , ( 10031 ) 1909 - 1920 .

Van Der Heijden M, Retz M, Perez-Gracia JL, Necchi A, Powles T, Sridhar SS, Neigisch G, Theodore C et al. ( 2016 ) . 1142 Efficacy of atezolizumab (MPDL3280A) in platinum-treated metastatic urothelial carcinoma (mUC): Update from the IMvigor 210 phase II clinical trial . European Urology Open Science vol. 15 , ( 3 ) e1142 - e1142a .

Castellano D, Albers P, Gschwend JE, Culine S, Bullmunt J, Hussain M, Shen X, Nelson B et al. ( 2016 ) . 1143 A phase III study of the efficacy and safety of adjuvant atezolizumab (anti-PDL1) vs observation in patients with muscle-invasive urothelial carcinoma of the bladder (IMvigor 010) . European Urology Open Science vol. 15 , ( 3 )

Beaumont JL, Salsman JM, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ et al. ( 2016 ) . Quality‐adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma . Cancer vol. 122 , ( 7 ) 1108 - 1115 .

Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E et al. ( 2016 ) . A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK) . Annals of Oncology vol. 27 , ( 5 ) 880 - 886 .

McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR et al. ( 2016 ) . Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study . Journal of Clinical Oncology vol. 34 , ( 8 ) 833 - 842 .

Heng DYC, Park J, Signorovitch JE, Yang H, Song J, Patel D, Lin C, Powles T ( 2016 ) . Outcomes of second targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU . Journal of Clinical Oncology . vol. 34 , 558 - 558 .

Powles T, Hussain SA, Protheroe A, Birtle A, Chakraborti PR, Huddart R, Jagdev S, Bahl A et al. ( 2016 ) . PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours . Journal of Clinical Oncology . vol. 34 , 430 - 430 .

Escudier BJ, Motzer RJ, Powles T, Tannir NM, Davis ID, Donskov F, Grünwald V, Heng DYC et al. ( 2016 ) . Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 34 , 499 - 499 .

Ramos J, Wong Y-N, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, Hussain SA, Baniel J et al. ( 2016 ) . Venous thromboembolism (VTE) risk in patients with localized urinary tract tumors (UTT) . Journal of Clinical Oncology . vol. 34 , 422 - 422 .

Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N et al. ( 2016 ) . Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma . Molecular Cancer Therapeutics vol. 15 , ( 1 ) 172 - 183 .

Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A et al. ( 2016 ) . A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer . EUROPEAN UROLOGY vol. 69 , ( 3 ) 450 - 456 .

Powles T, Escudier B, Motzer RJ, Tannir NM, Scheffold C, Aftab DT, Chouieri TK ( 2016 ) . Clinical outcomes based on MET expression level in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC) . BJU INTERNATIONAL . vol. 118 , 4 - 4 .

Park SH, Castellano D, Petrylak DP, Galsky MD, van der Heijden MS, Loriot Y, Ogawa O, Su W-P et al. ( 2016 ) . DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC) . ANNALS OF ONCOLOGY . vol. 27 ,

Smith K, Sheaff M, Elia G, Clear A, Trevisan G, Foxler D, Bridge K, Shepherd S et al. ( 2016 ) . Loss of LIM-domain proteins LIMD1, Ajuba and WTIP as a novel molecular mechanism for disease aetiology in clear cell renal cell carcinoma (ccRCC) . EUROPEAN JOURNAL OF CANCER . vol. 61 , S206 - S206 .

Choueiri TK, Gross-Goupil M, Porta C, Suarez Rodriguez C, Patel C, Neuwirth R, Enke A, Zohren F et al. ( 2016 ) . Phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Ka-selective inhibitor TAK-117 versus everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy . BJU INTERNATIONAL . vol. 118 , 13 - 14 .

Lardas M, Stewart F, Scrimgeour D, Hofmann F, Marconi L, Dabestani S, Bex A, Volpe A et al. ( 2015 ) . Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus . European Urology vol. 70 , ( 2 ) 265 - 280 .

Harris R, Oake K, Hawkins RE, Jones RJ, Powles T, Montgomery DA ( 2015 ) . Patient needs in advanced Renal Cell Carcinoma: What are patients’ priorities and how well are we meeting them? . Patient Experience Journal vol. 2 , ( 2 ) 142 - 152 .

Powles T, Nickles D, Van Allen E, Chappey C, Zou W, Kowanetz M, Kadel E, Denker M et al. ( 2015 ) . Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) . Journal for ImmunoTherapy of Cancer vol. 3 , ( Suppl 2 )

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F et al. ( 2015 ) . Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy . European Urology vol. 69 , ( 1 ) 4 - 6 .

Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, Necchi A, Flechon A et al. ( 2015 ) . Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options—An Analysis From the Global Germ Cell Cancer Group . Journal of Clinical Oncology vol. 34 , ( 4 ) 345 - 351 .

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE et al. ( 2015 ) . Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma . New England Journal of Medicine vol. 373 , ( 19 ) 1814 - 1823 .

Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F et al. ( 2015 ) . Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project † . Annals of Oncology vol. 26 , ( 12 ) 2392 - 2398 .

Stewart GD, O'Mahony FC, Laird A, Eory L, Lubbock ALR, Mackay A, Nanda J, O'Donnell M et al. ( 2015 ) . Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer . Clinical Cancer Research vol. 21 , ( 18 ) 4212 - 4223 .

Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A et al. ( 2016 ) . A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer . European Urology . vol. 69 , 450 - 456 .

Rosenberg J, Petrylak D, Abidoye O, Van der Heijden MS, Hofman-Censits J, Necchi A, O'Donnell PH, Balmanoukian A et al. ( 2015 ) . 21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210) . European Journal of Cancer . vol. 51 ,

Harshman L, Werner L, Wong YN, Yu E, Alva A, Crabb S, Powles T, Rosenberg J et al. ( 2015 ) . 2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC) . European Journal of Cancer . vol. 51 ,

Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F, Hammers H, Hutson T et al. ( 2015 ) . 4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial . European Journal of Cancer . vol. 51 , s708 - s709 .

Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, Bex A, Bensalah K et al. ( 2015 ) . Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy . EUROPEAN UROLOGY vol. 69 , ( 4 ) 660 - 673 .

Olson TA, Murray MJ, Rodriguez-Galindo C, Nicholson JC, Billmire DF, Krailo MD, Dang HM, Amatruda JF et al. ( 2015 ) . Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration . Journal of Clinical Oncology vol. 33 , ( 27 ) 3018 - 3028 .

Bex A, Powles T, Karam JA ( 2015 ) . Role of targeted therapy in combination with surgery in renal cell carcinoma . International Journal of Urology vol. 23 , ( 1 ) 5 - 12 .

Group EBCTC ( 2015 ) . Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials . The Lancet vol. 386 , ( 10001 ) 1353 - 1361 .

Mulders PF, De Santis M, Powles T, Fizazi K ( 2015 ) . Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy . Cancer Immunology, Immunotherapy vol. 64 , ( 6 ) 655 - 663 .

Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Cruz Zambrano C, Burris HA, Kim JW et al. ( 2015 ) . A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC) . Journal of Clinical Oncology . vol. 33 , 4501 - 4501 .

Harshman LC, Werner L, Wong Y-N, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE et al. ( 2015 ) . Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC) . Journal of Clinical Oncology . vol. 33 , 4524 - 4524 .

De Santis M, Mulders P, Fizazi K, Gray TE, McCoy C, Stubbs A, Powles T ( 2015 ) . First prospective, open-label, phase 2 study of sipuleucel-T (sip-T) in European men with metastatic, castration-resistant prostate cancer (mCRPC) . Journal of Clinical Oncology . vol. 33 , e16015 - e16015 .

Hussain SA, Jackson R, Shields A, Dickinson L, Cornford P, Jones RJ, Lester JF, Chester JD et al. ( 2015 ) . Phase II randomised placebo controlled neoadjuvant chemotherapy study of nintedanib with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer . Journal of Clinical Oncology . vol. 33 , tps4574 - tps4574 .

Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, Hutson T, Harter P et al. ( 2015 ) . Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients . European Journal of Cancer vol. 51 , ( 10 ) 1293 - 1302 .

Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong Y, Yu EY, Powles T et al. ( 2015 ) . Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer . Cancer vol. 121 , ( 15 ) 2586 - 2593 .

Stewart G, Van Neste C, Meynert A, Semple C, O'Mahony F, Laird A, Mackay A, Trooskens G et al. ( 2015 ) . 779 Effect of sunitinib therapy on intratumoural heterogeneity and differential expression of genetic mutations and DNA methylation in metastatic renal cell cancer . European Urology Open Science vol. 14 , ( 2 ) e779 - e779a .

Feldman DR, Powles T ( 2015 ) . Salvage high-dose chemotherapy for germ cell tumors . Urologic Oncology Seminars and Original Investigations vol. 33 , ( 8 ) 355 - 362 .

Powles T ( 2015 ) . Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg? . European Urology vol. 68 , ( 2 ) 280 - 282 .

Powles T ( 2015 ) . The development of immunotherapy in urothelial bladder cancer . Nature Reviews Clinical Oncology vol. 12 , ( 4 ) 193 - 194 .

Kurtoglu M, Davarpanah NN, Qin R, Powles T, Rosenberg JE, Apolo AB ( 2015 ) . Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma . Clinical Genitourinary Cancer vol. 13 , ( 5 ) 410 - 420 .

Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M et al. ( 2015 ) . SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair . Oncogene vol. 34 , ( 46 ) 5699 - 5708 .

Kim JW, Bellmunt J, Powles T, Loriot Y, Vogelzang NJ, Cruz Zambrano C, Burris HA, Teng S-LM et al. ( 2015 ) . Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study . Journal of Clinical Oncology . vol. 33 , 297 - 297 .

Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C et al. ( 2015 ) . Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial . Clinical Cancer Research vol. 21 , ( 5 ) 1071 - 1077 .

Stewart G, Van Neste C, Meynert A, Semple C, O'Mahony F, Laird A, Mackay A, Trooskens G et al. ( 2015 ) . Effect of sunitinib treatment on mutations and methylation in metastatic renal cancer . Journal of Clinical Oncology . vol. 33 , 492 - 492 .

Ferguson J, McKibben M, Parker JS, Wallen E, Wood CG, Powles T, Rathmell K ( 2015 ) . Evaluation of the effects of neoadjuvant pazopanib for renal cell carcinoma on intratumor genetic heterogeneity . Journal of Clinical Oncology . vol. 33 , 425 - 425 .

Fitzpatrick A, Soosaipillai G, Wilson P, Powles T, Shamash J ( 2015 ) . High Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma in the VEGF Targeted Era . Clinical Oncology vol. 27 , ( 3 ) e7 - e8 .

Ramos J, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong Y-N, Bellmunt J, De Giorgi U et al. ( 2015 ) . Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT) . Journal of Clinical Oncology . vol. 33 , 318 - 318 .

Gurung PMS, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ et al. ( 2015 ) . Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer . International Journal of Cancer vol. 136 , ( 3 ) 709 - 720 .

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T et al. ( 2015 ) . EAU Guidelines on Renal Cell Carcinoma: 2014 Update . European Urology vol. 67 , ( 5 ) 913 - 924 .

Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R et al. ( 2015 ) . A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer . Eur Urol vol. 67 , ( 1 ) 100 - 110 .

Mather SJ, Nock BA, Maina T, Gibson V, Ellison D, Murray I, Sobnack R, Colebrook S et al. ( 2014 ) . GRP receptor imaging of prostate cancer using [(99m)Tc]Demobesin 4: a first-in-man study . Mol Imaging Biol vol. 16 , ( 6 ) 888 - 895 .

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA et al. ( 2014 ) . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer . Nature vol. 515 , ( 7528 ) 558 - 562 .

Escudier B, Porta C, Powles T, Eisen T, Sternberg CN, Mehmud F, Cella D ( 2014 ) . Reply to S. Barni et Al and M. Sun et Al . J Clin Oncol vol. 32 , ( 33 ) 3783 - 3784 .

Xiao Y, Rabe C, Kowanetz M, Powles T, Vogelzang NJ, Petrylak DP, Loriot Y, Denker M et al. ( 2014 ) . Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer . Journal for ImmunoTherapy of Cancer vol. 2 , ( Suppl 3 )

Choueiri TK, Escudier B, Pal SK, Jonasch E, Heng D, Powles T, Arkenau HT, Clark E et al. ( 2014 ) . 395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC) . European Journal of Cancer . vol. 50 , 126 - 127 .

Stewart GD, O'Mahony FC, Laird A, Rashid S, Martin SA, Eory L, Lubbock ALR, Nanda J et al. ( 2014 ) . Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer . Eur Urol vol. 66 , ( 5 ) 956 - 963 .

Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TBL, Canfield SE, Staehler M, Powles T et al. ( 2014 ) . Local treatments for metastases of renal cell carcinoma: a systematic review . The Lancet Oncology vol. 15 , ( 12 ) e549 - e561 .

Rodriguez‐Vida A, Bianchini D, Van Hemelrijck M, Hughes S, Malik Z, Powles T, Bahl A, Rudman S et al. ( 2014 ) . Is there an antiandrogen withdrawal syndrome with enzalutamide? . BJU International vol. 115 , ( 3 ) 373 - 380 .

Ghazaly E, Perry J, Kitromilidou C, Powles T, Joel S ( 2014 ) . Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: comparison with a validated HPLC-fluorescence method . J Chromatogr B Analyt Technol Biomed Life Sci vol. 969 , 213 - 218 .

Berlato C, Kahn MN, Schioppa T, Thompson R, Maniati E, Canosa M, Kulbe H, Sheldon C et al. ( 2014 ) . Abstract 1076: Antagonists of the chemokine receptor CCR4 reverse the tumor-promoting microenvironment of renal cancer . Cancer Research . vol. 74 , 1076 - 1076 .

Bellmunt J, Petrylak DP, Powles T, Braiteh F, Vogelzang N, Cruz C, Burris H, Eder JP et al. ( 2014 ) . 808O Inhibition of Pd-L1 By Mpdl3280A Leads to Clinical Activity in Pts with Metastatic Urothelial Bladder Cancer (Ubc) . Annals of Oncology vol. 25 ,

McDermott DF, Sznol M, Sosman JA, Soria J-C, Gordon MS, Hamid O, Delord J, Fasso M et al. ( 2014 ) . 809O Immune Correlates and Long Term Follow Up of a Phase Ia Study of Mpdl3280A, an Engineered Pd-L1 Antibody, in Patients with Metastatic Renal Cell Carcinoma (Mrcc) . Annals of Oncology vol. 25 ,

Beyer J, Lorch A, Powles T, Kramar A, van Alstine L, Giannatempo P, Sava T, Albany C et al. ( 2014 ) . 813PD Brain Metastases in Male Germ Cell Tumors (Gct): a Large Retrospective Analysis on Behalf of the Swenoteca and the G3 Consortium . Annals of Oncology vol. 25 ,

Kramar A, Filleron T, Sylvester R, Escudier B, Joniau S, Mulders P, Negrier S, Powles T ( 2014 ) . 833P International Guidelines for the Definition of Time to Event Endpoints (Tee) in Renal Cell Cancer (Rcc) Randomised Clinical Trials (Rct): Results of the Datecan Project . Annals of Oncology vol. 25 ,

Powles T, Hawkins R, Ralph C, Larkin J, Jones RJ, Chowdhury S, Boleti E, Fife K et al. ( 2014 ) . LBA24 A Randomised Phase Ii Study of Cediranib with or Without Src Inhibition (Saracatinib) in Metastatic Clear Cell Renal Cancer (Rcc) Patients Resistant to Vegf Targeted Therapy . Annals of Oncology . vol. 25 ,

Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, Powles T, Warde PR et al. ( 2014 ) . Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance . Journal of Clinical Oncology vol. 33 , ( 1 ) 51 - 57 .

Powles T, Foreshew S-JS, Shamash J, Sarwar N, Crabb S, Sahdev A, Nixon J, Lim L et al. ( 2014 ) . A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer . Eur J Cancer vol. 50 , ( 12 ) 2057 - 2064 .

Powles T, Davies R, Rini B ( 2014 ) . Mammalian target of rapamycin inhibitors: the beginning of the end or the end of the beginning? . Eur Urol vol. 66 , ( 2 ) 282 - 283 .

Gurung PMS, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ et al. ( 2014 ) . Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle‐invasive bladder cancer . International Journal of Cancer vol. 136 , ( 3 ) 709 - 720 .

Stewart GD, Harrison DJ, Berney DM, Powles T ( 2014 ) . The molecular biology of renal cancer: another piece of the puzzle . Eur Urol vol. 66 , ( 1 ) 85 - 86 .

Powles T, Oudard S, Escudier BJ, Brown JE, Hawkins RE, Castellano DE, Ravaud A, Staehler MD et al. ( 2014 ) . A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT) . Journal of Clinical Oncology . vol. 32 , 4525 - 4525 .

Galsky MD, Harshman LC, Crabb SJ, Wong Y-N, Yu EY, Chowdhury S, Powles T, Pal SK et al. ( 2014 ) . Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) . Journal of Clinical Oncology . vol. 32 , 4512 - 4512 .

Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS, Loriot Y, Cruz Zambrano C, Bellmunt J et al. ( 2014 ) . Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC) . Journal of Clinical Oncology . vol. 32 , 5011 - 5011 .

Jones RJ, Chester JD, Dixon-Hughes J, Alexander L, Bahl A, Hussain SA, Birtle A, Jagdev S et al. ( 2014 ) . Pazopanib versus paclitaxel in relapsed urothelial tumors: A randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive transitional cell carcinoma of the urothelium (PLUTO) . Journal of Clinical Oncology . vol. 32 , tps4589 - tps4589 .

Choueiri TK, Escudier BJ, Powles T, Cella D, Ru QC, Scheffold C, Motzer RJ ( 2014 ) . Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear cell renal cell carcinoma (METEOR) . Journal of Clinical Oncology vol. 32 , ( 15_suppl ) tps4601 - tps4601 .

Beaumont JL, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ, Cella D ( 2014 ) . Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN) . Journal of Clinical Oncology . vol. 32 , 4581 - 4581 .

Cuzick JM, Brentnall A, Segal C, Sestak I, Kealy R, Howell A, Powles TJ, Orr N et al. ( 2014 ) . Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials . Journal of Clinical Oncology . vol. 32 , 1519 - 1519 .

Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U et al. ( 2014 ) . Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study . J Clin Oncol vol. 32 , ( 14 ) 1412 - 1418 .

Stewart GD, Laird A, O'Mahony FC, Eory L, Lubbock ALR, Nanda J, O'Donnell M, Mackay A et al. ( 2014 ) . 197 The effect of anti-VEGF tyrosine kinase inhibitors on biomarkers and tumour heterogeneity in metastatic clear cell renal cancer . European Urology Open Science vol. 13 , ( 1 )

Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJG, Powles T ( 2014 ) . Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations . Eur Urol vol. 65 , ( 4 ) 766 - 777 .

Bharwani N, Miquel ME, Powles T, Dilks P, Shawyer A, Sahdev A, Wilson PD, Chowdhury S et al. ( 2014 ) . Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma . Br J Cancer vol. 110 , ( 3 ) 616 - 624 .

Fitzpatrick AM, Greenwood M, Foreshew A, Nixon J, Sahdev A, Sarwar N, Lim L, Jones RJ et al. ( 2014 ) . A phase Ib study exploring the combination of everolimus and dovitinib in VEGF-refractory clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Kwan A, Shamash J, Powles T, Ansell W, Chowdhury S, Harland SJ, Lamont A, Wade R et al. ( 2014 ) . An audit of adjuvant carboplatin in patients with stage I testicular seminoma (Anglian Germ Cell Cancer Group, UK) . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Choueiri TK, Figueroa DJ, Liu Y, Gagnon RC, Deen KC, Carpenter C, Bartlett-Pandite AN, De Souza P et al. ( 2014 ) . Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

McDermott DF, Kluger HM, Sosman JA, Infante JR, Soria J-C, Hamid O, Delord J-P, Fasso M et al. ( 2014 ) . Immune correlates and long-term follow-up of a Phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC) . BJU INTERNATIONAL . vol. 114 , 12 - 12 .

Rodriguez-Vida A, Bianchini D, Hughes S, Lorente D, Crawley D, Van Hemelrijck M, Voskoboynik M, Chau NM et al. ( 2014 ) . Is there an anti-androgen withdrawal effect with enzalutamide? . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Patel N, Arya M, Muneer A, Powles T, Sullivan M, Hines J, Kelly J ( 2014 ) . Molecular aspects of upper tract urothelial carcinoma . Urol Oncol vol. 32 , ( 1 ) 28.e11 - 28.e20 .

Powles T ( 2014 ) . ROLE OF AUTOLOGOUS TRANSPLANTATION IN GERM CELL TUMOR (GCT). OVERVIEW OF TIGER STUDY . BONE MARROW TRANSPLANTATION . vol. 49 , S98 - S98 .

Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME et al. ( 2014 ) . Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity . CLINICAL GENITOURINARY CANCER vol. 12 , ( 4 ) 262 - 269 .

Stewart G, Laird A, O'Mahony F, Eory L, Lubbock A, Nanda J, O'Donnell M, Mackay A et al. ( 2014 ) . The effect of sunitinib on biomarkers and tumor heterogeneity in metastatic clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A et al. ( 2013 ) . The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer . Clin Cancer Res vol. 19 , ( 24 ) 6924 - 6934 .

Powles T, Kelly J ( 2013 ) . Innovation: London Cancer-multidisciplinary approach to urological cancer . Nat Rev Clin Oncol vol. 10 , ( 11 ) 609 - 610 .

Bhattacharyya M, Powles T, Mutsvangwa K, Wilson P, Oliver T, Shamash J ( 2013 ) . A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder . Urol Oncol vol. 31 , ( 6 ) 878 - 882 .

Powles T, Kayani I, Sharpe K, Lim L, Peters J, Stewart GD, Berney D, Sahdev A et al. ( 2013 ) . A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer . Ann Oncol vol. 24 , ( 8 ) 2098 - 2103 .

Tookman L, Rashid S, Matakidou A, Phillips M, Wilson P, Ansell W, Jamal-Hanjani M, Chowdhury S et al. ( 2013 ) . Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma . Acta Oncol vol. 52 , ( 5 ) 987 - 993 .

Cho DC, Sosman JA, Sznol M, Gordon MS, Hollebecque A, Hamid O, McDermott DF, Delord J-P et al. ( 2013 ) . Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC) . Journal of Clinical Oncology vol. 31 , ( 15_suppl ) 4505 - 4505 .

Powles T, Sarwar N, Stockdale A, Boleti E, Jones RJ, Protheroe A, Chowdhury S, Peters J et al. ( 2013 ) . Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study . Journal of Clinical Oncology vol. 31 , ( 15_suppl ) 4508 - 4508 .

Galsky MD, Chowdhury S, Bellmunt J, Wong Y-N, Recine F, Pal SK, Moshier EL, Ladoire S et al. ( 2013 ) . Treatment patterns and outcomes in “real world” patients (pts) with metastatic urothelial cancer (UC) . Journal of Clinical Oncology vol. 31 , ( 15_suppl ) 4525 - 4525 .

Powles T, Crusz SM ( 2013 ) . Sequencing Systemic Therapies in Advanced RCC: Is There a Best Strategy? . American Society of Clinical Oncology Educational Book ( 33 ) e172 - e174 .

Gurung PMS, Counsell N, Douglas J, Tan W, Feber A, Short S, Crabb S, West C et al. ( 2013 ) . 58 DNA damage response (DDR) genes are predictive of response to radiotherapy for muscle invasive bladder cancer . European Urology Open Science vol. 12 , ( 1 ) e58 - e59 .

Birtle A, Lewis R, Chester J, Donovan J, Johnson M, Jones R, Kockelbergh R, Powles T et al. ( 2013 ) . 81 Peri-operative chemotherapy or surveillance in upper tract urothelial cancer (POUT – CRUK/11/027) – a randomised controlled trial to define standard post-operative management . European Urology Open Science vol. 12 , ( 1 ) e81 - e82 .

Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb S, Shamash J et al. ( 2013 ) . The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López . Eur J Cancer vol. 49 , ( 4 ) 986 - 987 .

Pal P, Roy A, Moore G, Muzslay M, Lee E, Alder S, Wilson P, Powles T et al. ( 2013 ) . Keypad mobile phones are associated with a significant increased risk of microbial contamination compared to touch screen phones . Journal of Infection Prevention vol. 14 , ( 2 ) 65 - 68 .

O'Mahony FC, Nanda J, Laird A, Mullen P, Caldwell H, Overton IM, Eory L, O'Donnell M et al. ( 2013 ) . The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers . Journal of Visualized Experiments ( 71 )

Choueiri TK, Escudier B, Powles T, Cella D, Lee Y, Laird DA, Scheffold C, Motzer RJ ( 2013 ) . A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR) . BJU INTERNATIONAL . vol. 112 , 4 - 4 .

Nichols CR, Roth B, Albers P, Einhorn LH, Foster R, Daneshmand S, Jewett M, Warde P et al. ( 2013 ) . Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 31 , ( 28 ) 3490 - 3493 .

Rini BI, Powles T ( 2013 ) . Biology and Treatment of Advanced Renal Cell Carcinoma: A Global Perspective . SEMINARS IN ONCOLOGY vol. 40 , ( 4 ) 419 - 420 .

Jamal-Hanjani M, Karpathakis A, Kwan A, Mazhar D, Ansell W, Shamash J, Harper P, Rudman S et al. ( 2013 ) . Bone metastases in germ cell tumours: lessons learnt from a large retrospective study . BJU INTERNATIONAL vol. 112 , ( 2 ) 176 - 181 .

Cho DC, Sosman JA, Sznol M, Gordon MS, Hollebecque A, Hamid O, McDermott DF, Delord J-P et al. ( 2013 ) . Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,

Powles T, Sharpe K, Berney D, Kayani I, Doshi R, Stewart GD, Reynolds A, Bex A et al. ( 2013 ) . Dynamic molecular changes with VEGF targeted therapy in metastatic clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,

Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, Yu M, O'Rourke M et al. ( 2013 ) . Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer . CLINICAL GENITOURINARY CANCER vol. 11 , ( 2 ) 175 - 181 .

Crusz SM, Tang YZ, Sandev A, Kayani I, Harris L, Beltran L, Peters J, Swanton C et al. ( 2013 ) . Heterogeneous response and progression patterns of renal cell carcinoma metastases in individual patients reveal intra-tumour heterogeneity of anti-angiogenic drug resistance . EUROPEAN JOURNAL OF CANCER . vol. 49 , S641 - S641 .

Lim L, Mathias J, Lampron M, Fehr M, Gruenwald V, Khan M, Crabb S, Choueiri T et al. ( 2013 ) . Liver toxicity in patients with metastatic renal cell carcinoma treated with pazopanib therapy . EUROPEAN JOURNAL OF CANCER . vol. 49 , S660 - S660 .

Hodi FS, Powles T, Cassier P, Kowanetz M, Herbst RS, Soria JC, Mokatrin A, Stroh M et al. ( 2013 ) . MPDL3280A (anti-PDL1): Clinical activity, safety and biomarkers of an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors . EUROPEAN JOURNAL OF CANCER . vol. 49 , S184 - S184 .

Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E et al. ( 2013 ) . Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer . ANNALS OF ONCOLOGY vol. 24 , ( 4 ) 878 - 888 .

Powles T, Sarwar N, Stockdale A, Boleti E, Jones RJ, Protheroe A, Chowdhury S, Peters J et al. ( 2013 ) . Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,

Mulder P, De Santis M, Fizazi K, Whitmore J, Sheikh N, McCoy C, Stubbs A, Powles T ( 2013 ) . Preliminary product parameters from P11-1, a Phase 2, open-label trial of sipuleucel-T in European men with metastatic castrate-resistant prostate cancer (mCRPC) . EUROPEAN JOURNAL OF CANCER . vol. 49 , S696 - S696 .

Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T, Bex A ( 2013 ) . Probability of Downsizing Primary Tumors of Renal Cell Carcinoma by Targeted Therapies Is Related to Size at Presentation . UROLOGY vol. 81 , ( 1 ) 111 - 115 .

Powles T, Bascoul-Mollevi C, Kramar A, Lorch A, Beyer J ( 2013 ) . Prognostic impact of LDH levels in patients with relapsed/refractory seminoma . JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY vol. 139 , ( 8 ) 1311 - 1316 .

Powles T, Crusz SM ( 2013 ) . Sequencing systemic therapies in advanced RCC: is there a best strategy? . Am Soc Clin Oncol Educ Book

Hardt A, Wilson P, Powles T, Shamash J ( 2013 ) . The Outcome of Brain Metastases in Patients with Metastatic Germ Cell Tumours - Is Cranial Irradiation Necessary? . CLINICAL ONCOLOGY vol. 25 , ( 4 ) E70 - E71 .

Powles T, Kollmannsberger C, Feldman DR ( 2013 ) . The conundrum of clinical trials in adult germ-cell tumours . Lancet Oncol vol. 14 , ( 1 ) 14 - 15 .

Powles T ( 2013 ) . The mechanism of resistance to targeted therapy . EUROPEAN JOURNAL OF CANCER . vol. 49 , S38 - S38 .

Galsky MD, Chowdhury S, Bellmunt J, Wong Y-N, Recine F, Pal SK, Moshier EL, Ladoire S et al. ( 2013 ) . Treatment patterns and outcomes in "real world" patients (pts) with metastatic urothelial cancer (UC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,

Powles T, Albers P ( 2012 ) . Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy . Clin Genitourin Cancer vol. 10 , ( 4 ) 213 - 218 .

Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb SJ, Shamash J et al. ( 2012 ) . An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer . Eur J Cancer vol. 48 , ( 17 ) 3171 - 3176 .

Lim L, Powles T ( 2012 ) . The management of low-stage non-seminomatous germ cell tumors . Oncology Reviews vol. 6 , ( 2 )

Sharpe K, Lu Y, Berney D, Rofe C, Powles T ( 2012 ) . 501 Preclinical Data Investigating the Use of Saracatinib in Renal Cell Carcinoma . Annals of Oncology vol. 23 ,

Powles TB, Jones RJ, Crabb S, Sarker S, Boleti E, Shamash J, Sarwar N, Chowdhury S ( 2012 ) . 822P A Phase I Dose Escalation Study Investigating Dovitinib and Everolmus in Combination in Metastatic Clear Cell Renal Cancer Patients who have Previously Failed VEGF Targeted Therapy . Annals of Oncology vol. 23 ,

Valladares FP, Choueiri TK, Hutson TE, Powles TB, Porta C, Bracarda S, Lampron ME, Cerbone L et al. ( 2012 ) . 840P Sequential Targeted Therapy Following Pazopanib (PZ) in Patients (PTS) with Metastatic Renal Cell Cancer (MRCC): Efficacy and Toxicity . Annals of Oncology vol. 23 ,

Lim FL, Shamash J, Wilson P, Powles T ( 2012 ) . 880 Liver Toxicity in Patients with Metastatic Renal Cell Carcinoma Treated with Pazopanib Therapy . Annals of Oncology vol. 23 ,

Birtle AJ, Lewis R, Chester J, Donovan J, Johnson M, Jones RJ, Kockelbergh R, Powles TB et al. ( 2012 ) . 887 Peri-Operative Chemotherapy or Surveillance in Upper Tract Urothelial Cancer (POUT - CRUK/11/027) - A New Randomised Controlled Trial to Define Standard Post-Operative Management . Annals of Oncology vol. 23 ,

Powles T, Hutson TE ( 2012 ) . Difficulty in predicting survival in metastatic renal cancer . Lancet Oncol vol. 13 , ( 9 ) 859 - 860 .

Lim L, Powles T ( 2012 ) . New prognostic models in metastatic renal cancer . Translational Andrology and Urology vol. 1 , ( 3 ) 144 - 145 .

Powles T, Bex A ( 2012 ) . Integration of Surgery in Metastatic Renal Cancer . Renal Cell Carcinoma , Springer Nature

de Bruijn RE, Kroon BK, Horenblas S, Prevoo W, Powles T, Bex A ( 2012 ) . Tumordownsizing met targetedtherapie van niercelcarcinomen is effectiever bij kleine primaire tumoren . Tijdschrift voor Urologie vol. 2 , ( 3 ) 76 - 77 .

Powles T ( 2012 ) . Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns . Clin Genitourin Cancer vol. 10 , ( 2 ) 67 - 68 .

Rashid S, Lim L, Powles T ( 2012 ) . Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy . Curr Treat Options Oncol vol. 13 , ( 2 ) 201 - 211 .

Bex A, Powles T, Blank CU, Chowdhury S, Horenblas S, Peters J, Boleti E, Haanen JBAG ( 2012 ) . Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC) . Journal of Clinical Oncology vol. 30 , ( 15_suppl ) 4611 - 4611 .

Badreldin W, Chowdhury S, Harland SJ, Mazhar D, Powles T, Wilson P, Shamash J ( 2012 ) . The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours: A non-cisplatin-based regimen . Journal of Clinical Oncology vol. 30 , ( 15_suppl ) 4529 - 4529 .

Kitromilidou C, McDonald D, Cutillas P, Ghazaly E, Perry J, Csaba B, Joel S, Powles T ( 2012 ) . Abstract 1792: The potential role of targeting HER1-4 in bladder cancer . Cancer Research vol. 72 , ( 8_Supplement ) 1792 - 1792 .

Shamash J, Jacob J, Agrawal S, Powles T, Mutsvangwa K, Wilson P, Stebbing J ( 2012 ) . Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study . Clin Cancer Res vol. 18 , ( 8 ) 2352 - 2359 .

Stewart GD, O'Mahony F, Eory L, Nanda J, Laird A, O'Donnell M, Mullen P, Riddick A et al. ( 2012 ) . Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression . J Clin Oncol vol. 30 , ( 5_suppl )

Gurung PMS, Williamson M, West C, Counsell N, Ahmed A, Benthani F, Feber A, Dewinter P et al. ( 2012 ) . 669 The tumour suppressor gene, AIMP3 sensitises bladder cancer to chemo/radiotherapy in vitro and is a prognostic marker for overall survival in patients treated with radiotherapy for muscle invasive disease . European Urology Open Science vol. 11 , ( 1 ) e669 - e669a .

Powles TB, Jones RJ, Crabb S, Sarker S, Boleti E, Shamash J, Sarwar N, Chowdhury S ( 2012 ) . A PHASE I DOSE ESCALATION STUDY INVESTIGATING DOVITINIB AND EVEROLMUS IN COMBINATION IN METASTATIC CLEAR CELL RENAL CANCER PATIENTS WHO HAVE PREVIOUSLY FAILED VEGF TARGETED THERAPY . ANNALS OF ONCOLOGY . vol. 23 , 272 - 272 .

Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP et al. ( 2012 ) . A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer . EUROPEAN UROLOGY vol. 62 , ( 3 ) 523 - 533 .

Blick C, Hall P, Pwint T, Al-Terkait F, Crew J, Powles T, Macaulay V, Munro N et al. ( 2012 ) . Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder . CANCER vol. 118 , ( 16 ) 3920 - 3927 .

Kitromilidou C, Ghazaly E, Joel S, Powles T ( 2012 ) . COMBINING HER1-4 TARGETED THERAPIES AND CHEMOTHERAPY IN BLADDER CANCER . ANNALS OF ONCOLOGY . vol. 23 , 35 - 35 .

Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D et al. ( 2012 ) . Contrasting effects of sunitinib within in vivo models of metastasis . ANGIOGENESIS vol. 15 , ( 4 ) 623 - 641 .

Lim FL, Shamash J, Wilson P, Powles T ( 2012 ) . LIVER TOXICITY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH PAZOPANIB THERAPY . ANNALS OF ONCOLOGY . vol. 23 , 290 - 290 .

Porta C, Tortora G, Linassier C, Papazisis K, Awada A, Berthold D, Maroto JP, Powles T et al. ( 2012 ) . Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement . MEDICAL ONCOLOGY vol. 29 , ( 3 ) 1896 - 1907 .

Thillai K, Allan S, Powles T, Rudman S, Chowdhury S ( 2012 ) . Neoadjuvant and adjuvant treatment of renal cell carcinoma . EXPERT REVIEW OF ANTICANCER THERAPY vol. 12 , ( 6 ) 765 - 776 .

Bex A, Powles T, Blank CU, Chowdhury S, Horenblas S, Peters J, Boleti E, Haanen JBAG ( 2012 ) . Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 30 ,

Birtle AJ, Lewis R, Chester J, Donovan J, Johnson M, Jones RJ, Kockelbergh R, Powles TB et al. ( 2012 ) . PERI-OPERATIVE CHEMOTHERAPY OR SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER ( POUT - CRUK/11/027) - A NEW RANDOMISED CONTROLLED TRIAL TO DEFINE STANDARD POST-OPERATIVE MANAGEMENT . ANNALS OF ONCOLOGY . vol. 23 , 292 - 292 .

Sharpe K, Lu Y, Berney D, Rofe C, Powles T ( 2012 ) . PRECLINICAL DATA INVESTIGATING THE USE OF SARACATINIB IN RENAL CELL CARCINOMA . ANNALS OF ONCOLOGY . vol. 23 , 172 - 172 .

Shaw GL, Hussain M, Nair R, Bycroft J, Beltran L, Green JSA, Powles T, Peters JL ( 2012 ) . Performing Cytoreductive Nephrectomy following Targeted Sunitinib Therapy for Metastatic Renal Cell Carcinoma: A Surgical Perspective . UROLOGIA INTERNATIONALIS vol. 89 , ( 1 ) 83 - 88 .

Stewart GD, O'Mahony F, Eory L, Nanda J, Laird A, O'Donnell M, Mullen P, Riddick A et al. ( 2012 ) . Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression . JOURNAL OF CLINICAL ONCOLOGY vol. 30 , ( 5 )

Stewart GD, O'Mahony FC, Eory L, Nanda J, Laird A, O'Donnell M, Mullen P, Riddick ACP et al. ( 2012 ) . Proteomic analysis of pre- and postsunitinib treated renal cancer tissue to assess tumour heterogeneity and differential protein expression . SCOTTISH MEDICAL JOURNAL vol. 57 , ( 4 ) 245 - 246 .

Doshi R, O'Donnel M, Bex A, Beltran L, Sahdev A, Peters J, Harrison DJ, Stewart GD et al. ( 2012 ) . Renal Cell Carcinoma before and after Sunitinib Therapy. Morphological and Molecular Changes . LABORATORY INVESTIGATION . vol. 92 , 201A - 201A .

Pons Valladares F, Choueiri TK, Hutson TE, Powles TB, Porta C, Bracarda S, Lampron ME, Cerbone L et al. ( 2012 ) . SEQUENTIAL TARGETED THERAPY FOLLOWING PAZOPANIB (PZ) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CANCER (MRCC): EFFICACY AND TOXICITY . ANNALS OF ONCOLOGY . vol. 23 , 278 - 278 .

Bex A, Powles T ( 2012 ) . Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when . EXPERT REVIEW OF ANTICANCER THERAPY vol. 12 , ( 6 ) 787 - 797 .

Porta C, Powles T ( 2012 ) . Sequential therapy in metastatic renal cell carcinoma: what comes next? . MEDICAL ONCOLOGY vol. 29 , ( 3 ) 1914 - 1915 .

Karpathakis A, Jamal-Hanjani M, Kwan A, Mazhar D, Rudman SM, Powles T, Shamash J, Chowdhury S ( 2012 ) . Testicular germ cell tumors with bony metastases: Diagnosis, management, and outcomes (a case series) . JOURNAL OF CLINICAL ONCOLOGY vol. 30 , ( 5 )

Badreldin W, Chowdhury S, Harland SJ, Mazhar D, Powles T, Wilson P, Shamash J ( 2012 ) . The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours: A non-cisplatin-based regimen . JOURNAL OF CLINICAL ONCOLOGY . vol. 30 ,

Boleti E, Sarwar N, Jones RR, Chowdhury S, Crabb SJ, Shamash J, Peters J, Oades G et al. ( 2012 ) . The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 30 , ( 5 )

Gurung PMS, Williamson M, West C, Counsell N, Ahmed A, Benthani F, Feber A, Dewinter P et al. ( 2012 ) . The tumour suppressor gene, AIMP3 sensitises bladder cancer to chemo/radiotherapy in vitro and is a prognostic marker for overall survival in patients treated with radiotherapy for muscle invasive disease . EUROPEAN UROLOGY SUPPLEMENTS vol. 11 , ( 1 ) E669 - U430 .

Kalin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A, Cerny T et al. ( 2011 ) . Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome . EUR UROL vol. 60 , ( 6 ) 1235 - 1243 .

Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF et al. ( 2011 ) . Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis . BJU INT vol. 108 , ( 8 ) 1279 - 1283 .

Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF et al. ( 2011 ) . Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis . BJU Int vol. 108 , ( 8 ) 1279 - 1283 .

Stephenson AJ, Aprikian AG, Gilligan TD, Oldenburg J, Powles T, Toner GC, Waters WB ( 2011 ) . Management of Low-stage Nonseminomatous Germ Cell Tumors of Testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009 . UROLOGY vol. 78 , ( 4 ) S444 - S455 .

Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P et al. ( 2011 ) . Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer . Clin Cancer Res vol. 17 , ( 18 ) 6021 - 6028 .

Rimmer Y, Chester J, Joffe J, Stark D, Shamash J, Powles T, White J, Wason J et al. ( 2011 ) . Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour . BRIT J CANCER vol. 105 , ( 6 ) 766 - 772 .

Bex A, Powles T ( 2011 ) . Reply from Authors re: Simon P. Kim, R. Houston Thompson. Sunitinib Prior to Planned Cytoreductive Nephrectomy: Is This the New Litmus Test for Metastatic Renal Cell Carcinoma? Eur Urol 2011;60:455-6 . EUR UROL vol. 60 , ( 3 ) 456 - 457 .

Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E et al. ( 2011 ) . The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer . Eur Urol vol. 60 , ( 3 ) 448 - 454 .

Bex A, Powles T ( 2011 ) . Reply to The sequence of cytoreductive nephrectomy: glass half empty or glass half full? . ANN ONCOL vol. 22 , ( 7 ) 1691 - 1691 .

Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Flechon A et al. ( 2011 ) . Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database . J CLIN ONCOL vol. 29 , ( 16 ) 2178 - 2184 .

Powles T ( 2011 ) . Stage I nonseminomatous germ cell tumor of the testis: more questions than answers? . Hematol Oncol Clin North Am vol. 25 , ( 3 ) 517 - viii .

Shamash J, Jacob J, Powles T, Agrawal S, Mutsvangwa K, Saunders N, Wilson P, Stebbing J ( 2011 ) . Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study . J Clin Oncol vol. 29 , ( 15_suppl )

Stewart GD, O'Mahony FC, Powles T, Riddick ACP, Harrison DJ, Faratian D ( 2011 ) . What can molecular pathology contribute to the management of renal cell carcinoma? . NAT REV UROL vol. 8 , ( 5 ) 255 - 265 .

Bex A, Blank C, Chowdhury S, Nichol D, Peters J, Horenblas S, O'Brien T, Sarwar N et al. ( 2011 ) . 1768 PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC) . Journal of Urology vol. 185 , ( 4 ) e709 - e710 .

Powles T, Chowdhury S, Shamash J, Bazeos A, Gillessen S, Saunders N, Lim L, Sarwar N et al. ( 2011 ) . Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib . Ann Oncol vol. 22 , ( 4 ) 815 - 820 .

Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, Reynolds AR ( 2011 ) . Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib . Oncogene vol. 30 , ( 10 ) 1183 - 1193 .

Hussain M, Nair R, Bycroft J, Green JSA, Powles T, Peters JL ( 2011 ) . A COMPARISON OF OPEN RADICAL NEPHRECTOMY COMPLICATION RATES IN PATIENTS TREATED WITH NEOADJUVANT SUNITINIB FOR METASTATIC RENAL CELL CARCINOMA VERSUS NON-METASTATIC RENAL CELL CARCINOMA . EUR UROL SUPPL vol. 10 , ( 2 ) 103 - 103 .

Powles T, Chowdhury S, Avril N, Bomanji J, Shamash J, Sarwar N, Rockall A, Sahdev A et al. ( 2011 ) . Sequential FDG-PET/CT as a surrogate marker of response to sunitinib in metastatic clear cell renal cancer . J Clin Oncol vol. 29 , ( 7_suppl )

Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T ( 2011 ) . Sunitinib and other targeted therapies for renal cell carcinoma . Br J Cancer vol. 104 , ( 5 ) 741 - 745 .

Powles T, Blank C, Chowdhury S, Peters J, Haanen J, O'Brien T, Rockall AR, Sahdev AS et al. ( 2011 ) . THE OUTCOME OF PATIENTS TREATED WITH UPFRONT SUNITINIB PRIOR TO NEPHRECTOMY IN METASTATIC CLEAR CELL RENAL CANCER . EUR UROL SUPPL vol. 10 , ( 2 ) 102 - 103 .

Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, Beard R, Wilson P et al. ( 2011 ) . A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol . BRIT J CANCER vol. 104 , ( 4 ) 620 - 628 .

Powles T, Kayani I, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N et al. ( 2011 ) . The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer . Annals of Oncology vol. 22 , ( 5 ) 1041 - 1047 .

Lerner SP, Powles T, Hahn NM, Gardner T, Cheng L, Green J, Berney D, Taber D et al. ( 2011 ) . A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 trial . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Fizazi K, Powles T, George DJ, Poehlein CH ( 2011 ) . A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Blick C, Hall P, Pwint T, Munro N, Crew J, Powles T, Macaulay VM, Al-Terkait F et al. ( 2011 ) . Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 7 )

Chen GJ, Sonpavde G, Vale CL, Fisher D, Powles T ( 2011 ) . Association of progression-free survival (PFS) at 2 or 3 years with overall survival (OS) at 5 years for locally advanced bladder cancer (BC): Evaluation of individual patient data (IPD) from seven randomized trials comparing local therapy with or without neoadjuvant chemotherapy (NC) . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Feldman DR, Huddart R, Hall E, Beyer J, Powles T ( 2011 ) . Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial . JOURNAL OF CANCER vol. 2 , 374 - 377 .

Shamash J, Jacob J, Powles T, Agrawal S, Mutsvangwa K, Saunders N, Wilson P, Stebbing J ( 2011 ) . Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Powles T, Chowdhury S, Avril N, Bomanji J, Shamash J, Sarwar N, Rockall A, Sahdev A et al. ( 2011 ) . Sequential FDG-PET/CT as a surrogate marker of response to sunitinib in metastatic clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 7 )

Powles T, Chowdhury S, Bower M, Saunders N, Lim L, Shamash J, Sarwar N, Sadev A et al. ( 2011 ) . The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer . UROL INT vol. 86 , ( 1 ) 53 - 59 .

Powles T, Mollevi C, Kramar A, Lorch A, Beyer J ( 2011 ) . The prognostic significance of LDH levels in patients with relapsed/refractory seminoma and their predictive value of the new international prognostic score . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Laroche-Clary A, Le Morvan V, Yamori T, Robert J ( 2010 ) . Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models . Molecular Cancer Therapeutics vol. 9 , ( 12 ) 3315 - 3321 .

Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T et al. ( 2010 ) . Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials . EUR UROL vol. 58 , ( 6 ) 819 - 828 .

LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD, Allred DC, Armstrong R et al. ( 2010 ) . Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women . Journal of the National Cancer Institute vol. 102 , ( 22 ) 1706 - 1715 .

Gerlinger M, Wilson P, Powles T, Shamash J ( 2010 ) . Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy . Eur J Cancer vol. 46 , ( 16 ) 2913 - 2918 .

Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U et al. ( 2010 ) . Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy . Journal of Clinical Oncology vol. 28 , ( 33 ) 4906 - 4911 .

Poffiri E, Miscoria M, Lim L, Shamash J, Chowdhury S, Powles T ( 2010 ) . THE OUTCOME OF PATIENTS WHO FAIL SUNITINIB AND DO NOT HAVE ACCESS TO SUNITINIB THERAPY . ANNALS OF ONCOLOGY . vol. 21 , 292 - 292 .

Oliver T, Chung PWM, Powles T, Jewett MAS ( 2010 ) . Treatment: Seminoma: Stage I . Cancer of the Testis , Springer Nature

Shamash J, Stebbing J, Sweeney C, Sonpavde G, Harland S, Dawkins G, Brock C, Abelman W et al. ( 2010 ) . A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer . Cancer vol. 116 , ( 15 ) 3595 - 3602 .

Gillessen S, Powles T, Lim L, Wilson P, Shamash J ( 2010 ) . Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience . Ann Oncol vol. 21 , ( 8 ) 1589 - 1593 .

Matakidou A, Mutsvangwa K, Ansell W, Lim L, Powles TB, Oliver RT, Shamash J ( 2010 ) . Single-agent carboplatin AUC10 for metastatic seminoma with IGCCCG good prognosis disease; a feasibility study of the Orchid Clinical Trials Group . Ann Oncol vol. 21 , ( 8 ) 1730 - 1731 .

Powles T, Jones R, Chowdhury S, Shamash J, Mantle M, Lim L, Hutson T ( 2010 ) . The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe? . BJU Int vol. 106 , ( 4 ) 453 - 457 .

Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF, Sharp S, Chaplin T et al. ( 2010 ) . The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers . Am J Pathol vol. 176 , ( 6 ) 2607 - 2615 .

Avril N, Dambha F, Murray I, Shamash J, Powles T, Sahdev A ( 2010 ) . The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers . Int J Urol vol. 17 , ( 6 ) 501 - 511 .

Powles T, Kayani I, Blank CU, Chowdhury S, Horenblas S, Sarwar N, Nathan PD, Boleti E et al. ( 2010 ) . The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer . Journal of Clinical Oncology vol. 28 , ( 15_suppl ) 4603 - 4603 .

Bharwani N, Miquel M, Sahdev A, Powles T, Reznek R, Rockall A ( 2010 ) . Diffusion-Weighted MRI in the Assessment of Tumor Response to Novel Targeted Therapies in Metastatic Renal Cell Carcinoma . AMERICAN JOURNAL OF ROENTGENOLOGY . vol. 194 ,

Powles T, Peters J, Horenblas S, Meinhardt W, O'Brien T, Sahdev A, Lim L, Green J et al. ( 2010 ) . 101 PRESURGICAL SUNITINIB IN METASTATIC CLEAR CELL RENAL CANCER (MRCC): SURGICAL SAFETY AND EFFECT ON THE PRIMARY TUMOUR . European Urology Open Science . vol. 9 , 64 - 65 .

El-Hariry I, Powles T, Lau MR, Sternberg CN, Ravaud A, von der Maase H, Zantl N, Harper P et al. ( 2010 ) . Amplification of epidermal growth factor receptor gene in renal cell carcinoma . EUR J CANCER vol. 46 , ( 5 ) 859 - 862 .

Escudier BJ, Cella D, Gschwend JE, Powles T, Sternberg CN, Hodge R, Lau M, Neary M et al. ( 2010 ) . A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC) . JOURNAL OF CLINICAL ONCOLOGY vol. 28 , ( 15 )

Chowdhury S, Harper P, Powles T ( 2010 ) . Castration Refractory Prostate Cancer: Cinderella Finally Comes to the Ball . ONKOLOGIE vol. 33 , ( 12 ) 655 - 656 .

Chowdhury S, O'Brien TS, Sarwar N, Shamash J, McGrath S, Agrawal S, Lim L, Rudman SM et al. ( 2010 ) . The effect of sunitinib on immune parameters and haemopoetic stem cell markers in patients with untreated cleat cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 28 , ( 15 )

Matakidou A, Mutsvangwa K, Ansell W, Powles T, Oliver T, Shamash J ( 2009 ) . Single-agent Carboplatin AUC10 for Metastatic Seminoma with IGCCCG Good Prognosis Disease; a Feasibility Study of the Orchid Clinical Trials Group . CLIN ONCOL-UK vol. 21 , ( 10 ) 800 - 800 .

Bycroft J, Foley C, Ndirika S, Powles T, Green J, Peters J ( 2009 ) . An Operative Experience of Nephrectomy following Sunitinib Treatment in Patients with Metastatic Renal Cell Carcinoma . Journal of Clinical Urology vol. 2 , ( 6 ) 256 - 256 .

Perry J, Powles T, Shamash J, Veerupillai A, McGrowder E, Noel E, Lu Y-J, Oliver T et al. ( 2009 ) . The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines . Cancer Chemother Pharmacol vol. 64 , ( 5 ) 925 - 933 .

Murugaesu N, Powles T, Bestwick J, Oliver RTD, Shamash J ( 2009 ) . Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis . Osteoporos Int vol. 20 , ( 9 ) 1627 - 1630 .

Powles T, Thirlwell C, Nelson M, Bower M ( 2009 ) . Immune Reconstitution Inflammatory Syndrome Mimicking Relapse of AIDS Related Lymphoma in Patients with HIV 1 Infection . Leukemia & Lymphoma vol. 44 , ( 8 ) 1417 - 1419 .

Josephs DH, Hutson TE, Pickering LM, Larkin JM, Choueiri TK, Patel TV, Mcdermott DF, Powles T et al. ( 2009 ) . Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis . JOURNAL OF CLINICAL ONCOLOGY . vol. 27 ,

Hahn NM, Powles T, Sweeney CJ ( 2009 ) . Development of novel agents for bladder cancer . Update on Cancer Therapeutics vol. 3 , ( 4 ) 160 - 169 .

Nathan P, Wagstaff J, Porfiri E, Powles T, Eisen T ( 2009 ) . UK guidelines for the systemic treatment of renal cell carcinoma . BRIT J HOSP MED vol. 70 , ( 5 ) 284 - 286 .

Powles T, Robinson D, Stebbing J, Nelson M, Mandalia S, Moller H, Gazzard B, Bower M ( 2009 ) . Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection . HIV MED vol. 10 , 4 - 4 .

Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M ( 2009 ) . The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease . Ann Oncol vol. 20 , ( 4 ) 775 - 779 .

Gerlinger M, Wilson P, Powles T, Oliver RTD, Shamash J ( 2009 ) . ESTABLISHED PROGNOSTIC MODELS FAIL TO PREDICT THE OUTCOME OF DOSE DENSE CHEMOTHERAPY FOR THE TREATMENT OF RECURRENT GERM CELL TUMOURS (GCTS) . EUR UROL SUPPL vol. 8 , ( 4 ) 358 - 358 .

Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Moller H et al. ( 2009 ) . Highly Active Antiretroviral Therapy and the Incidence of Non-AIDS-Defining Cancers in People With HIV Infection . J CLIN ONCOL vol. 27 , ( 6 ) 884 - 890 .

Stancliffe M, Powles T, Bower M ( 2009 ) . HIV-related lung cancer in the age of HAART . Multidisciplinary Respiratory Medicine vol. 4 , ( 3 ) 225 - 228 .

Perry J, Kitromilidou C, McGrowder E, Madadi L, Joel S, Powles T ( 2009 ) . Lapatinib combination studies in solid tumor cell lines . CANCER RESEARCH . vol. 69 ,

Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM et al. ( 2009 ) . The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma . Lung Cancer vol. 63 , ( 1 ) 94 - 97 .

Nelson M, Powles T, Zeitlin A, Sen P, Scourfield A, Bower M, Gazzard B, Stebbing J ( 2009 ) . Thyroid Dysfunction and Relationship to Antiretroviral Therapy in HIV-Positive Individuals in the HAART Era . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 50 , ( 1 ) 113 - 114 .

Oliver T, Shamash J, Powles T, Reznek R, Badenoch D, Nargund V ( 2008 ) . POD-2.08: Chemotherapy for Testis Conservation in Patients with Germ Cell Cancer (GCC): Is It Safe and Could Combination with Tumour Enucleation Increase the Frequency of Success? . Urology vol. 72 , ( 5 ) s35 - s36 .

Oliver T, Powles T, Somasundram U, Shamash J ( 2008 ) . UP.07: 20-Year Phase 1/2 Study of Single Agent Carboplatin in Metastatic Seminoma: Could it Have Been Accelerated By 72 Hr PET Scan Response? . Urology vol. 72 , ( 5 )

Jones R, Nelson M, Bower M, Powles T, Mandalia S, Gazzard B, Stebbing J ( 2008 ) . Triple-class antiretroviral agent resistance in a large cohort: Prevalence and clinical outcomes . ARCH INTERN MED vol. 168 , ( 17 ) 1926 - 1927 .

Gaughan EM, Dezube BJ, Aboulafia D, Bower M, Strebbing J, Powles T, Pantanowitz L ( 2008 ) . Human immunodeficiency virus-associated renal cell carcinoma: A transatlantic case series . CLIN GENITOURIN CANC vol. 6 , ( 2 ) 86 - 90 .

Bazoes A, Bower M, Powles T ( 2008 ) . Smoke and mirrors: HIV-related lung cancer . Curr Opin Oncol vol. 20 , ( 5 ) 529 - 533 .

Powles T, McFaul S, Stebbing J, Wilson P, Oliver T, Tranter N, Shamash J ( 2008 ) . The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer . Onco Targets Ther vol. 1 , 35 - 39 .

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I et al. ( 2008 ) . Corrigendum to: “European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I” [Eur Urol 2008;53:478–96] and to: “European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part II” [Eur Urol 2008;53:497–513] . European Urology vol. 54 , ( 2 )

Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T et al. ( 2008 ) . British HIV Association guidelines for HIV-associated malignancies 2008 . HIV MED vol. 9 , ( 6 ) 336 - 388 .

Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B, Bower M ( 2008 ) . Use of antidepressants and risk of cancer in individuals infected with HIV . J CLIN ONCOL vol. 26 , ( 14 ) 2305 - 2310 .

Bower M, Stebbing J, Tuthill M, Campbell V, Krell J, Holmes P, Ozzard A, Nelson M et al. ( 2008 ) . Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma . BLOOD vol. 111 , ( 8 ) 3986 - 3990 .

Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP et al. ( 2008 ) . Novel agents for muscle-invasive and advanced urothelial cancer . BJU INT vol. 101 , ( 8 ) 937 - 943 .

Macdonald DC, Nelson M, Bower M, Powles T ( 2008 ) . Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era . WORLD J GASTROENTERO vol. 14 , ( 11 ) 1657 - 1663 .

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I et al. ( 2008 ) . European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part I . EUR UROL vol. 53 , ( 3 ) 478 - 496 .

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Alyaba F, Bamberg M, Bodrogi I et al. ( 2008 ) . European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II . EUR UROL vol. 53 , ( 3 ) 497 - 513 .

Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T ( 2008 ) . The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis . ANN ONCOL vol. 19 , ( 3 ) 443 - 447 .

Stebbing J, Powles T, Bower M ( 2008 ) . AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count . AIDS vol. 22 , ( 4 ) 551 - 552 .

Shamash J, Davies A, Ansell W, Mcfaul S, Wilson P, Oliver T, Powles T ( 2008 ) . A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer . BRIT J CANCER vol. 98 , ( 1 ) 22 - 24 .

Perry J, Nsubuga E, Joel S, Shamash J, El-Hariry I, Powles T ( 2008 ) . A synergistic interaction between lapatinib and topoisomerase I inhibitors in cisplatin sensitive and resistant cancer cell lines . JOURNAL OF CLINICAL ONCOLOGY vol. 26 , ( 15 )

Liu WM, Scott KA, Shamash J, Joel S, Powles TB ( 2008 ) . Enhancing the in vitro cytotoxic activity of Delta(9)-tetrahydrocannabinol in leukemic cells through a combinatorial approach . LEUKEMIA LYMPHOMA vol. 49 , ( 9 ) 1800 - 1809 .

Berney DM, Warren AY, Verma M, Kudahetti S, Robson JM, Williams MW, Neal DE, Powles T et al. ( 2008 ) . Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over . Mod Pathol vol. 21 , ( 1 ) 54 - 59 .

Gerlinger M, Wilson P, Powles T, Shamash J ( 2008 ) . Non-castrate status at the end of chemotherapy for metastatic hormone-resistant prostate cancer (HRPC) correlates with a better overall survival . JOURNAL OF CLINICAL ONCOLOGY vol. 26 , ( 15 )

Bower M, Stebbing J, Tuthill MH, Krell J, Campbell V, Nelson M, Gazzard B, Powles T ( 2008 ) . Recovery of cellular immunity following chemotherapy for AIDS related non Hodgkin's lymphoma . JOURNAL OF CLINICAL ONCOLOGY vol. 26 , ( 15 )

Oliver T, Powles T, Nargund V, Berney D ( 2008 ) . Spontaneous Regression of Renal Cell Carcinoma and the Role of Prognostic Factors . Clinical Management of Renal Tumors , Springer Nature

Bazeos A, Powles T, Stebbing J, Mandalia S, Bower M ( 2008 ) . The increasing incidence of HIV-associated multicentric Castlemans disease . JOURNAL OF CLINICAL ONCOLOGY vol. 26 , ( 15 )

Waters L, Nelson M, Mandalia S, Bower M, Powles T, Gazzard B, Stebbing J ( 2008 ) . The risks and incidence of K65R and L74V mutations and subsequent virologic responses . CLIN INFECT DIS vol. 46 , ( 1 ) 96 - 100 .

Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A et al. ( 2007 ) . Brief communication: rituximab in HIV-associated multicentric Castleman disease . Ann Intern Med vol. 147 , ( 12 ) 836 - 839 .

Powles T, Stebbing J, Montoto S, Nelson M, Gazzard B, Orkin C, Webb A, Bower M ( 2007 ) . Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease . Blood vol. 110 , ( 12 ) 4132 - 4133 .

Davies CL, Chinn R, Nelson M, Rasanesan M, Gazzard B, Powles T, Bower M, Stebbing J ( 2007 ) . Outcome in AIDS-related systemic non-Hodgkin lymphoma and leptomeningeal disease is not predicted by a CT brain scan . AM J NEURORADIOL vol. 28 , ( 10 ) 1988 - 1990 .

Shamash J, Stebbing J, Powles T ( 2007 ) . Germ-cell tumors . NEW ENGL J MED vol. 357 , ( 17 ) 1771 - 1772 .

Shamash J, Powles T, Ansell W, Berney D, Stebbing J, Mutsvangwa K, Wilson P, Asterling S et al. ( 2007 ) . Erratum: GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours . British Journal of Cancer vol. 97 , ( 8 ) 1188 - 1188 .

Sonpavde, N. K, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR et al. ( 2007 ) . Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer . Cancer vol. 110 , ( 12 ) 2628 - 2639 .

Young AM, Powles T, Holmes P, Wang J, Nelson M, Anderson J, Bower MD, Brock CS ( 2007 ) . An HIV-associated mediastinal germ cell tumour complicated by acute myeloid leukaemia . Journal of HIV therapy vol. 12 , ( 3 ) 68 - 71 .

Bazeos A, Powles T, Stebbing J ( 2007 ) . HIV-associated Castleman's disease: from case reports to evidence . Journal of HIV therapy vol. 12 , ( 3 ) 61 - 62 .

Walters Z, Shamash J, Powles T ( 2007 ) . Prostate cancer in HIV-positive individuals: what we know and what we don't . J HIV Ther vol. 12 , ( 3 ) 66 - 67 .

Stebbing J, Nathan B, Jones R, McKenna A, Powles T, Bower M, Holmes P, Gazzard B et al. ( 2007 ) . Virological failure and subsequent resistance profiles in individuals exposed to atazanavir . AIDS vol. 21 , ( 13 ) 1826 - 1828 .

Shamash J, Powles T, Ansell W, Stebbing J, Mutsvangwa K, Wilson P, Asterling S, Liu S et al. ( 2007 ) . GAMEC - a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours . BRIT J CANCER vol. 97 , ( 3 ) 308 - 314 .

Stebbing J, Sanitt A, Teague A, Powles T, Nelson M, Gazzard B, Bower M ( 2007 ) . CD8 count measurement has independent prognostic significance in individuals with AIDS-Kaposi sarcoma . Journal of Clinical Oncology vol. 25 , ( 18_suppl ) 20500 - 20500 .

Bower M, Powles T, Williams S, Newsom-Davis T, Atkins M, Stebbing J, Montoto S, Nelson M et al. ( 2007 ) . Rituximab induces long-term remissions in patients with HIV-associated multicentric Castleman's disease . Journal of Clinical Oncology vol. 25 , ( 18_suppl ) 8049 - 8049 .

Powles T, Oliver T, Ostrowski M, Levay J, Shamash J, Williams M ( 2007 ) . The long term side effects of adjuvant carboplatin for stage 1 seminoma . Journal of Clinical Oncology vol. 25 , ( 18_suppl ) 5089 - 5089 .

Powles T, Murray I, Brock C, Oliver T, Avril N ( 2007 ) . Molecular positron emission tomography and PET/CT imaging in urological malignancies . Eur Urol vol. 51 , ( 6 ) 1511 - 1520 .

Stebbing J, Sanitt A, Teague A, Powles T, Nelson M, Gazzard B, Bower M ( 2007 ) . Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma . J CLIN ONCOL vol. 25 , ( 16 ) 2230 - 2235 .

Shamash J, Powles T, Mutsvangwa K, Wilson P, Ansell W, Walsh E, Berney D, Stebbing J et al. ( 2007 ) . A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours . ANN ONCOL vol. 18 , ( 5 ) 925 - 930 .

Powles T, Ell PJ ( 2007 ) . Does PET imaging have a role in renal cancers after all? . LANCET ONCOL vol. 8 , ( 4 ) 279 - 281 .

Stebbing J, Powles T ( 2007 ) . Stress in the workplace amongst medical professionals . J POSTGRAD MED vol. 53 , ( 2 ) 83 - 84 .

Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P et al. ( 2007 ) . A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia . BRIT J CANCER vol. 96 , ( 5 ) 732 - 737 .

Powles T, Perry J, Shamash J, Liu W, Oliver T, Joel S ( 2007 ) . A comparison of the platinum analogues in bladder cancer cell lines . UROL INT vol. 79 , ( 1 ) 67 - 72 .

Bower M, Powles T, Williams S, Newsom-Davis T, Atkins M, Stebbing J, Montoto S, Nelson M et al. ( 2007 ) . Rituximab induces long-term remissions in patients with HIV-associated multicentric Castleman's disease . JOURNAL OF CLINICAL ONCOLOGY . vol. 25 ,

Powles T, Oliver T, Ostrowski M, Levay J, Shamash J, Williams M ( 2007 ) . The long term side effects of adjuvant carboplatin for stage 1 seminoma . JOURNAL OF CLINICAL ONCOLOGY . vol. 25 ,

Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al. ( 2006 ) . Erratum: The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours . British Journal of Cancer vol. 95 , ( 12 ) 1709 - 1709 .

Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al. ( 2006 ) . The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours . Br J Cancer vol. 95 , ( 9 ) 1145 - 1147 .

Powles T, Macdonald D, Nelson M, Stebbing J ( 2006 ) . Hepatocellular cancer in HIV-infected individuals: tomorrow's problem? . EXPERT REV ANTICANC vol. 6 , ( 11 ) 1553 - 1558 .

Stebbing J, Powles T, Bower M ( 2006 ) . New therapies for hepatitis infection . Future Virology vol. 1 , ( 5 ) 533 - 535 .

PAGE K, POWLES T, SLADE MJ, DE BELLA MT, WALKER RA, COOMBES RC, SHAW JA ( 2006 ) . The Importance of Careful Blood Processing in Isolation of Cell‐Free DNA . Annals of the New York Academy of Sciences . vol. 1075 , 313 - 317 .

Powles T, Oliver T, Bower M ( 2006 ) . Non-AIDS-defining cancers in people with HIV infection: a sleeping giant? . J HIV Ther vol. 11 , ( 3 ) 57 - 60 .

Stebbing J, Powles T, Nelson M, Bower M ( 2006 ) . Significance of Variation Within HIV, EBV, and KSHV Subtypes . Journal of the International Association of Providers of AIDS Care (JIAPAC) vol. 5 , ( 3 ) 93 - 102 .

Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Stebbing J ( 2006 ) . Highly Active Antiretroviral Therapy and Human Immunodeficiency Virus–Associated Primary Cerebral Lymphoma . Journal of the National Cancer Institute vol. 98 , ( 15 ) 1088 - 1091 .

Oliver R, Powles T, Ell P, Somasundram U, Shamash J ( 2006 ) . 22 year phase 1/2 study of single agent carboplatin in metastatic seminoma: Potential for acceleration by a new surrogate end point, 72 hr PET scan response? . Journal of Clinical Oncology vol. 24 , ( 18_suppl ) 14565 - 14565 .

Stebbing J, Mazhar D, Palmieri C, Thirlwell C, Powles T, Nelson M, Gazzard B, Bower M ( 2006 ) . Non cutaneous AIDS-associated Kaposi’s sarcoma . Journal of Clinical Oncology vol. 24 , ( 18_suppl ) 9555 - 9555 .

Bower M, Mazhar D, Newsom Davis T, Powles T, Mandalia S, Gazzard B, Stebbing J ( 2006 ) . The influence of HAART on HIV-associated primary cerebral lymphoma: Declining incidence and improving survival . Journal of Clinical Oncology vol. 24 , ( 18_suppl ) 17512 - 17512 .

Powles T, Young A, Short D, Savage P, Pappin C, Schmid P, Seckl M ( 2006 ) . The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy . Journal of Clinical Oncology vol. 24 , ( 18_suppl ) 5033 - 5033 .

Powles T, Young A, Short D, Savage P, Pappin C, Schmid P, Seckl M ( 2006 ) . The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy . JOURNAL OF CLINICAL ONCOLOGY . vol. 24 , 263S - 263S .

Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M ( 2006 ) . A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy . The Lancet vol. 367 , ( 9521 ) 1495 - 1502 .

Liu WM, Powles TB ( 2006 ) . Cannabinoids: Do they have a role in cancer therapy? . LETT DRUG DES DISCOV vol. 3 , ( 2 ) 76 - 82 .

Powles T, Savage P, Short D, Young A, Pappin C, Seckl MJ ( 2006 ) . Residual lung lesions after completion of chemotherapy for gestational trophoblastic neoplasia: should we operate? . BRIT J CANCER vol. 94 , ( 1 ) 51 - 54 .

Bhardwa JM, Powles T, Berney D, Baithun S, Nargund VH, Oliver RTD ( 2005 ) . Assessing the size and stage of testicular germ cell tumours: 1984-2003 . BJU Int vol. 96 , ( 6 ) 819 - 821 .

Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, Young AM, Powles T et al. ( 2005 ) . A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy . Annals of Internal Medicine vol. 143 , ( 4 ) 265 - 273 .

Stebbing J, Mandalia S, Young A-M, Dhillon T, Newshom-Davis T, Thirlwell C, Powles T, Nelson M et al. ( 2005 ) . A new prognostic index for systemic AIDS-related lymphoma . Journal of Clinical Oncology vol. 23 , ( 16_suppl ) 9530 - 9530 .

Shamash J, Powles T, Mutsangwa K, Cotton L, Oliver T ( 2005 ) . A phase II study of irinotecan, paclitaxel and oxaliplatin (IPO) in patients with multiply relapsed germ cell tumours (GCT) . Journal of Clinical Oncology vol. 23 , ( 16_suppl ) 4527 - 4527 .

Shamash J, Powles T, Mutsangwa K, Cotton L, Oliver T ( 2005 ) . A phase II study of irinotecan, paclitaxel and oxaliplatin (IPO) in patients with multiply relapsed germ cell tumours (GCT) . JOURNAL OF CLINICAL ONCOLOGY . vol. 23 , 384S - 384S .

Powles TB, Bhardwa J, Shamash J, Mandalia S, Oliver T ( 2005 ) . The changing presentation of germ cell tumours of the testis between 1983 and 2002 . BJU INT vol. 95 , ( 9 ) 1197 - 1200 .

Waterston AM, Gumbrell L, Bratt T, Waller S, Gustav-Aspland J, L‘Hermenier C, Bellenger K, Campbell M et al. ( 2005 ) . Phase I study of TNFα AutoVaccIne in Patients with metastatic cancer . Cancer Immunology, Immunotherapy vol. 54 , ( 9 ) 848 - 857 .

Berney DM, Argyle K, Cheang M, Powles T, Oliver RTD ( 2005 ) . Erythropoietin and erythropoietin receptor expression in renal cell carcinomas . JOURNAL OF PATHOLOGY . vol. 205 , 14 - 14 .

Bower M, Powles T, Stebbing J, Thirlwell C ( 2005 ) . Potential Antiretroviral Drug Interactions With Cyclophosphamide, Doxorubicin, and Etoposide . Journal of Clinical Oncology vol. 23 , ( 6 ) 1328 - 1329 .

Shamash J, Powles T, Wilson P, Ansell W, Oliver T ( 2005 ) . Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, cisplatin, and mitomycin chemotherapy . J CLIN ONCOL vol. 23 , ( 6 ) 1323 - 1325 .

Powles T, te Poele R, Shamash J, Chaplin T, Propper D, Joel S, Oliver T, Liu WM ( 2005 ) . Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway . Blood vol. 105 , ( 3 ) 1214 - 1221 .

Liu WM, Baird R, Sarker D, Powles T ( 2005 ) . Antiapoptotic Effect of Growth Factors in Leukemia . Journal of Clinical Oncology vol. 23 , ( 3 ) 649 - 649 .

Stebbing J, Mandalia S, Young AM, Dhillon T, Newshom-Davis T, Thirlwell C, Powles T, Nelson M et al. ( 2005 ) . A new prognostic index for systemic AIDS-related lymphoma . JOURNAL OF CLINICAL ONCOLOGY . vol. 23 , 844S - 844S .

Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, Nelson M, Gazzard B ( 2004 ) . HIV-Associated Anal Cancer . JAIDS Journal of Acquired Immune Deficiency Syndromes vol. 37 , ( 5 ) 1563 - 1565 .

Marvin V, Stebbing J, Powles T, Bower M ( 2004 ) . The pharmacogenomics of anti-cancer chemotherapy . Minerva Biotecnologica vol. 16 , ( 3 ) 181 - 188 .

Oliver T, Shamash J, Powles T, Somasundram U ( 2004 ) . 20 year phase 1/2 study of single agent carboplatin in metastatic seminoma: Could it have been accelerated by 72 hr PET scan response? . JOURNAL OF CLINICAL ONCOLOGY . vol. 22 , 447S - 447S .

Powles T, Shamash J, Ong J, MacDonald D, Kyle F, Palmiera C, Moller H, Oliver T ( 2004 ) . The rising incidence of stage 1 seminoma; a reflection of earlier diagnosis of germ cell cancer of the testis in last 20 years . Journal of Clinical Oncology vol. 22 , ( 14_suppl ) 4521 - 4521 .

Powles T, Shamash J, Ong J, MacDonald D, Kyle F, Palmiera C, Moller H, Oliver T ( 2004 ) . The rising incidence of stage I seminoma; a reflection of earlier diagnosis of germ cell cancer of the testis in last 20 years . JOURNAL OF CLINICAL ONCOLOGY . vol. 22 , 387S - 387S .

Powles T, Bower M, Shamash J, Stebbing J, Ong J, Daugaard G, De Ruiter A, Johnson M et al. ( 2004 ) . Outcome of patients with HIV-related germ cell tumours: a case-control study . BRIT J CANCER vol. 90 , ( 8 ) 1526 - 1530 .

Powles T, Bower M ( 2004 ) . HIV and the Risk of Lung Cancer . Journal of Clinical Oncology vol. 22 , ( 7 ) 1348 - 1349 .

Powles T, Powles J, Nelson M, Sandison A, Peston D, Buchannan J, Mandalia S, Gazzard B et al. ( 2004 ) . Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus . J LARYNGOL OTOL vol. 118 , ( 3 ) 207 - 212 .

Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S ( 2004 ) . Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity . Oncogene vol. 23 , ( 4 ) 981 - 990 .

Powles T, Shamash J, Liu W ( 2004 ) . Erythropoietin to treat anaemia in patients with head and neck cancer . LANCET vol. 363 , ( 9402 ) 82 - 82 .

Kaanders JH, van der Kogel AJ ( 2004 ) . Erythropoietin to treat anaemia in patients with head and neck cancer . The Lancet vol. 363 , ( 9402 ) 78 - 79 .

Stebbing J, Wildfire A, Portsmouth S, Powles T, Thirlwell C, Hewitt P, Nelson M, Patterson S et al. ( 2003 ) . Paclitaxel for anthracycline-resistant AIDS-related Kaposi’s sarcoma: clinical and angiogenic correlations . Annals of Oncology vol. 14 , ( 11 ) 1660 - 1666 .

Powles T, Nelson M, Bower M ( 2003 ) . HIV-related lung cancer - a growing concern? . International Journal of STD & AIDS vol. 14 , ( 10 ) 647 - 651 .

Powles T, Shamash J, Berney D, Oliver RTD ( 2003 ) . Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group . BRIT J CANCER vol. 89 , ( 6 ) 1140 - 1141 .

Powles T, Thirwell C, Newsom-Davis T, Nelson M, Shah P, Cox S, Gazzard B, Bower M ( 2003 ) . Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? . British Journal of Cancer vol. 89 , ( 3 ) 457 - 459 .

Powles T, Liu W, Shamash J, Oliver T, Joel S ( 2003 ) . The effect of recombinant erythropoeitin on renal cancer cell lines and its role in chemosensitivity . BRITISH JOURNAL OF CANCER . vol. 88 , S66 - S66 .

Powles T, Shamash J, Joel S, Oliver T, Liu W ( 2003 ) . The role of CB1 and CB2 receptors in cannabis induced apoptosis in vitro . BRITISH JOURNAL OF CANCER . vol. 88 , S25 - S25 .

Powles T, Bower M, Daugaard G, Shamash J, De Ruiter A, Johnson M, Fisher M, Anderson J et al. ( 2003 ) . Multicenter study of human immunodeficiency virus-related germ cell tumors . J CLIN ONCOL vol. 21 , ( 10 ) 1922 - 1927 .

Bower M, Powles T, Nelson M, Shah P, Cox S, Mandelia S, Gazzard B ( 2003 ) . HIV-related lung cancer in the era of highly active antiretroviral therapy . AIDS vol. 17 , ( 3 ) 371 - 375 .

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P ( 2003 ) . Overview of the main outcomes in breast-cancer prevention trials . Lancet vol. 361 , ( 9354 ) 296 - 300 .

Powles T, Nelson M, Bower M ( 2003 ) . HIV-related testicular cancer . International Journal of STD & AIDS vol. 14 , ( 1 ) 24 - 27 .

Powles T, Daugaard G, Nelson M, Oliver T, Fisher M, Stebbing J, Johnson M, Gazzard B et al. ( 2002 ) . Multi-centre cohort study of testicular, cancer in men with HIV . BRIT J CANCER vol. 86 , S19 - S19 .

Powles T, Imami N, Nelson M, Gazzard BG, Bower M ( 2002 ) . Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma . AIDS vol. 16 , ( 4 ) 531 - 536 .

Powles T, Bower M, Nelson M, Oliver RTD ( 2002 ) . HIV related testicular cancer . GERM CELL TUMOURS V . Editors: Harden, P, Joffe, JK, Jones, WG , 51 - 52 .

Behr TM, Béhé M, Wörmann B ( 2001 ) . Trastuzumab and Breast Cancer . New England Journal of Medicine vol. 345 , ( 13 ) 995 - 998 .

Palmieri C, Powles T, Vigushin D ( 2001 ) . Trastuzumab and breast cancer . New England Journal of Medicine vol. 345 , ( 13 ) 996 - 997 .

Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG ( 2000 ) . Changes in acquired immunodeficiency syndrome–related lymphoma since the introduction of highly active antiretroviral therapy . Blood vol. 96 , ( 8 ) 2730 - 2734 .

Powles T, Matthews G, Bower M ( 2000 ) . AIDS related systemic non-Hodgkin's lymphoma . Sexually Transmitted Infections vol. 76 , ( 5 )

Powles T, Bower M ( 2000 ) . HIV-associated Hodgkin's disease . International Journal of STD & AIDS vol. 11 , ( 8 ) 492 - 494 .

Gill J, Powles T, Bower M ( 2000 ) . The molecular genetics of human herpesvirus 8 . British Journal of Hospital Medicine vol. 61 , ( 5 ) 306 - 309 .

Kaltsas GA, Powles TB, Evanson J, Plowman PN, Drinkwater JE, Jenkins PJ, Monson JP, Besser GM et al. ( 2000 ) . Hypothalamo-Pituitary Abnormalities in Adult Patients with Langerhans Cell Histiocytosis: Clinical, Endocrinological, and Radiological Features and Response to Treatment . The Journal of Clinical Endocrinology & Metabolism vol. 85 , ( 4 ) 1370 - 1376 .